Regulation of cardiac ischaemia/reperfusion injury or hypertrophy by interferon-gamma and cardiotrophin-1 signalling pathways. by Carroll, C.J.
REFERENCE ONLY 2809880816
Degree
UNIVERSITY OF LONDON THESIS
Year Name of Author Chilis-,
TérHfi
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOAN
Theses may not be lent to individuals, but the University Library may lend a copy to 
approved libraries within the United Kingdom, for consultation solely on the premises 
of those libraries. Application should be made to: The Theses Section, University of 
London Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the University of London Library. Enquiries should be addressed to 
the Theses Section of the Library. Regulations concerning reproduction vary 
according to the date of acceptance of the thesis and are listed below as guidelines.
A.
B.
C.
D.
Before 1962. Permission granted only upon the prior written consent of the 
author. (The University Library will provide addresses where possible).
1962 - 1974. In many cases the author has agreed to permit copying upon 
completion of a Copyright Declaration.
1975- 1988. 
Declaration.
Most theses may be copied upon completion of a Copyright
1989 onwards. Most theses may be copied.
This thesis comes within category D.
□ This copy has been deposited in the Library of
□ This copy has been deposited in the University of London Library, Senate House, Malet Street, London WC1E 7HU.

Regulation of cardiac ischaemia/reperfusion 
injury or hypertrophy by interferon-gamma and 
cardiotrophin-1 signalling pathways
Christopher J Carroll
Medical Molecular Biology Unit 
Institute of Child Health 
University College London
A thesis submitted for the Degree of Doctor of Philosophy in the University of London
2008
UMI Number: U591469
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Disscrrlation Publishing
UMI U591469
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Cardiac ischaemia/reperfusion (I/R)-injury and hypertrophy are two causes of heart 
failure. The molecular pathways that regulate these processes include those that are 
stimulated by the cytokines, interferon-gamma (IFNy) and cardiotrophin-1 (CT-1). 
This thesis describes the investigation of components of the IFNy or CT-1 signalling 
pathways and their regulation of I/R-injury or hypertrophy.
The transcription factor, signal transducer and activator of transcription 1 (STATl), is 
the primary mediator of the IFNy signalling pathway and promotes apoptosis of 
cardiac cells following I/R-injury or stimulation with IFNy. It is unclear what 
contribution the caspase-8 and caspase-9 apoptotic pathways have in STATl 
mediated I/R-injury and IFNy induced apoptosis. Therefore, to investigate this 
relationship, constructs conditionally overexpressing specific caspase inhibitors were 
used to generate transgenic mice with inactivated caspase -8 or -9 pathways.
STATl and the transcription factor p53 proteins are known to associate and this 
interaction has been demonstrated to be necessary for the maximal activation of 
distinct p53 target genes. STATl and p53 double knockout mice were generated to 
further investigate the role of these proteins in I/R-injury. A proteomic approach was 
used to identify proteins regulated by STATl and/or p53 in the heart where the 
expression of the cytokine, interleukin-6, was regulated by STATl and p53.
The CT-1 cytokine has cardioprotective and hypertrophic effects. CT-l expression is 
induced by another cardioprotective cytokine, urocortin. The mechanism by which 
urocortin protects the heart from I/R-injury is not fully understood, however, 
prevention of mitochondrial damage has been shown to be involved. In this study 
the protective effect of urocortin was shown to involve the mitochondrial 
permeability transition pore. Furthermore, the hypertrophic effect of CT-1 in cultured 
cardiac cells has been shown to be dependent on induction of heat shock protein 56 
(hsp56). Transgenic mice overexpressing hsp56 were generated to test the 
cardioprotective and hypertrophic effects of hsp56 in vivo. Taken together, the data 
presented here demonstrate clearly that a number of key molecules regulate cardiac 
(patho)physiology in vivo. Targeting these signalling pathways may provide novel 
routes for therapeutic intervention in heart disease.
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Introduction
Diseases of the heart and circulatory system are the main cause of death in the UK 
and account for over 208,000 deaths each year rwww.heartstats.orol  and heart 
failure represents the fastest growing subclass of cardiovascular disease over the 
past decade (Heineke and Molkentin, 2006). Cardiac ischaemia/reperfusion injury 
and hypertrophy are two causes of heart failure and are regulated by complex 
intracellular signalling pathways. Therefore, elucidation of these pathways involved is 
required to enable the generation of effective therapies for the causes of heart 
failure.
In this introduction, the structure and function of the normal working heart, 
ischaemia/reperfusion injury and hypertrophy, and the principal experimental 
systems used in laboratory based cardiovascular research will be described first. 
Then, the basic principles of signal transduction and apoptotic cell death, a feature of 
cardiac disease, will be described. Evidence for the role of apoptosis in 
ischaemia/reperfusion injury and the signalling pathways involved in 
ischaemia/reperfusion-induced apoptosis, and hypertrophy, will then be discussed. 
This is followed by further discussion on the role of the interferon-gamma and 
cardiotrophin-1 signalling pathways in the regulation ischaemia/reperfusion injury or 
hypertrophy.
1.1 The cardiovascular system
Animal cells require a supply of oxygen and nutrients, which they metabolise to 
produce usable energy in the form of adenosine 5'-triphosphate (ATP). In animals 
with specialised tissues, the supply of oxygen and nutrients is carried in the blood. 
The blood is transported through vessels known as vasculature, and the beating 
heart maintains the circulation of the blood throughout these vessels.
The mammalian heart is a four-chambered organ consisting of the left and right 
ventricles and atria. During the contraction phase of the heartbeat, termed systole, 
blood is ejected from the ventricles of the heart into the arteries as blood from the
20
Çhciplc  ^ One  ______________________________________________________Introduction
veins fill the atria. When the heart relaxes, the diastole phase, blood from the atria 
fills the ventricles. The blood is circulated from the heart to tissues via the arterial 
system and returns via the venous system. Oxygenated blood from the lungs is 
received by the left atrium via the pulmonary vein and is ejected from the left 
ventricle into the aorta, the major artery that feeds systemic circulation. The aorta 
divides into the arteries that direct flow to all parts of the body. In order to reach all 
the cells packed within tissues the arteries branch into smaller vessels that comprise 
the microcirculation. Arteries branch into arterioles and these in turn branch into 
even smaller vessels, the capillaries. The capillaries are the smallest of the blood 
vessels and it is from the capillaries that oxygen and nutrients are exchanged for 
carbon dioxide and waste products of metabolism with nearby cells. In the heart 
there is at least one capillary adjacent to each cell (Davidson and Duchen, 2007). 
Deoxygenated blood from the capillaries enters the venous system of blood vessels. 
Blood travels from capillaries to venules to veins and then to the superior or inferior 
vena cava, the major veins that return blood to the heart from the systemic 
circulation. Deoxygenated blood from the systemic circulation enters the right atrium 
and fills the right ventricle during relaxation. The right ventricle supplies the 
deoxygenated blood to the lungs via the pulmonary circulation where the blood is 
oxygenated in the capillaries of the lungs. The principles for pulmonary circulation 
are similar to those for systemic circulation. Oxygenated blood is returned to the left 
atrium via the pulmonary vein thereby to complete the circulation.
1.1.1 Heart cells
Cardiomyocytes are specialised cells of the heart muscle tissue, or myocardium, 
which contract to form the heartbeat and move blood though the body. 
Cardiomyocytes constitute approximately 75% of the total volume of the 
myocardium (Brilla et al., 1991). The remainder consists of pacemaker and 
conducting cells, blood vessels and extracellular space. The contractile proteins of 
cardiomyocytes are organised into contractile units, known as sarcomeres, which are 
grouped in bundles to form myofibrils. Cardiomyocytes are joined together by 
connective tissue made of collagen to form myofibres.
Ventricular myocytes are responsible for ejecting blood from the heart and propelling
it around the body and their anatomy is different to myocytes in the atrium,
pacemaker and conducting tissue. Ventricular cardiomyocytes are cylindrical in
21
9]aRler_gne________________________________________________________ Introduction
shape, measuring approximately 10 to 25 fxm in diameter and 50 to 100 pim in length 
(reviewed by Opie, 2004). Each cell is bound by a plasma membrane known as the 
sarcolemma that invaginates to form a tubular network called T-tubules that are 
linked to the sarcoplasmic reticulum, which allows the flow of calcium that is involved 
in contraction and relaxation. Myocytes are packed with longitudinally arranged 
myofibrils, which are the structures responsible for the cross-striated appearance of 
myocytes when viewed under the light microscope. Some myocytes are 
multinucleated and highly abundant in mitochondria, the organelles where oxygen 
dependent energy metabolism takes place, which are interspersed between the 
myofibrils and beneath the sarcolemma (reviewed by Opie, 2004).
1.1.2 The sarcomere
The sarcomere is the fundamental unit of contraction in myocytes (Figure 1.1) The 
sarcomere contains overlapping thin and thick filaments comprised of actin and 
myosin respectively. During contraction, the thin and thick filaments of the 
sarcomere slide along each other, thus pulling together the two poles of the 
sarcomere. The structures of the sarcomere are referred to as bands or lines, which 
were assigned because of the patterns of the sarcomere when observed in electron 
microscopic images. The ends of the sarcomere are the Z lines (also called Z bands 
or Z discs) to which the actin filaments are joined by elastic filaments made of the 
protein titin. The actin thin filaments stretch part way towards the centre of the 
sarcomere. The middle of the sarcomere is the M line from which the myosin thick 
filaments are bound and extend part way towards the Z lines and overlap with the 
actin thin filaments. The dark region where actin and myosin filaments overlap is the 
anisostropic, or A band, and the lighter regions either side where there are only actin 
thin filaments are the isotropic, or I bands. In the centre of the A band is the H zone 
where there are only myosin thick filaments appearing as light regions, which are 
attached to proteins in the dark M line in the centre. Cross-bridge cycling is the 
process by which actin and myosin interact to contract and relax the sarcomere, a 
process that is regulated by proteins of the troponin family. Contraction is initiated by 
an increase in cellular calcium released from the sarcoplasmic reticulum, which 
happens in response to a wave of electricity that reaches the ventricular myocytes 
from the conducting cells. Relaxation occurs as the interaction of actin and myosin is 
displaced, an action that is dependent on ATP.
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Figure 1.1 Contractile units of the cardiac myocyte. Myofibrils run 
longitudinally throughout the length of the cardiac myocyte. Sarcomeres are the 
basic contractile unit consisting of the contractile proteins actin (thin filament) and 
myosin (thick filament). Contraction and relaxation occurs through interaction of the 
thin and thick filaments. I (inostropic) band, A (anisotropic) band, H band and Z 
(Zuckung) line are the names given to the sarcomeric structures when viewed under 
electron microscopy.
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7.2 Cardiovascular disease
Cardiovascular disease is the number one cause of mortality in the Western world, 
with heart failure representing the fastest growing subclass over the past decade 
(Heineke and Molkentin, 2006). Heart failure is defined as a deficiency in the 
capability of the heart to pump blood in response to systemic demands. The common 
disease stimuli that induce heart failure include: long-standing hypertension; 
myocardial infarction or ischaemia associated with coronary heart disease; 
myocarditis due to an infectious agent; congenital malformations; familial 
hypertrophic and dilated cardiomyopathies; and diabetic cardiomyopathy (Heineke 
and Molkentin, 2006). In each case the heart attempts to overcome the primary 
defect before myocardial failure develops (reviewed by Opie, 2004). Here, cardiac 
ischaemia/reperfusion injury and hypertrophy will be discussed in turn.
1.2.1 Ischaemia
Ischaemia exists when the blood supply is insufficient to meet the normal levels of 
oxidative metabolism (reviewed by Opie, 2004). Ischaemia in the heart can lead to a 
decline in heart function and when severe it can lead to irreversible damage to the 
heart muscle. The heart initially adapts to the state of ischaemia by reducing the rate 
of contraction and increasing the rate of anaerobic energy production by glycolysis. 
The aim of these adaptations is to avoid cell death. After the onset of ischaemia 
there is a rapid decline in intracellular phosphocreatine, a high energy phosphate 
which helps preserve levels of ATP, and is one of the main signals to reduce 
contraction and probably to increase glycolysis (Kloner and Jennings, 2001).
During ischaemia there are changes in fatty acid metabolism, leading to the 
accumulation of metabolites that have various inhibitory effects on cell function, and 
an increase in phospholipase mediated breakdown of phospholipids into products 
that may adversely affect membranes (reviewed by Opie, 2004). The levels of 
calcium increase and as ATP decreases the energy-requiring sodium pumps fail with 
consequent increases in sodium and loss of potassium. There is an accumulation of 
CO2 and protons in ischaemic tissue that decreases the pH from the normal value of 
approximately 7.0 to 6.5 (Cross et al., 1995).
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Myocardial Ischaemia may manifest itself in contractile failure, chest pain known as 
angina, shortness of breath and electrocardiographic changes. Myocardial infarction 
(MI) is the event went ischaemic tissue becomes irreversibly damaged with 
consequent cell death of ventricular myocytes.
1.2.2 Ischaemia/reperfusion injury
Reperfusion is necessary for salvaging the ischaemic myocardium, however, a 
paradox exists in that reperfusion can result in enhanced levels of tissue injury and 
increased infarct size (Eefting et al., 2004). The events that occur when the 
ischaemic myocardium is reperfused include a fall in diastolic pressure (DP), reduced 
developed pressure (dP), states of myocardial dysfunction known as stunning and 
hibernation, arrhythmias and cell death. These events are collectively known as 
ischaemia/reperfusion (I/R)-injury or simply, reperfusion injury (Opie, 1989). I/R- 
injury triggers a cascade of key pathogenic cellular events such as a massive influx of 
calcium, mitochondrial damage and rapid depletion of high-energy stores, leading to 
both necrotic and apoptotic cell death (Searabelli et al., 2002). Cell death after injury, 
and the form that it takes, is largely dependent on levels of intracellular ATP and 
other high-energy phosphates (Leist and Nicotera, 1997). For example, viable cells 
have an ADP:ATP ratio of <0.11, apoptotic cells a ratio between 0.11 and 1.0 and 
necrotic cells a ratio up to 15 (Bradbury et al., 2000). The degree of myocyte death 
and severity of haemodynamic consequences are major determinants of the clinical 
outcome of I/R-injury, and therapies for MI must improve both cell survival and 
promote mechanical recovery (Scarabelli et al., 2002).
Evidence that reperfusion causes damage has been demonstrated in studies that 
have shown the extent of the damage can be reduced when therapy is given at the 
point of reperfusion. For example, in a canine model of I/R injury, when adenosine 
was given at reperfusion there was significant reduction in the infarct sizes compared 
to hearts that were not given adenosine (Olafsson et al., 1987).
The most common cause of myocardial ischaemia is coronary artery disease, also 
known as atherosclerosis, and the main risk factors for atherosclerosis are high 
cholesterol, hypertension and tobacco smoking. Atherosclerosis is an inflammatory 
disease that renders the endothelium of arterial vasculature susceptible to the uptake 
of inflammatory cells and lipoprotein molecules thereby creating a lesion that is a
25
Chapter O n e ______________________________________________________ Introduction
mixture of inflammation and fat (Ross, 1999). Atherogenesis is the process that 
refers to the development of these lesions, also known as atheromatous plaques. As 
a lesion develops, there is narrowing of the lumen of the artery thereby reducing the 
blood flow. Partial obstruction is not usually sufficient to cause MI. However, when a 
lesion ruptures, and becomes unstable, this precipitates a thrombus (blood clot) at 
the site of the lesion resulting in complete obstruction of the flow of blood. The 
region of cardiac tissue supplied by an occluded coronary artery is described as the 
area at risk.
1.2.3 Oxidative stress in I/R-injury
Free radicals are highly reactive chemical species with unpaired electrons in their 
outer orbitals. Those derived from oxygen, such as superoxide anion ( O2-) and 
hydroxyl ( 0H-), are called reactive oxygen species (ROS). ROS are mainly derived 
from mitochondria as by-products of oxidative phosphorylation. ROS are involved in 
biological processes, for example, nitric oxide ( NO) is a signalling molecule that 
regulates vascular tone. However, excessive production of ROS causes damage to 
lipids, proteins and DNA (Esposito et al., 1999, Melov et al., 1999).
ROS are generated when oxygen is reintroduced to ischaemic tissue. ROS mediated 
reperfusion injury has been reported in a number of tissues including the heart 
(Becker, 2004). In early reperfusion of the heart a 'bursT of ROS generation has 
been observed (Bolli et al., 1989a, Wang et al., 1998). In a canine model of I/R 
injury, reperfusion mediated generation of ROS contributed to reperfusion injury 
(Bolli et al., 1989b).
The generation of ROS are normally kept in check by endogenous free radical 
scavengers. Such scavengers include the enzymes superoxide dismutase (SOD) and 
glutathione reductase, and also non-enzymatic scavengers such as vitamin A. The 
experimental use of free radical scavengers in models of I/R-injury lends further 
support to the role of oxidative stress in I/R-injury. The free radical scavenger, 
epigallocatechin-3-gallate (ECGC), is a constituent of green tea and has been shown 
to protect cultured neonatal rat cardiac myocyte cells from I/R injury (Townsend et 
al., 2004b).
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1.2.4 Mitochondrial damage in I/R-injury
In cardiac myocytes the primary role of mitochondria is to provide sufficient ATP 
through oxidative phosphorylation to meet the high-energy demands of the beating 
heart. When inhibition of oxidative phosphorylation occurs in ischaemia, glycolysis 
alone is unable provide sufficient ATP, leading to heart dysfunction. Mitochondrial 
damage may occur under stressful conditions leading to loss of the mitochondrial 
membrane potential (Am'P), resulting in cell death.
The mitochondrial permeability transition pore (MPTP) is a non-specific pore in the 
mitochondrial inner membrane of which the core components are the adenine 
nucleotide translocase (ANT) and cyclophilin D (CyP-D) (Halestrap et al., 2004). 
Under normal conditions the pore is closed, however, in stressful conditions such as 
reperfusion there is opening of the pore. Normally the inner mitochondrial membrane 
is only permeable to a few selected metabolites and ions, however, all molecules 
under 1.5 kDa may pass freely through an open MPTP (Crompton, 1999). When the 
MPTP opens, the permeability barrier of the inner mitochondrial membrane becomes 
disrupted with two major consequences. Opening of the pore allows passage to small 
molecular weight solutes but not proteins, and this results in an osmotic pressure 
that causes the mitochondria to swell. Swelling causes the outer membrane to 
rupture with release of proteins such as cytochrome c and apoptosis inducing factor 
(AIF), which are involved in apoptosis. Secondly, the inner membrane becomes 
freely permeable to protons which causes uncoupling of oxidative phosphorylation 
from ATP synthesis thereby reducing the available supply of ATP in the cell 
(Halestrap et al., 2004). If the pore remains open the cell will undergo irreversible 
damage resulting in necrotic cell damage and even if it closes it may undergo 
apoptosis since there was release of proapoptotic molecules such as cytochrome c 
and AIF (Halestrap et al., 2004).
The principal factor responsible for MPTP opening is mitochondrial calcium overload, 
especially when this is accompanied by oxidative stress, adenine nucleotide 
depletion, elevated phosphate concentrations, and mitochondrial depolarisation 
(Halestrap et al., 2004). These are exactly the conditions that exist in reperfusion 
and there is evidence that MPTP opening is important in the transition from 
reversible to irreversible reperfusion injury (Crompton, 1999). Inhibitors of MPTP 
opening have demonstrated that reperfusion injury is mediated by the opening of
27
  __________________________________   Introduction
this pore. Sanglifehrin A (SfA), an inhibitor of MPTP opening, was able to reduce 
reperfusion injury in the isolated rat heart (Clarke et al., 2002).
Tetra methyl rhodamine methyl ester (TMRM) and mitotracker are fluorescent dyes 
used experimentally in isolated cardiac myocytes to measure changes in the 
mitochondrial potential as an index of MPTP opening and mitochondrial damage. 
TMRM and mitotracker have a net positive charge and accumulate in the negative 
environment of healthy mitochondria. However, opening of MPTP and concomitant 
reduction in membrane potential results in loss of TMRM or mitotracker. In the 
isolated perfused heart model, the mitochondrial entrapment of a radioactive marker, 
[^H]2-deoxyglucose (^H-DOG), is used to measure MPTP opening.
1.2.5 Cardiac hypertrophy
Cardiac hypertrophy is the process by which the ventricular myocytes and 
consequently the heart become larger in response to the increased wall tension 
caused by volume or pressure stress, mutations of sarcomeric proteins or loss of 
myocardial cells following I/R-injury. This results in left ventricular hypertrophy (LVH) 
and is characterised by an increase in thickness and mass of the left ventricular wall, 
which can normalise the wall tension. This compensatory response of the heart to 
increased workload is initially a mechanism that is physiologically normal in athletes, 
however, sustained hypertrophy in response to disease stimuli may increase the risk 
of cardiomyocyte loss and heart failure.
Sustained increases in haemodynamic function that are caused by either 
physiological or pathological stimuli eventually lead to changes in the heart/body 
weight ratio (reviewed by Opie, 2004). Different pathological stimuli cause distinctive 
forms of myocyte hypertrophy. Volume overload hypertrophy results in chamber 
dilation and cells have increased length due to addition of sarcomeric units in series. 
The elongation observed in volume overload hypertrophy is defined as eccentric 
hypertrophy. Chronic volume overload hypertrophy can result in irreversible loss of 
cardiac function. This type of hypertrophy is distinct to that caused by pressure 
overload where addition of sarcomeric units is not observed (Wollert et al., 1996). An 
increased pressure load causes a thicker myocyte and is defined as concentric 
hypertrophy. There are also differences observed between physiological and 
pathological induced hypertrophy. Exercise-induced hypertrophy is not normally
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associated with accumulation of collagen in the myocardium and only a small 
increase in ventricular wall thickness is observed (lemitsu et al., 2001).
Adult cardiomyocyte hypertrophy is characterised by increased cell size, enhanced 
protein synthesis and a higher organisation of the sarcomere. A key feature of 
hypertrophy is the activation of the foetal gene program. In response to 
haemodynamic load there are increases in immediate-early genes such as c-fos, c- 
myc and c-jun (reviewed by Opie, 2004), which are genes that are activated rapidly 
in response to certain stimuli and have been shown to regulate growth. The 
expression of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP) are also 
induced. There are changes in relative quantities of isoforms of sarcomeric proteins. 
For example, there is a relative decrease in the alpha form of myosin heavy chain 
(aMHC) and a relative increase in the beta form (pMHC).
The generation of ATP in the adult myocardium depends on the mitochondrial 
oxidation of long-chain fatty acids. Cardiac hypertrophy is associated with a reduction 
of fatty acid oxidation and metabolic reversion of the heart to increased glucose 
utilization, which is also a characteristic feature of the foetal heart (Depre et al., 
1998).
Although the hypertrophic response of the heart to pathological stimuli has been 
generally considered to be a compensatory response that becomes pathological, 
more recent evidence suggests that this initial response is not beneficial and that the 
entire process is maladaptive. For example, in surgically induced pressure overload in 
mice, inhibition of hypertrophy had no effect on haemodynamic function (Hill et al., 
2000). Therefore, this raises the hopes that therapeutic inhibition of hypertrophy 
would not interfere with a necessary function of hypertrophy in response to 
pathological stimuli.
1.3 Experimental systems for studying heart disease
There are three commonly used experimental systems in the investigation of heart 
function and disease; cultured cardiac cells {in vitro), the isolated perfused 
mammalian heart known as Langendorff perfusion {ex vivo) and in live animals {in 
vivo). Those studies that demonstrate their findings in vivo are often considered to
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be more significant than those demonstrated ex vivo, and ex vivo more significant 
than in vitro. The generally held belief is that in vivo experimentation is conducted in 
the natural context of the organism whereas ex vivo and in vitro systems are artificial 
ones. However, for various reasons all these systems are commonly used. For 
example, experiments in cultured cells are easier, cheaper and do not require the 
same licensing as working with animals. Moreover, one adult rodent heart or several 
rodent neonatal hearts provides enough cells to conduct many different experimental 
conditions compared to one in each in vivo or ex vivo experiment.
Experiments in vitro may be conducted in freshly isolated C'primary") cardiac 
myocytes or in immortalised cardiac myocyte cell lines. Two commonly used 
immortalised cell lines used are the H9c2 and CLEM cell lines derived from rat. 
Immortalised cell lines represent the most practical cardiac model, as they are readily 
available and relatively easy to maintain. However, freshly isolated myocytes are the 
preferred in vitro model, as immortalised cell lines have lost certain characteristics of 
cardiac myocytes, notably the terminal differentiated phenotype of adult cardiac 
myocytes. Of particular concern with immortalised cell lines would be the profile of 
activated genes in dividing cells and the effect this will have on investigating diseases 
that involve cell death because the protein products of these growth-promoting 
genes often promote resistance to cell death.
Primary cultures of human cardiac myocytes may be prepared from biopsies. 
However, as the possibility to obtain biopsies is limited the possibility of thorough 
investigation is difficult. Primary cultures of cardiac myocytes are most commonly 
isolated from neonatal mouse, rat or rabbit species. The neonatal rat cardiac 
myocyte (NRCM) preparation is probably the most commonly used in vitro cardiac 
model. However, since the advent of transgenic mice the use of neonatal mouse 
cardiac myocyte (NMCM) cells is increasing.
A preparation of cardiac myocytes from neonatal rodents is often chosen instead of 
adults because they are comparatively simple to prepare. However, the phenotypical 
differences that exist between adult and neonatal cells make it difficult to interpret 
predominantly adult related conditions such as ischaemia when conducted in 
neonatal cells. For example, unlike adult cells, neonatal cells have been shown to 
grow and regenerate as they can readily maintain and assemble myofibrils (Rothen- 
Rutishauser et al., 1998). Calcium handling has been shown to be different between
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neonatal and adult cardiac myocytes; the Immature myocardium has a reduced 
ability to sequester calcium and produces smaller L-type calcium currents (Maginot et 
al., 1998). There is also lower phosphodiesterase activity in NRCM cells (Picq et al.,
1995), which implies differences in cyclic nucleotide signalling. Thus, although 
neonatal cardiac myocyte cultures are an important system many studies often 
extend their investigations into adult rat ventricular cells (ARVC) or adult mouse 
ventricular cells (AMVC).
The isolated perfused mammalian heart was developed by Oscar Langendorff in 
1897, hence it is also known as Langendorff perfusion. Crystalloid perfusates are 
delivered to the heart by retrograde perfusion via a canula inserted in the ascending 
aorta. The Langendorff perfusion model was first applied in the study of heart 
biology and later on to test the effects of cardiovascular drugs and single gene 
alterations on heart function and to identify novel therapies to protect the heart from 
ischaemia and other insults (Skrzypiec-Spring et al., 2007). Limitations of the 
Langendorff model include the absence of normal neurohumoral influences and 
neuronal regulation. However, the isolated perfused heart is sometimes preferred to 
an in vivo approach, as it allows assessment of the direct effect of cardioprotective 
agents in the absence of interfering peripheral haemodynamic and neurohumoral 
alterations (Scarabelli et al., 2002).
In vivo experimentation is the gold standard for assessing the effect of drugs in 
cardiovascular function and disease. The most commonly used in vivo model of I/R- 
injury is conducted in the rat or mouse, whereby ischaemia is induced by ligature of 
the left coronary artery and subsequently released to allow reperfusion.
Transgenic mice are used to assess the role of any given gene product in 
cardiovascular function and disease. This may be achieved by targeted deletion of 
specific genes to generate "knockout" mice or by introduction of specific mutations to 
generate "knock-in" mice. Alternatively, transgenes are introduced to mice to over­
express specific genes. Transgenic animals may then be used for in vivo experiments 
or cardiomyocytes or whole hearts may be isolated for in vitro or ex vivo 
experimentation respectively.
Some transgenic systems may be more sophisticated, whereby the expression of the 
transgene may be regulated temporally and/or spatially. The tetracycline (Tet)-
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inducible system facilitates regulated expression of foreign genes in cultured 
mammalian cells (Gossen and Bujard, 1992), in vivo (Fishman et al., 1994) and in 
transgenic animals (Passman and Fishman, 1994). The Tet-inducible system is 
based on the regulatory elements of the TnlO-specified tetracycline-resistance 
operon in Exoli, in which transcription of resistance-mediating genes is negatively 
regulated by the tetracycline repressor {tetR). In the presence of tetracycline, the 
tetR does not bind to its operators located within the promoter region of the operon, 
enabling transcription of resistance genes (Figure 1.2A). By combining tetR with the 
C-terminal domain of VP16 from herpes simplex virus (HSV), which is known to be a 
strong transactivator, a hybrid transactivator known as the tetracycline transactivator 
(tTA) was generated that stimulates minimal promoters fused to the tetracycline 
operator {tetO) sequences (Gossen and Bujard, 1992) (Figure 1.2B). These 
promoters are virtually silent in the presence of low concentrations of tetracycline or 
derivatives of tetracycline (e.g. doxycycline), which prevents the tetracycline- 
controlled tTA from binding to tetO sequences. Thus, this system is known as the 
Tet-off system. A variant of the Tet-off system is the Tet-on system. The tTA protein 
used in the Tet-on system differs from the Tet-Off transactivator by four amino 
acids. The Tet-on transactivator binds the tetO and induces gene expression only 
when bound by tetracyclines (Figure 1.2C).
By using a tTA expression plasmid and a tTA responder plasmid in which a gene of 
interest is inserted, tetracycline regulated expression was achieved in cultured cells 
and subsequently in vivo (Fishman et al., 1994). Furthermore, by using tissue 
specific promoters to drive expression of the tTA, transgenic mice can be generated 
in which expression of tTA target genes can be restricted to selected tissues (Figure 
1.3). The generation of transgenic mice expressing tTA under the control of a rat a 
myosin heavy chain promoter (aMHC-tTA mice) restricts expression of the tTA in the 
heart only. Thus, when mated with mice harbouring tTA responsive transgenes, only 
the progeny inheriting both transgenes will express the target gene, and expression 
will be restricted to those cells that would normally express aMHC, cardiac myocytes 
(Passman and Fishman, 1994, Redfern et al., 2000).
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Figure 1.2 The Tet-inducible system. (A) The Tet-inducible system is based on 
the Tet operon from E.coli. The tet repressor (tetR) protein binds the Tet operon and 
inhibits the expression of the tetracycline resistance gene. Tetracycline binds tetR 
and alters its conformation, preventing it from binding the tetO and thereby allowing 
expression of the tetracycline resistance gene. (B) The tTA system (Tet-off): the tTA 
protein is a hybrid of tetR and the C-terminal domain of the VP16 transcriptional 
transactivator from herpes simplex virus. The tTA protein stimulates minimal 
promoter sequences, such as the cytomegalovirus promoter (CMV), fused to the tetO 
and induces gene expression. Tetracycline binds tTA and inhibits expression. (C) The 
rtTA system (Tet-on): a mutant of tTA, rtTA, differs in sequence to tTA at four amino 
acids. In this system, Tet-on, tetracycline binds to and alters the conformation of 
rtTA, enabling it to bind fefOand induce gene expression.
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Figure 1.3 Generating transgenic mice using the tTA system. The tTA system 
(or rtTA system) in transgenic mice is a binary system requiring two distinct 
transgenics to be produced. The Tet-mouse carries the tTA transgene. The Tet- 
responder mouse carries the transgene for the gene of interest to be expressed, 
which is fused to the fett>minCMV promoter. These mice are bred with each other to 
produce compound transgenic mice carrying both transgenes. These mice will 
express tTA, which will induce expression of the Tet-responsive transgene. 
Expression will be inhibited in mice given tetracycline, or derivatives of tetracyclines. 
In the rtTA system, compound transgenic mice will only express the Tet-responsive 
transgene when given tetracycline, or its derivatives. Regulation of spatial expression 
in the tTA system is achieved by choosing an appropriate promoter for the 
expression of the tTA gene in a particular tissue. The promoter of the aMHC gene is 
used restrict expression of tTA and responder transgene to the heart.
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1.4 Signal transduction
Signal transduction is the process by which cells receive and convert one kind of 
signal or stimuli into another and is important for normal physiological function and 
the development of disease. These signals ultimately lead to an array of cellular 
responses such as growth, differentiation, migration, division and death. These 
signals are translated, or "transduced", by ordered sequences that involve 
biochemical reactions inside the cell, which are mediated by proteins and may 
involve altered messenger RNA (mRNA) and protein synthesis. These sequences are 
referred to as signal transduction pathways or cascades whereby the signalling 
mediators involved nearer the apex of the pathway are "upstream" of those 
mediators that follow "downstream". These pathways enable the cell to enact an 
appropriate response for a given signal. "Crosstalk" is when mediators of distinct 
pathways interact and the term "convergence" is used to describe when signal 
transduction pathways affect a common target.
Kinases are enzyme proteins that play a key role in mediating signal transduction 
pathways by activating or repressing other proteins. This activity of kinases occurs in 
the form of phosphorylation, the process by which they catalyze the transfer of a 
phosphate group from ATP and its covalent attachment to the protein at specific 
amino acid residues. Cascades of kinases exist whereby upstream kinases 
phosphorylate downstream kinases. Transphosphorylation is the process of a protein 
being phosphorylated by a kinase. However, kinases may also phosphorylate 
themselves, thereby undergoing autophosphorylation. Stimulation of signal 
transduction pathways may result in phosphorylation of transcription factors, proteins 
that bind deoxyribonucleic acid (DNA) and regulate the synthesis of mRNA for 
specific genes. Altered synthesis of mRNA may lead to altered levels of the 
corresponding protein in the cell. Enhancing the quantity of a specific protein in the 
cell may result in increasing the effect of a particular function performed by that 
protein, and vice versa for reducing the quantity of a protein. Although some 
signalling pathways require synthesis of new proteins to produce the intended effect, 
some pathways require only existing proteins in the cell to execute the intended 
signal.
Signals that mediate communication between cells usually take the form of small 
molecules that bind cell surface-receptors, specific proteins in the plasma membrane
35
Introduction
of the cell, and initiate downstream events inside the cell. For example, 
neurotransmitters such as acetylcholine (ACh) are chemical messengers that signal 
from one neuronal cell to another by binding ion channels, proteins that form pores 
in the plasma membrane and allow passage of specific ions in order to propagate an 
action potential (Kistler et al., 1982). Cytokines such as tumour necrosis factor a 
(TNFa) and peptide hormones such as insulin are small proteins that bind plasma 
membrane receptors and regulate a variety of cellular events including activation of 
inflammatory cells and metabolism of glucose respectively. However, steroids 
represent a type of extracellular signalling molecule that crosses the plasma 
membrane of the cell because of their lipophilic and hydrophobic nature. Steroids 
locate their specific intracellular receptor, usually a transcription factor kept inactive 
by proteins known as chaperones, inside the cytoplasm or nucleus of the cell (Beato 
et al., 1996).
The endocrine system represents the organs of the body that synthesise signalling 
molecules, termed hormones, which are secreted systemically and may reach all the 
tissues in the body via the blood. However, signalling molecules may be synthesised 
and excreted by cells that then act locally on other cells, a process known as 
paracrine signalling, or they may act on the cell from which it was secreted in what is 
then described as autocrine signalling.
Cell surface receptors are transmembrane proteins that consist of extracellular and 
intracellular domains. Binding of a molecule, or ligand, to a cell-surface receptor 
stimulates a series of events in the cell, with different types of receptor stimulating 
different intracellular responses. Three major types of cell-surface receptors are; 
receptors that themselves act as ion channels; receptors that themselves act as 
enzymes or are closely associated with cytoplasmic enzymes; and G-protein coupled 
receptors (GPCRs).
Receptor tyrosine kinases (RTKs) are transmembrane proteins with a ligand binding 
extracellular domain and an intracellular kinase domain. Ligand binding of the 
receptor initiates an interaction between two identical receptors to form a dimer. 
Dimer formation results in autophosphorylation of tyrosine residues within the 
cytoplasmic tyrosine kinase domains of RTKs causing their conformation to change. 
This results in the kinase domain of the receptor being activated, initiating a
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signalling cascade of phosphorylation of downstream cytoplasmic molecules (Li and 
Hristova, 2006).
GPCRs are a family of membrane proteins composed of seven-transmembrane 
domains, and are linked to a guanine nucleotide binding protein (G-protein). GPCRs 
represent the largest category of plasma membrane receptors including adrenergic 
receptors, olfactory receptors and opioid receptors. Ligand binding of the receptor 
will alter its conformation and will activate the bound G-protein. The activated G- 
protein will dissociate from the receptor and diffuse along the inner plasma 
membrane to interact with downstream proteins. These proteins are either ion 
channels or enzymes that mediate the next step in the pathway. These enzymes 
catalyze the generation of "second messengers" that relay the message from the 
plasma membrane to inside the cell. Gg-protein (subscript s denotes stimulatory) 
activates the enzyme adenylyl cyclase, which catalyzes the conversion of adenosine 
triphosphate (ATP) to cyclic 3%5'-adenosine monophosphate, called simply cyclic AMP 
(cAMP). Inside the cell cAMP binds to and activates cAMP-dependent kinase, which is 
known to phosphorylate several other kinases in pathways that lead to many 
different cellular responses.
1.5 Cell death
Cell death is an important feature of normal physiology and disease and occurs in 
different forms, the best understood being necrosis (oncosis) and apoptosis, 
although there is growing evidence for a third form of cell death known as 
autophagy. Necrosis is a rapid and irreversible process that occurs when cells are 
severely damaged. The characteristic morphology of necrosis includes swelling of the 
cell and its organelles, disruption of mitochondria, membrane rupture, and cell lysis 
(Searie et al., 1982). The contents released from the lysed cell act as a stimulus for 
inflammation with macrophage infiltration, fibroblast activation, and ultimately scar 
formation. Apoptosis is a mechanism of cell death morphologically distinct from 
necrosis with accompanying biochemical hallmarks that are unique to apoptotic cell 
death. These morphological characteristics include cell shrinkage, chromatin 
condensation, DNA fragmentation, membrane blebbing and formation of apoptotic 
bodies (Kerr et al., 1972). Biochemical techniques for the detection of characteristic 
features of apoptosis have been developed and are commonly used experimentally
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for identifying apoptosis and the signalling pathways that contribute to this form of 
cell death. For example, Terminal transferase dUTP nick end labelling (TUNEL) is a 
method commonly used for detecting DNA fragmentation (Gavrieli et al., 1992). 
Another commonly used method is annexin V labelling of phosphatidylserine (PS), a 
phospholipid found within the plasma membrane of the cell. Annexin V is a 
phospholipid binding protein with high affinity for PS. PS is not normally exposed to 
the extracellular environment. However, an early event in apoptosis is the 
externalisation of PS, enabling its detection by annexin V.
Apoptosis represents a mode of cell death that, unlike necrosis, is highly regulated by 
signal transduction pathways. Apoptosis is important in normal physiology, notably 
development, and is now recognised to contribute to the pathology of many 
diseases. Prevention of cell death is a desirable effect in diseases for which loss of 
non-renewable tissue is a pathogenic factor. Thus, dissection of the apoptotic 
signalling pathways involved in disease is required to provide a better understanding 
of this process and how these pathways may be targeted therapeutically.
1.5.1 Apoptotic signalling pathways
Apoptosis has been found to be largely dependent on a family of proteases called 
caspases. However, there are also caspase independent mechanisms involved in 
apoptosis such as those involving apoptosis inducing factor (AIF) (Joza et al., 2001).
Caspases are cysteine proteases that were first implicated in apoptosis with the 
discovery that CED-3, the product of a gene required for cell death in the nematode 
Caenorhabditis elegans, is related to mammalian interleukin-lp-converting enzyme 
(ICE or caspase-1) (Miura et al., 1993, Thorn berry et al., 1992). The 'c' refers to a 
cysteine protease mechanism, whereas 'aspase' reflects their ability to cleave after 
aspartic acid (Alnemri et al., 1996). To date, fourteen members of the caspase (ICE- 
related protease) family have been identified, and although caspase-1 has no 
obvious role in cell death several other members of this protease family have distinct 
roles in inflammation and apoptosis (Thornberry and Lazebnik, 1998).
Caspases are similar in their amino acid sequence, structure and substrate specificity
(Nicholson and Thornberry, 1997). They are all expressed as precursor enzymes (30
to 50 kDa) that contain three domains; an NHz-terminal (prodomain of variable
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length), a large subunit (~20kDa), and a small subunit (~10kDa). Activation occurs 
as a result of proteolytic cleavage between domains, followed by association of the 
large and small subunits to form a heterodimer. The crystal structures of caspase-1 
and caspase-3 have been determined and in both cases two heterodimers associate 
to form a tetramer with two catalytic sites that appear to function independently 
(Walker et al., 1994, (Rotonda et al., 1996).
Two features of the precursor protein are key to the mechanism of activation of 
these enzymes; their cleavage sites and the NHz-terminal domain. All domains are 
derived from the proenzyme by cleavage at caspase consensus sites enabling 
activation by themselves and each other. Granzyme B, a serine protease, is the only 
other protein known to cleave caspases other than caspases themselves 
(Waterhouse and Trapani, 2002). Caspases are among the most specific of 
proteases, with an almost absolute requirement for cleavage after aspartic acid. The 
NHz-terminal domain is highly variable in sequence and length and determines where 
caspases function in the apoptotic cascade. Long prodomain caspases such as 
caspase-8 and caspase-9 are initiator caspases and exert their activity not on cell 
death directly, but by activating short prodomain caspases. Short prodomain 
caspases such as caspase-3 cleave numerous substrates that may result in apoptosis, 
and are termed effector caspases.
There are two well-characterized and distinctly different apoptotic signalling 
pathways. These are the extrinsic death-receptor dependent pathway (Figure 1.4) 
and the intrinsic mitochondrial dependent pathway (Figure 1.5). These pathways 
signal via distinct initiator caspases that then activate common effector caspases, 
which cleave target substrates resulting in disassembly of the cell (Boldin et al.,
1996).
Death receptors are a family of eight plasma membrane receptors that belong to the 
tumour necrosis factor (TNF) superfamily of receptors. The death receptor pathway 
involves the binding of extracellular death signal proteins such as TNF-la and Fas 
ligand to their cognate cell surface receptors. This leads to intracellular association of 
proteins that interact through a conserved region known as the death domain (DD), 
one example of which is Fas-associated death domain (FADD) protein that binds to 
the Fas receptor. FADD then recruits procaspase-8 through the death effector 
domain (DED) resulting in autoprocessing of procaspase-8 molecules that then 
activate downstream caspases such as caspase-3.
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The intrinsic mitochondrial dependent pathway for caspase activation involves 
mitochondrial derived cytochrome c and apoptosis protease activating factor-1 (Apaf- 
1) protein mediated activation of caspase-9. Apoptotic stimuli that permeabilise the 
outer mitochondrial membrane facilitate the release of cytochrome c into the 
cytoplasm, enabling it to bind to Apaf-1. This complex, which also involves binding of 
dATP to Apaf-1, recruits procaspase-9 through its caspase recruitment domain 
(CARD) to complete the structure known as the apoptosome. At the apoptosome, 
procaspase-9 is cleaved to produce active caspase-9, which then cleaves procaspase- 
3 to produce the active form (Li et al., 1997).
In addition to caspases -8 and -9, more recent studies also indicate an initiator role 
for caspase-2 (Lassus et al., 2002, Robertson et al., 2002). These findings suggest 
that in some cells caspase-9 may not be the initiator caspase in stress-mediated 
apoptosis because caspase-2 is required upstream of mitochondria for the release of 
cytochrome c and other apoptotic factors (Read et al., 2002).
The substrates targeted for cleavage by caspases and the subsequent contributions 
made to apoptotic cell death are varied. One class of substrates are those that are 
activated by caspase cleavage, which include the caspases themselves. However, 
caspases also inactivate proteins that protect living cells from apoptosis. One target 
for cleavage is I^/DFF45 (Enari et al., 1998), which is an inhibitor of the nuclease 
responsible for the fragmentation of DNA, CAD (caspase-activated 
deoxyribonuclease). CAD and its inhibitor exist as a complex in non-apoptotic cells, 
however, during apoptosis the inhibitor is inactivated by caspases, leaving CAD free 
to function as a nuclease. Another example of protein inactivation that leads to 
apoptosis is that of poly (ADP-ribose) polymerase (PARP), one of the earlier 
discovered substrates of caspases that is an early marker of apoptosis (Lazebnik et 
al., 1994). PARP-1 protects the genome by responding to DNA damage and 
facilitating DNA repair and loss of PARP-1 results in chromatin condensation and DNA 
fragmentation (Shall and de Murcia, 2000).
Other targets for caspases that contribute to apoptosis include direct disassembly of 
cell structures. For example, caspases mediate the destruction of nuclear lamina, a 
rigid structure that underlies the nuclear membrane and is involved in chromatin 
organisation (Takahashi et al., 1996). Head-to-tail polymers of intermediate filament
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proteins called lamlns form lamina. During apoptosis, lamins are cleaved at a single 
site by caspases, causing lamina to collapse and contribute to chromatin 
condensation (Thornberry and Lazebnik, 1998). Caspases also disrupt cell structures 
indirectly by cleaving several proteins involved in cytoskeleton regulation, including 
gelsolin (Kothakota et al., 1997), focal adhesion kinase (FAK) (Wen et al., 1997), and 
p21-activated kinase 2 (PAK2) (Rudel and Bokoch, 1997).
There are many anti-apoptotic proteins that exert their activity by disrupting the 
caspase pathways. This effect is quite often mediated by proteins competing with 
caspases for binding sites in caspase adaptor molecules. Many of these proteins are 
splice variants of caspases themselves that lack the catalytic domain that is required 
for cleavage and therefore compete with the active form. Others are products of 
distinct genes that contain the binding domains found in caspases and compete in a 
similar manner. Caspase-9 short (C9s) is a splice variant of caspase-9 that lacks the 
central large subunit that contains the catalytic site. The variant C9s competes with 
its full length counterpart for binding APAF-1 in the apoptosome but because it does 
not contain the catalytic site apoptosis is reduced because of the reduction in active 
caspase-9 binding APAF-1 (Srinivasula et al., 1999). Cellular flice-like inhibitory 
protein (c-FLIP or FLIP) bears sequence homology to caspase-8 and inhibits caspase- 
8 mediated apoptosis. c-FLIP contains the DED found in caspase-8 that is required 
for recruitment to the Fas adaptor molecule FADD. Binding of c-FLIP to FADD results 
in a reduction of caspase-8 processing and a subsequent reduction in apoptosis 
(Scaffidi et al., 1999).
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Figure 1.4 The extrinsic (death-receptor) apoptotic signalling pathway.
Death receptor binding of cognate ligand, such as Fas/FasL, leads to activation of the 
extrinsic apoptotic signalling pathway. Fas/FasL binding results in recruitment of the 
adaptor protein, fas-associated death domain protein (FADD), through the death 
domains (DD) of FADD and the intracellular part of Fas receptor. Procaspase-8 is 
then recruited to the FasR/FADD complex and associates with FADD through death 
effector domains (DED). Autoproteolysis of procaspase-8 results in cleavage of the 
prodomain containing the DED domain, the large and small subunits. Association of 
the large and small subunits form the active caspase-8 protein, which then cleaves 
caspase-3. Caspase-3 cleavage results in association of its large and small subunits 
and formation of the active caspase-3 protein. Activated caspase-3 then cleaves 
substrates leading cell death.
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Figure 1.5 The Intrinsic (mitochondrial) apoptotic signalling pathway.
Mitochondrial Injury that results in release of cytochrome c activates the intrinsic 
apoptotic signalling pathway. Association of apoptosis activating factor (APAF-1) and 
procaspase-9 through their caspase recruitment domains (CARD), cytochrome c and 
dATP form the apoptosome. Formation of the apoptosome results In autoproteolysis 
of procaspase-9 and cleavage of the prodomain containing the CARD domain, the 
large and small subunits. Association of the large and small subunits form the active 
caspase-9 protein, which then cleaves caspase-3. Caspase-3 cleavage results In 
association of its large and small subunits and formation of the active caspase-3 
protein. Activated caspase-3 then cleaves substrates leading cell death.
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Apoptosis inducing factor (AIF) is a phylogenetically ancient mitochondrial 
flavoprotein that has been implicated in apoptosis and acts in a caspase-independent 
manner. Similar to cytochrome c, AIF is released from the intermembrane space of 
the mitochondria following the reduction of the mitochondrial membrane potential 
(AmW), the key mechanism allowing translocation of various proteins in the 
mitochondrial apoptotic pathway. However, unlike cytochrome c, AIF is not known to 
associate with any caspases but is instead shuttled directly to the nucleus where it 
induces peripheral chromatin condensation and large-scale DNA fragmentation.
1.5.2 Apoptosis In I/R-injury
Loss of myocardial cells is a major pathogenic factor following I/R injury (MacLellan 
and Schneider, 1997). Adult cardiomyocytes are terminally differentiated cells and 
once destroyed are rarely replaced (Gill et al., 2002). Although a large portion of cell 
loss during cardiac I/R occurs through necrosis (Buja and Entman, 1998), much 
research has provided evidence that apoptosis contributes to this loss. Apoptosis has 
been observed in cultured NRCM cells following hypoxia (Tanaka et al., 1994), 
although in the rabbit heart apoptosis was only observed when hypoxia was followed 
by reperfusion (Gottlieb et al., 1994). Although re perfusion is required to reduce the 
extent of apoptosis following ischaemia it accelerates apoptosis in cells that have 
already entered the apoptotic cascade (Fliss and Gattinger, 1996).
Caspase-dependent apoptosis in I/R injury has been demonstrated with the use of 
caspase inhibitors. Yaoita and colleagues demonstrated that hearts of rats that were 
subjected to I/R by coronary occlusion showed reduced infarct size and fewer 
apoptotic cells when the rats were also treated with zVAD-fmk (a global caspase 
inhibitor) (Yaoita et al., 1998). However, specific caspase inhibitors have enabled a 
better understanding of the caspase pathways involved in I/R injury. For example, 
use of specific chemical and genetic inhibitors have been used to examine the 
relative contributions of initiator caspases in apoptosis of cardiac myocytes during 
ischaemia versus reperfusion injury (Stephanou et al., 2001a). Data from this study 
suggests that ischaemia induces apoptosis through the mitochondrial mediated 
caspase-9 pathway and reperfusion-induced cell death is additionally mediated via 
the death receptor mediated caspase-8 pathway.
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The roles of caspases in apoptosis have been assessed using transgenic mice. Heart- 
targeted over-expression of caspase-3 in mice increases infarct size and depresses 
cardiac function (Condorelli et a!., 2001). These transgenic mice, which constitutively 
express caspase-3 under the rat a-myosin heavy chain promoter, had depression of 
cardiac function and abnormal nuclear and myofibrillar ultra-structural damage. 
When subjected to I/R, the hearts of these mice also showed increased infarct size.
Several lines of caspase-deficient mice have been generated that exhibit cell death 
abnormalities (Bergeron et al., 1998, Kuida et al., 1998, Woo et al., 1998). These 
knockouts do not exhibit a global suppression of cell death, but rather tissue- and 
cell type-specific or stimulus-dependent defects of apoptosis (Kuida et al., 1998). The 
preferential apoptosis defects suggest that different sets of caspases are involved in 
separate cell death pathways in vivo.
1.5.3 Additional regulation of apoptosis in I/R-injury
Stressful conditions such as ischaemia and reperfusion induce apoptosis via the 
death receptor or mitochondrial pathways. However, extracellular molecules acting 
on other cell surface receptors activate intracellular signalling pathways that 
modulate these apoptotic programmes. Multiple signalling pathways are activated in 
ischaemia and/or reperfusion and some of these pathways may promote cell death 
whereas others are involved in cell survival. A number of studies have implicated the 
mitogen activated protein kinase (MARK) pathway as a survival pathway in both 
cardiac cells (Adderley and Fitzgerald 1999, Maulik 1996, Sheng 1997) and other cell 
types (Allen 1999, Cano and Mahadevan 1995, Cobb and Goldsmith 1995, Downward 
1998, Schaeffer and Weber 1999, Xia 1995). Extracellular regulated kinase (ERK), 
one sub-family of MAP kinases, is composed of the kinases p42 and p44; their names 
denote their size in kilodaltons. Phosphorylation and activation of p42/p44 MARK is 
mediated by MAP kinases MEK (MARK kinase) 1/2. The MEKl/2-p42/p44 cascade can 
mediate cellular protection when activated in I/R (Yue et al., 2000). Activation of the 
phosphatidylinositol-3-OH kinase (PI3K)-protein kinase B (Akt) signalling cascade has 
also been shown to confer protection against I/R injury (Matsui et al., 1999, Matsui 
et al., 2001). Activation of the pro-survival pathways MEK1/2-ERK1/2 and PI3K-Akt in 
I/R has been named the reperfusion injury salvage kinase (RISK) pathway 
(Hausenloy and Yellon, 2004). However, activation of the p38 MARK signalling
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cascade has been demonstrated to promote apoptotic cell death In I/R Injury (Ma et 
al., 1999).
The targets of these signalling cascades may be components of apoptotic pathways 
such as caspases. For example, caspase-9 Is phosphorylated by ERK2 resulting In Its 
Inhibition and promotion of cell survival (Allan et al., 2003). Cell surface receptor and 
kinase cascade mediated regulation of apoptosis may occur through regulation of 
other Intracellular proteins that Influence cell death, such as the B-cell lymphoma-2 
(Bcl-2) family of proteins. The Bcl-2 family Includes pro- and anti apoptotic members 
that regulate mitochondrial membrane permeablllsatlon. Cardiac over-expresslon of 
the proapoptotic protein Bcl-2 attenuates apoptosis and protects against myocardial 
I/R Injury In transgenic mice (Chen et al., 2001). Langendorff perfused hearts from 
these mice showed Improved recovery compared to hearts from wild-type mice 
following I/R. When Bcl-2 transgenic mice were subjected to coronary artery 
occlusion followed by reperfuslon, transgenic hearts had significantly fewer TUNEL 
positive myocytes than hearts from non-transgenic llttermates. However, 
phosphorylation of Bcl-2 by p38 MARK has been demonstrated to Inhibit Its antl- 
apoptotlc potential (De Chlara et al., 2006)
Although Ischaemia Is essentially a damaging stimulus, short episodes of Ischaemia 
are able to protect against a subsequent more lethal dose of Ischaemia, a concept 
known as Ischaemic preconditioning (IRC). IRC was first described by Murry and 
colleagues (Murry et al., 1986) and Is one of the most powerful and consistent 
protectors against severe Ischaemia (reviewed by Opie, 2004). The protection 
conferred by IRC against subsequent ischaemia was found to last for 2-3 hours. 
However, a second window of protection occurring between 1-3 days after the Initial 
IRC episode has been described (Marber and Yellon, 1996).
Adenosine Is an endogenous trigger of classical IRC, which activates Its G-coupled 
receptor to transmit the signal to protein kinase C (RKC), which then leads to 
activation of the mitochondrial ATR-sensltlve potassium channel (K atp)  (Rrzyklenk et 
al., 1996, Speechly-DIck et al., 1995). Opening of mitochondrial Katp channels have 
been proposed to protect the mitochondria from calcium overload during I/R (Murata 
et al., 2001).
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1.6 Hypertrophic signalling pathways
Multiple signalling pathways have been shown to regulate the stimulation of 
hypertrophic growth. Two key pathways involved are the calcium-calcineurin 
pathway and the angiotensin II (A-II) pathways. Increases in intracellular calcium 
and binding of calmodulin lead to activation of calcineurin, an essential mediator in 
the growth response to pressure overload (Shimoyama et al., 1999). Calcineurin is a 
serine-threonine phosphatase that dephosphorylates transcription factors of the 
NFAT (nuclear factor of activated T-cells) family. Dephosphorylation of NFAT family 
proteins unmasks their nuclear localisation signals (NLS), which results in their 
translocation to the nucleus and gene induction. The role of the calcineurin/NFAT 
pathway in hypertrophy has been demonstrated in transgenic mice. Transgenic mice 
expressing constitutively active calcineurin develop enlarged hearts that leads to 
heart failure (Molkentin et al., 1998). A-II is released from the heart in response to 
mechanical strain (Amedeo Modesti et al., 2002). A-II binds its cognate membrane 
receptor to induce hypertrophy via multiple signalling pathways including the MARK 
pathway (Ruwhof and van der Laarse, 2000).
The MARK signalling pathway is involved in mediating hypertrophic signals, including 
those elicited by A-II stimulation. Over-expression of MARK phosphatase 1 (MKR-1), 
which inhibits different MARK signalling pathways, blocked both agonist-induced 
hypertrophy in vitro and pressure overload-associated hypertrophy in vivo (Bueno et 
al., 2001). MEK5 is involved in transducing hypertrophic signals that result in 
eccentric cardiomyocyte hypertrophy, which occurs in response to volume-overload 
induced myocyte growth (Nicol et al., 2001).
AlphalA-adrenergic agonists stimulate cardiac myocyte hypertrophy. Rhenylephrine 
(RE) is a potent hypertrophic drug that binds the alphalA-adrenergic receptor. 
Transduction of the RE signal involves activation of ERKl/2, p38 MARK and Akt. 
Hypertrophy induced by RE in NRCM cells has been demonstrated to be dependent 
on the ability of ERKl/2 to phosphorylate the transcription coactivator p300 and the 
highly related cAMR response binding protein (CREB)-binding protein (GBR) 
(Gusterson et al., 2002). The role of p300 as a transcriptional coactivator is found for 
basal and non-constitutive cardiac transcription factors. It has histone acetylase 
transferase (HAT) activity, which modifies associated transcription factors and 
chromatin by acétylation, thereby relaxing chromatin structure and promoting gene
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activation. Inhibition of p300 attenuates PE induced hypertrophy in NRCM cells 
(Gusterson et al., 2003) and mice deficient in p300 have reduced expression of 
aMHC and a-actinin resulting in structural defects (Yao 1998).
Enzymes known as histone deacetylases (HDACs) inhibit the HAT activity exhibited 
by transcriptional co-activators such as p300 thereby inhibiting physiological 
responses such as hypertrophy, which are dependent on de novo mRNA synthesis. 
HDACs inhibit hypertrophy through direct association with myocyte enhancer factor 2 
(MEF2), a transcription factor that positively regulates hypertrophic signalling 
pathways including the calcineurin pathway (Zhang et al., 2002). Several other 
signalling pathways have been shown to be involved in mediating hypertrophic 
signals. Various PKC isoforms have been implicated in mediating hypertrophy. For 
example, transgenic mice overexpressing PKC-p develop cardiac hypertrophy, which 
results in sudden death (Bowman et al., 1997).
There is evidence to suggest that physiological and pathological hypertrophy differ at 
the molecular level. lemitsu and colleagues found the mRNA expression levels for 
some hypertrophy-associated genes differed between spontaneously hypertensive 
and exercised rats (lemitsu et al., 2001). Therefore, it is important to further 
characterise hypertrophic signalling pathways and understand how pathological and 
physiological pathways differ in order to help identify the most suitable molecules to 
be targeted for therapy.
Thus far, some of the best understood signalling pathways that regulate I/R-injury 
and hypertrophy have been described. The role of the interferon-gamma and 
cardiotrophin-1 signalling pathways in the regulation of cardiac I/R-injury and 
hypertrophy will now be discussed.
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1.7 Interferon gamma signalling pathway
Interferon gamma (IFNy) belongs to a small family of cytokines named interferons 
(IFNs) that are secreted by cells of the immune system and have antiviral and 
antiproliferative effects. They were originally discovered by their ability to interfere 
with viral replication, hence the name interferon. IFNs are classified into three 
groups based on their amino acid sequence and recognition of cell-surface receptors. 
There are six type I IFNs and IFNy is the only type II Interferon. Recently, a third 
type of IFN was identified, named IFN-lambda (IFNX) (Ank et al., 2006).
IFNy is a peptide with a molecular mass of 17 kDa. Two molecules of IFNy interact to 
form a homodimer before binding its receptor. The IFNy receptor is expressed in 
nearly all cell types (Bach et al., 1997). The receptor consists of two polypeptides 
known as the alpha and beta chains or IFNGR-1 and IFNGR-2, which are 90 kDa and 
65 kDa respectively. The IFNy homodimer binds the IFNGR-1 chain but it does not 
interact directly with IFNGR-2, although IFNGR-2 is thought to stabilise IFNy and 
IFNGR-1 interaction (Ank et al., 2006).
The intracellular signalling cascade following IFN stimulation is mediated by the 
Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway 
(Darnell et al., 1994). Most STAT-activating cytokine receptors do not have intrinsic 
tyrosine kinase activity, however, their intracellular domains are closely associated 
with the tyrosine kinases known as Janus kinases (JAKs,) of which there are four 
members; JAKl, JAK2, JAK3 and TYK2 (Aaronson and Horvath, 2002). Binding of 
IFNy to its transmembrane receptor results in trans- and auto- phosphorylation of the 
intracellular IFNy receptor bound tyrosine kinases JAKl and JAK2 (Ihle, 1995).
JAK phosphorylation of IFN receptors creates docking sites on the receptor for latent 
transcription factors known as signal transducers and activators of transcription 
(STAT) proteins. Phosphorylation of STAT proteins by JAKs on activating tyrosine 
residues leads to homo- and hetero- dimérisation. STAT dimers then translocate to 
the nucleus where they bind their target promoters and act to enhance or repress 
gene transcription. STAT activation and translocation is a rapid process, occurring 
within minutes of receptor stimulation (Barry et al., 2007).
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1.8 Signal transducer and activator of transcription 1
The signal transducer and activator of transcription 1 (STATl) protein is a 
transcription factor that belongs to the family of STATs, which have been shown to 
play a role in development, cell growth, proliferation and apoptotic cell death 
(Stephanou and Latchman, 2003). To date, there are seven STAT family members 
that have been identified and are encoded by distinct genes (STATl, STAT2, STAT3, 
STAT4, STATS a, STATSp, STAT6) (Stephanou and Latchman, 2003, Murray, 2007). 
There are 24 exons in the STATl gene and the protein is expressed in two distinct 
isoforms, STATla (91 kDa) and STATlp (84 kDa), which are generated by 
alternative splicing (Schindler et al., 1992). STATs have a highly conserved structure 
consisting of amino terminal, coiled coil, DNA binding, linker, Src-homology-2 (SH2) 
and carboxyl transactivation domain (TAD) (Figure 1.6)
1.8.1 Activation of STATl
IFNy binding of the IFNGR-1 chain of the IFNy receptor results in phosphorylation of 
the intracellular domain, which creates a docking site for STATl (Greenlund et al., 
1994) (Figure 1.7). When STATl is recruited to the IFNy receptor interaction occurs 
via their SH2 domains. JAK phosphorylation and activation of STATl occurs at 
tyrosine residue Y701 in the transactivation domain (Shuai et al., 1993). Additional 
regulation of STAT function occurs by serine phosphorylation within the TAD (Decker 
and Kovarik, 2000). STATl transcriptional activity is enhanced by IFNy independent 
serine phosphorylation at residue S727 and it has been demonstrated that this is 
mediated by p38 MARK and PKCô (Kovarik et al., 1999, Uddin et al., 2002, DeVries et 
al., 2004). Serine phoshorylation may enhance transcriptional activity by the 
recruitment of co-factors. For example, serine phosphorylation of STAT3 has been 
shown to influence recruitment of the co-factor p300/CBP (Schuringa et al., 2001). 
The STATlp isoform lacks 38 amino acids encompassing the TAD, including the S727 
residue, and has been shown to be transcriptionally inactive and exerts a dominant- 
negative effect on gene activation by STATla (Baran-Marszak et al., 2004).
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Figure 1.6 The structure of STATl and experimental mutants. The 91 kDa
STATla protein is composed of the N-terminal, 4-Helix-Bundle (linker domain), DNA- 
binding, nuclear pore complex (NPC), Src-homology-2 (SH2) and transactivation 
domains (TAD). STATlp is 84 KDa and lacks the last 37 amino acids of STATla 
including the serine 727 site. STATl C-termlnal fragment, STATl fragment lacking 
TAD, STATl TAD and STATl TAD with serine 727 mutated to alanine are 
experimental mutants of STATl. The STATl fragment expressed in Statr^' mice is a 
truncated protein of 72 KDa.
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Figure 1.7 The Interferon gamma (IFNy) signalling pathway. Extracellular 
binding of IFNy and the IFNGR-1 chain of the IFNy pathway activates the intracellular 
Janus Kinase/Signal transducer and activator of transcription (JAK/STAT) pathway. 
Ligand binding results in tyrosine phosphorylation of the intracellular domains of the 
receptor by Jakl and Jak2, resulting in the recruitment of STATl to the receptor, 
which is also phosphorylated by Jakl and Jak2. Phosphorylated STATl molecules 
form dimers and are imported to the nucleus by p97, which interacts with the STATl 
dimer via NPI-1. STATl dimers induce synthesis of genes with gamma-activated 
sequences (GAS) in their promoters.
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1.8.2 Nucleocytoplasmic translocation of STATl
IFNy Stimulation results in the formation of STATl homodimers, which interact via 
their SH2 domains. STATl homodimers subsequently translocate to the nucleus 
through nuclear pore complexes (NPC), a network of pore forming proteins called 
nucleoporins found in the nuclear envelope. This movement is diffusion-controlled 
and not directed along permanent structures (Lillemeier et al., 2001). Some proteins 
are able to move within the cell and bind nucleoporins independently. However, 
STATl is an example of a cargo protein, which requires transport factors called 
importins and exportins to facilitate their movement in and out of the nucleus 
respectively (Wozniak et al., 1998). Recognition of cargo proteins by transport 
proteins occurs through amino acid sequences found on the cargo surface, for 
proteins shuttled in and out of the nucleus these are called nuclear localisation 
sequences (NLS) and nuclear export signals (NES) (Wozniak et al., 1998). The 
transport protein, p97 (importin-p), is an importin that directs activated STATl to the 
nucleus. STATl and p97 do not interact directly but are joined by NPI-1, an adaptor 
protein of the importin-a family (Sekimoto et al., 1996). Removal of STATl from the 
nucleus is mediated by the exportin named chromosomal regional maintenance 1 
(CRMl) (McBride et al., 2000).
The classic model of phosphorylation dependent STATl nuclear translocation is no 
longer definitive as un phosphorylated STATl has been shown to be constantly 
shuttling between the nucleus and the cytosol (Meyer et al., 2002). Binding the 
nucleoporins Nupl53 and Nup214 facilitate nuclear importation of unphosphorylated 
STATl. Nuclear export of STATl by CRMl was initially believed only to operate 
during termination of cytokine induced nuclear accumulation, however, it has been 
shown to function constitutively (Marg et al., 2004).
1.8.3 STATl gene transactivation
Over 200 genes are known to be regulated by IFNy (Boehm et al., 1997). These 
include major histocompatibility complex (MHC) genes, transcription factors, 
selectins, selectin ligands, chemokines, chemoattractants, integrins, cellular adhesion 
molecules, immunoglobulins, cytokines, cytokine receptors, tyrosine kinases and 
apoptosis-related genes (Boehm et al., 1997). STATl homodimers bind DNA in the
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promoter region of genes through the STATl DNA-binding domain. STATl 
homodimers recognise an 8- to 10-base pair inverted repeat element with a 
consensus sequence of 5'-TT(N4-6)AA-3', which is called a gamma activated sequence 
(GAS) element (Aaronson and Horvath, 2002).
STATl may be also be activated by type I IFNs. Type I stimulation results in the 
heterodimerisabon of STATl and STAT2. The STAT1/STAT2 dimer binds the protein 
interferon regulatory factor 9 (IRF9) to from a transcription-promoting complex 
known as interferon-stimulated gene factor 3 (ISGF3). This complex recognises a 
distinct DNA sequence in gene promoters, the IFN-stimulated response element 
(ISGF3), with the sequence S'-AGTTTNsTTTCM'.
1.8.4 Inhibition of STATl activity
Several different protein families mediate negative regulation of STATs in distinct 
ways. These negative regulators are essential for proper homeostasis of the immune 
response (Yoshimura et al., 2007). Suppressors of cell signalling (SOCS) proteins 
bind receptor sites and/or JAK catalytic sites in such a way as to block further STAT- 
protein activation (Yasukawa et al., 2000). SOCSl can inhibit JAK tyrosine activity 
through a kinase inhibitory region (KIR) found in SOCS proteins. A fragment 
corresponding to the KIR of SOCSl has been shown to inhibit JAK2 mediated 
phosphorylation of STATl (Waiboci et al., 2007).
A similar mechanism of inhibition exists for activated STATs, which are negatively 
regulated in the nucleus by protein inhibitor of activated stats (PIAS) proteins. PIAS 
proteins interact with only those STAT proteins that are tyrosine phosphorylated and 
block them from DNA binding (Greenhaigh and Hilton, 2001). For example, PIASl 
was shown to specifically inhibit gene activation by STATl (Liu et al., 1998).
Another mechanism of inhibition of activated STATs is carried out by tyrosine 
phosphatases. Phosphatases are enzymes that dephosphorylate proteins thereby 
reversing the effect of kinases. Dephosphorylation of STATs is mediated by 
phosphatases found in the cytosol and the nucleus. STATl has been shown to be 
inhibited by the nuclear phosphatase TC45 (ten Hoeve et al., 2002).
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1.8.5 Roles of STAT1
STATl is essential for mediating the immunoregulatory effects of IFNy. Mutations in 
genes encoding either chains of the IFNy receptor and STATl have been shown to 
result in enhanced susceptibility to mycobacterial infections (Newport et al., 1996, 
Jouanguy et al., 1996, Dupuis et al., 2001). Recently, humans with homozygous 
mutations in the alpha chain of the IFNy receptor were described (Noordzij et al., 
2007). Defects in the IFNy receptor-dependent signalling pathway were observed in 
these individuals. One became ill after Bacillus vaccination and subsequently died 
while the other suffered several infection episodes. The role of the IFNy/STATl 
pathway in host defence has also been demonstrated in mice. Transgenic mice that 
are deficient in either chains of the IFNy receptor have defects in their immune 
response, demonstrating that the receptor is necessary for killing intracellular 
pathogens, such as mycobacterium, by macrophages (Huang et al., 1993, Dalton et 
al., 1993). Transgenic mice lacking functional STATl are unresponsive to IFNy and 
are susceptible to viral disease (Durbin et al., 1996, Meraz et al., 1996). 
Furthermore, mice deficient in the STATl inhibitor, SOCSl, are hypersensitive to 
lipopolysaccharide (LPS), a component of the outer membrane of gram-negative 
bacteria and a potent stimulator of IFNy (Nakagawa et al., 2002).
The antiproliferative and pro-apoptotic effects of IFNs largely rely on STATl in 
promoting apoptotic death (Kim and Lee, 2007). The mechanism by which STATl 
mediates antiproliferation of tumours has been shown to occur at the level of the 
immune system. For example, the inhibition of tumour formation by IFNa in mice is 
dependent on STATl activating natural killer (NK) cells and not directly inducing 
apoptosis within the malignant cell (Lesinski et al., 2003). However, there is evidence 
showing that STATl is more intimately involved in regulating cell fate. For example, 
STATl activation has been shown to have prognostic significance in breast cancer; 
patients with high STATl activation had longer overall and relapse-free survival 
(Widschwendter et al., 2002). Furthermore, apoptotic cell death induced with 
chemotherapeutic agents in cancerous cells is modulated by STATl (Thomas et al., 
2004). Moreover, activation and expression of caspases in IFNy-induced apoptosis in 
various cell types is dependent on STATl (Chin et al., 1997).
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1.8.6 Regulation of cardiac I/R-injury by STATl
STATl has been implicated as a pro-apoptotic factor in the heart and in isolated 
cardiac ceils subjected to I/R. Stephanou and colleagues made a number of 
observations regarding STATl and its role in cardiac I/R-injury (Stephanou et ai., 
2000). They showed that STATl is tyrosine phosphorylated at residue Y701 during 
simulated ischaemia and is maintained following reperfusion in NRCM ceils, and 
following simulated I/R-injury in the isolated intact heart. Similarly, IFNy also induced 
STATl tyrosine phosphorylation and apoptosis of NRCM ceils. Furthermore, over­
expression of STATl using an expression construct introduced into NRCM ceils by 
transient transfection rendered them more susceptible to apoptosis following the 
simulated I/R cycle. Moreover, inhibiting STATl with an antisense construct reduced 
ischaemia-induced ceil death in NRCM ceils. Stephanou and colleagues also found 
that STATl induced cell death involved activation of caspase-1. Both STATl over­
expression and IFNy treatment or ischaemia activated the caspase-1 promoter in 
NRCM cells as determined by a luciferase reporter assay.
STATl up-regulates the expression of the Fas receptor and its ligand in NRCM ceils 
and in the isolated intact heart following I/R-injury (Stephanou et ai., 2001b). In this 
regard, it is interesting that hearts from transgenic mice lacking functional FasR show 
a considerable reduction in ceil death following I/R-injury compared to control hearts 
(Lee et ai., 2003). In addition to the earlier finding that STATl is tyrosine 
phosphorylated following I/R, it has also been demonstrated that serine 
phosphorylation at residue S727 also occurs, and is necessary for I/R induced 
expression of FasR/FasL and apoptosis in NRCM ceils (Stephanou et ai., 2001b). 
Phosphorylation of S727 appeared to be accomplished by p38 MARK activation during 
I/R, since it can be blocked both by a chemical inhibitor of p38 MARK, SB203580, 
and by a dominant negative form of MKK6, the upstream activator of p38 MARK 
(Stephanou et al., 2001b).
Furthermore, by mutating phosphorylation sites in STATl, it was shown that the 
induction of FasR/FasL gene expression and apoptosis is dependent on serine 
phosphorylation at residue S727 of STATl but tyrosine phosphorylation of residue 
701 is not required (Stephanou et ai., 2001b). The finding that STATl induces 
expression of the FasR/FasL and apoptosis in the absence of tyrosine 
phosphorylation may seem incompatible with the classic signalling pathway in which
56
Chapter O n e ______________________________________________________ Introduction
STATl is tyrosine phosphorylated and subsequently translocates to the nucleus. 
However, this may be partly explained by the finding that a proportion of the cell's 
STATl is constantly shuttled between the cytosol and the nucleus independently of 
tyrosine phosphorylation (Meyer et al., 2002). The constitutive expression of the low 
molecular mass polypeptide 2 (LMP2) has been shown to be mediated by a complex 
of unphosphorylated STATl and IRF-1 (Chatterjee-Kishore et al., 2000). Evidence 
that constitutive expression of genes is promoted by DNA-binding of 
unphosphorylated STATl on tyrosine 701 lends further support for the theory that 
STATl transcriptional activity does not require tyrosine phosphorylation.
The mechanism by which STATl is activated in response to I/R is unknown. IFNy 
expression has been detected in lymphocytes and NK cells only, thus precluding 
autocrine/paracrine stimulation by IFNy in isolated cultures of cardiac myocytes. 
Moreover, STAT phosphorylation has been observed in the rat heart within the first 
few minutes of reperfusion and therefore it is unlikely de novo synthesis of cytokines 
is the source of stimulation (McCormick et al., 2006). It has been postulated that the 
generation of ROS, which occurs at the onset of reperfusion, may be responsible for 
activating tyrosine and serine kinases in the cell by an unknown mechanism (Barry et 
al., 2007). Indeed, myocardial protection from I/R-injury by antioxidants is 
associated with a decrease in STAT phosphorylation. Epigallocatechin-3-gallate 
(EGCG), a polyphenol extract from green tea, inhibited I/R induced STATl 
phosphorylation and was associated with reduced infarct sizes in the isolated intact 
rat heart and reduced apoptotic death of isolated cardiac myocytes (Townsend et al., 
2004b). The free radical scavenger tempol has been shown to reduce infarct size and 
STAT phosphorylation in the rat heart in vivo (McCormick et al., 2006).
1.8.7 STATl functions as a transcriptional co-activator
STATl can influence gene regulation and apoptosis by interacting with other 
transcription factors and enhancing the regulatory effects of those transcription 
factors it binds with. Transcriptional regulators that have been discovered to bind 
STATl include CBP/p300, MCM5 and BRCAl (Zhang et al., 1996, Zhang et al., 1998, 
Ouchi et al., 2000).
One of the two reported STATl deficient mouse mutants expresses a truncated
STATl protein of 72 kDa, and given the design of the targeting vector, this product
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is mostly likely derived from an internal methionine that initiates at position 135 
(Meraz et al., 1996) (Figure 1.6). However, the product was found to be expressed 
at relatively low levels compared to the wild type STATl protein in mice and when 
the mutant protein was over-expressed in isolated mouse kidney fibroblasts it was 
found to be functionally inactive in response to IFNy (Meraz et al., 1996). Although 
the other mouse model has not been shown to express any STATl species, there is a 
similarity in the phenotypes of the two mouse models in that they both have 
compromised immune systems and have a reduced sensitivity to IFNy (Meraz et al., 
1996, Durbin et al., 1996). Unexpectedly, isolated myocytes and the intact heart 
from mice containing the truncated STATl protein are more sensitive to I/R-injury 
when compared to wild type littermates (Stephanou et al., 2002).
The finding that there is increased susceptibility to cardiac I/R injury in Statl'^' mice 
harbouring the truncated STATl protein seems to be counterintuitive as STATl is 
considered to be a predominantly pro-apoptotic factor and has been shown to induce 
apoptosis in cardiac I/R injury (Stephanou et al., 2000, Stephanou et al., 2001b). 
However, this unexpected result is supported by studies demonstrating that N- 
terminal deletion mutants of STATl are capable of mediating stress-induced 
apoptosis. Janjua and colleagues demonstrated that N-terminal deletion mutants of 
STATl, including mutants lacking the DNA-binding domain, when over-expressed in 
cells lacking endogenous STATl were sufficient for stress-induced apoptosis (Janjua 
et al., 2002). Furthermore, those mutants that lacked the DNA-binding domain were 
capable of inducing apoptosis, suggesting STATl may act as transcriptional co­
activator. Moreover, over-expression of the TAD enhanced stress-induced apoptosis. 
Similar effects were found in cardiac cells; NRCM cells transfected with the TAD of 
STATl were more susceptible to I/R injury compared to cells transfected with wild 
type STATl (Stephanou et al., 2002). The above-mentioned studies demonstrate 
that N-terminal STATl deletion mutants, including those lacking the DNA-binding 
domain are sufficient for inducing apoptotic death and that the TAD enhances 
apoptosis.
Although the overall structure of STATs is quite conserved within the coiled-coiled 
domain, the DNA-binding domain, the linker domain, the SH2 domain, and the TAD, 
the amino-terminal domain is less conserved among STATs and suggests this part of 
the protein may be Involved in mediating specific responses (Stephanou, 2004). 
Deletion of the N-terminal domain in the mutant STATl protein found in Statl'^'mcQ
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may have meant loss of regulatory elements that would normally mediate its 
inactivation, or interaction with transcription factors.
Another point to consider is that even though N-terminal deletion mutants of STATl 
are sufficient for inducing stress, the mutant protein in Statl'^' mice was found to be 
functionally inactive and Statl'^' mice are immunocompromised (Meraz et al., 1996). 
Functional inactivity was measured only in responses to IFNy- and pathogen-induced 
expression of classical STATl regulated genes and immune defects. However, I/R- 
induced activation of STATl and apoptosis in the heart is likely to be mediated via a 
different pathway and its functional role as a co-activator may be masked when only 
measuring the activity of genes to which it directly transactivates.
The effects of N-terminal deletion mutants of STATl and especially the unexpected 
truncated protein in the mouse may be considered to be an artificial system.
However, physiological relevance exists. Interestingly, it has been shown that STATl 
is cleaved by caspase-3 at position 694, which will ultimately release the C-terminal 
STATl TAD (King and Good bourn, 1998). Caspase-3 mediated release of the TAD 
may act as a positive feedback mechanism in apoptosis.
STATl interacts with the transcription factor p53, an interaction that is required for 
maximal activation of p53 responsive genes and apoptosis in cells subjected to DNA 
damage (Townsend et al., 2004a). Activation of the p53 target genes Bax and Noxa 
was reduced in cells deficient in STATl following treatment with DNA-damaging 
agents. In cells containing STATl, induction of Bax and Noxa was abolished when 
the p53 responsive element in the promoters of these genes was disrupted, thereby 
demonstrating that the reduction in activity was not a direct result of STATl 
mediated transcription but by an indirect mechanism that involves p53 (Townsend et 
al., 2004a).
The role of p53 in the regulation of I/R-injury is unclear, however, the expression 
and activation of p53 is induced in experimental models of different forms of heart 
disease that involve apoptosis. For example, rapid ventricular pacing in dogs induces 
heart failure and is associated with apoptotic cell death of ventricular myocytes and 
enhanced expression and activity of p53 (Leri et al., 1998). ARVC cells exposed to 
simulated hyperglycaemia underwent apoptosis and was associated with increased 
activation of p53 (Fiordaliso et al., 2001).
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NRCM cells exposed to hypoxia for 48 h resulted In apoptosis, as determined by 
intranucleosomal DNA cleavage, and increased p53 protein accumulation and 
transactivation activity (Long et al., 1997). Furthermore, apoptosis was induced in 
NRCM cells infected with a replication-defective adenovirus expressing human p53, 
whereas apoptosis was not observed in cells infected with control virus lacking an 
insert (Long et al., 1997). The expression of p53 mRNA and protein is up-regulated 
in reperfusion of ischaemic myocardium of Langendorff perfused rat (Maulik et al., 
2000, Xie et al., 2000). p53 induces cardiac rupture after MI in mice by positively 
regulating apoptosis in the area around the infarct (Matsusaka et al., 2006). 
Moreover, transgenic mice homozygous or heterozygous knockout for the p53 gene 
had a significantly better survival rate and a lower incidence of left ventricular 
rupture than wild type mice following MI (Matsusaka et al., 2006).
However, not all studies are in agreement that I/R-injury involves p53. An in vivo 
model of I/R injury, induced by occlusion of the left coronary artery, demonstrated 
that mice deficient in p53 were equally susceptible to I/R-injury and apoptosis when 
compared to wild type littermates (Bialik et al., 1997). Similar results were also found 
for NMCM cells and the isolated intact heart from mice deficient in p53 compared to 
wild type littermates (Bialik et al., 1997, Webster et al., 1999). These studies that 
used knockout mice appeared to have dismissed p53 involvement in cardiac I/R 
injury. However, more recent studies have once again implicated p53 has a regulator 
of reperfusion induced apoptosis (reviewed by Crow, 2006).
Findings from transgenic studies of p53-related proteins support the contention that 
p53 is a mediator of cardiac I/R injury. The Bcl-2 family member, Bax, is a 
proapoptotic protein that is positively regulated by p53. Genetic ablation of the Bax 
gene in mice resulted in increased resistance to I/R-injury over wild type littermates, 
as determined by improved functional recovery and reduced necrosis and apoptosis 
(Hochhauser et al., 2003). The PUMA gene is a transcriptional target of p53 and 
mediates p53-dependent and independent apoptosis. Langendorff perfused hearts 
from PUMA'^ ' mice are more resistant than hearts from wild type mice to I/R injury 
(Nickson et al., 2007, Toth et al., 2006a). Murine double minute 2 (Mdm2) is an E3 
ubiquitin ligase that regulates the degradation and activity of proteins including p53. 
Over-expression of Mdm2 in NRCM cells conferred protection from I/R-induced 
apoptosis, whereas inhibition of Mdm2 resulted in elevated p53 levels and promoted 
I/R-induced apoptosis (Toth et al., 2006b). Consistent with this latter finding,
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decreased expression of Mdm2 In a genetic mouse model was accompanied by 
decreased functional recovery of the heart following I/R-lnjury that was simulated by 
Langendorff perfusion (Toth et a!., 2006b).
Pharmacological Inhibition of p53 reduces the extent of I/R Injury. PIflthrln-alpha 
(PFT), a p53 Inhibitor, Improves cardiac functional recovery and attenuates p53- 
medlated apoptosis in vivo In the rat subjected to cardiac I/R by ligation of the left 
coronary artery (Uu et al., 2006). Inhibition of p53 with PFT has also been shown to 
lower the threshold of Isoflurane-lnduced cardioprotection during early reperfuslon In 
rabbits (Venkatapuram et al., 2006). Activation of p53 In I/R Injury has been 
suggested to be via caspase-3/MEKKl dependent pathway (ZebrowskI et al., 2006). 
MEKKl Is a MARK that undergoes proteolytic cleavage by caspase-3. In both In vitro 
and In vivo models of Ischaemic Injury, to produce a pathological kinase fragment 
that promotes phosphorylation and activation of p53 by an unknown mechanism 
(ZebrowskI et al., 2006).
The role of STATl In the regulation of I/R-lnjury Is not well understood. The 
evidence from studies In cultured cardiac cells suggests that It acts Independently of 
IFNy, although the pathways downstream of STATl may be similar to when STATl Is 
Induced by IFNy. Furthermore, the regulation may Involve Interaction with p53, and 
this should be Investigated further.
Another regulator of I/R-lnjury Is the extracellular ligand Cardlotrophln-1, and In 
contrast to STATl, It elicits cardioprotective effects rather than death-inducing ones. 
The pathways mediating Cardlotrophln-1 Induced effects Include the JAK-STAT 
pathway and specifically STAT3. Cardlotrophln-1 Is also a stimulator of hypertrophy, 
and the signalling pathways Involved In the regulation of hypertrophy and I/R-lnjury 
by Cardlotrophln-1 will now be discussed.
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1.9 Cardiotrophin-1 and heat shock protein 56
1.9.1 Cardiotrophin-1
Cardiotrophin-1 (CT-1) is a 201 amino acid peptide that belongs to the interleukin-6 
(IL-6)-type family of cytokines that comprises IL-6, IL-11, leukaemia inhibitory factor 
(UF), cardiotrophin like protein (CLC), ciliary neurotrophic factor (CNTF) and 
oncostatin M (OSM) (Heinrich et al., 2003). IL-6-type cytokines activate genes 
involved in differentiation, survival, apoptosis and proliferation (Heinrich et al., 
2003). IL-6-type cytokines bind cell surface receptor complexes containing the 
common signal transducing receptor chain glycoprotein 130 (gpl30). The signal 
transducing receptor, gpl30, is the most promiscuous of cytokine receptors, and is 
involved in transducing signals from all IL-6 type cytokines (Muller-Newen, 2003). 
The intracellular branch of the gpl30-transducing signal is mediated by the 
JAK/STAT pathway.
The receptors involved in the recognition of IL-6-type cytokines can be divided into 
two groups, the non-signalling a receptors (IL-6Ra, IL-llRa and CNTFRa) and the 
signal transducing receptors (gpl30, LIFR and OSMR). The intracellular domains of 
the transducing subunits are associated with JAKs and are tyrosine phosphorylated 
following cytokine stimulation. Each cytokine binds a particular combination of 
receptor complex that contains at least one gpl30 molecule. IL-6, IL-11 and OSM 
cytokines bind to their specific a receptor subunits. The cytokine and a receptor 
complex initiates the recruitment and binding of the signalling receptor subunit. An a 
receptor subunit has also been proposed to exist for CT-1 (Robledo et al., 1997). IL- 
6 and IL-11 signalling is mediated by homodimers of gpl30 and OSM signalling is 
mediated by homodimers of gpl30 or a heterodimer of gpl30 and OSMR. For CT-1 
and in the remainder of the IL-6-type cytokines (LIF, CNTF and CLC), signalling is 
mediated by a heterodimer of gpl30 and LIFR (Heinrich et al., 2003) (Figure 1.8).
CT-1 was discovered due to its ability to induce cardiac myocyte hypertrophy in vitro, 
as determined by an increase in cell size and induction of ANF secretion (Pennica et 
al., 1995). Tbe hypertrophic effect of CT-1 was supported in a subsequent in vivo 
study in which CT-1 was administered to mice by intraperitoneal injection every day 
for a fortnight (Jin et al., 1996). In this study there were increases in heart-to-body
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weight ratios of CT-1 treated mice compared to mice treated with a control 
substance.
CT-1 mRNA expression has been detected in numerous tissues including the heart 
and brain in adult mice and humans (Pennica et al., 1995, Pennica et al., 1996). The 
expression of CT-1 is increased both in human and experimental forms of heart 
failure. CT-1 mRNA expression has been shown to be increased in the ventricles of 
humans with cardiomyopathies and circulating levels of CT-1 are increased in 
humans with chronic heart failure (Zolk et al., 2002, Talwar et al., 1999). CT-1 and 
gplBO expression is augmented in both left and right ventricles following MI in the 
rat (Aoyama et al., 2000). The expression of CT-1 is increased in a canine model of 
CHF and this precedes the activation of BNP (Jougasaki et al., 2000, Jougasaki et al.,
2003). Interestingly, increased myocardial CT-1 gene expression precedes 
pathological heart failure in hypertensive rats, suggesting it is acting upstream in this 
pathway (Ishikawa et al., 1999).
Growth promoting factors are often also agents that confer resistance to stress and 
this is true for CT-1. Sheng and colleagues observed that treatment with CT-1 was 
able to enhance survival of cultured NRCM cells from cell death induced by serum 
starvation (Sheng et al., 1996). Moreover, NRCM cells pretreated with CT-1 were 
protected against a subsequent exposure to heat shock or simulated ischaemia 
(Stephanou et al., 1998). This effect was associated with the ability of CT-1 to induce 
accumulation of heat shock proteins (hsps) hsp70 and hsp90, whose expression has 
been previously shown to protect NRCM cells against both thermal and ischaemic 
stress (Heads et al., 1994, Heads et al., 1995, Cumming et al., 1996).
The cardioprotection conferred by CT-1 from ischaemic damage in vitro suggested 
that it might be used to minimise the effect of ischaemic damage in the human heart 
(Latchman, 2000). The finding that CT-1 exerts its protective effect by lessening the 
degree of apoptosis induced by serum removal or ischaemic stress supported such a 
possibility (Sheng et al., 1996, Stephanou et al., 1998). Further investigation 
revealed that CT-1 has a protective effect in NRCM cells when added after the 
ischaemic period at the onset of reoxygenation (Brar et al., 2001a). This effect was 
observed both in assays of total cell death and assays specifically measuring 
apoptotic cell death, such as TUN EL labelling or annexin V staining.
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Studies in neonatal cells provided preliminary data suggesting that there was a 
potential therapeutic use of CT-1. However, as I/R-injury is predominantly an adult 
disease, the need to investigate the effect of this cytokine in an adult model was of 
importance. ARCM cells and the Langendorff perfused rat heart were protected from 
I/R-injury when CT-1 was given prior to ischaemia or more importantly at the onset 
of reoxygenation/reperfusion, when the use of such protective agents would be 
clinically relevant in I/R-injury (Liao et al., 2002).
The JAK/STAT pathway mediates IL-6-type signalling. However, activation of 
additional signalling pathways are also induced by IL-6-type cytokines, including CT- 
1, by binding their receptor (Hirano et al., 1997). Furthermore, there is divergence 
downstream in the cardioprotective and hypertrophic signalling pathways, suggesting 
that one effect of CT-1 can potentially be manipulated without interrupting the other, 
thus harnessing the cardioprotective effect CT-1 and eliminating the deleterious 
hypertrophic effect. Dissecting the signalling pathways via which CT-1 signals to 
achieve cardioprotection and hypertrophy facilitates two possibilities; the therapeutic 
use of CT-1 or similar acting molecules in reperfusion injury and the inhibition of 
endogenous CT-1 or the pathways it activates to prevent the transition of 
hypertrophy to heart failure.
CT-1 induced activation of the p42/p44 MARK pathway has been observed, and 
results in the threonine phosphorylation of the nuclear factor (NF)-IL-6 (C/EBPp) 
transcription factor, allowing it to activate gene transcription (Sheng et al., 1996, 
Nakajima et al., 1993). CT-1 mediated protection from I/R injury is dependent on its 
ability to activate the p42/p44 MARK pathway. Pharmacological inhibition of the 
p42/p44 MARK pathway with RD98059 resulted in a blocking of the cardioprotective 
effect of CT-1 from I/R-induced death of NRCM cells, ARCM cells and in the 
Langendorff perfused rat heart (Brar et al., 2001a, Liao et al., 2002).
Receptor binding of CT-1 also results in the activation of the RI3-kinase/Akt pathway 
and is important for cardioprotection. NRCM cells treated with CT-1 results in 
phosphorylation of Akt (Kuwahara et al., 2000). NRCM cells treated with LY294002, 
an inhibitor of the RI3K/Akt pathway, attenuated cell death induced by serum 
withdrawal (Kuwahara et al., 2000). Again, inhibition of the RI3K pathway with 
LY294002 or wortmannin, demonstrated that the RI3K pathway mediates the
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protection conferred by CT-1 In NRCM cells from I/R induced death (Brar et al., 
2001b).
Although induced by stress, many hsps are highly expressed in unstressed cells with 
their synthesis being further enhanced in response to stressful stimuli. For example, 
hsp90 (each hsp is named on the basis of its mass in kilodaltons) is one of the most 
abundant proteins in unstressed cells accounting for approximately 1% of the total 
protein in mammalian cells (Latchman, 2001a). Thus, it is not surprising that hsps 
have functional roles that are required in normal cells, although they are needed to a 
greater extent in stressed cells.
Heat shock protein 56 (hspSS) has been implicated as a mediator of the hypertrophic 
response induced by CT-1 (Figure 1.8). Hsps were first identified as a result of their 
expression being induced in cells exposed to heat. However, it has been 
demonstrated that induction of hsps occurs not only in response to heat but also to a 
variety of stimuli including ischaemia, and they have therefore been referred to as 
"stress proteins" (Latchman, 2001a). Many hsps have a role in ensuring the correct 
folding and unfolding of proteins, a function known as chaperoning, and are thus 
also referred to as chaperone proteins. This function is particularly important in cells 
exposed to stress when incorrect folding and aggregation of proteins may occur with 
pathological consequences.
1.9.2 Heat shock protein 56
Hsp56 is an immunophilin, the name ascribed to proteins that bind 
immunosuppressive drugs such as FK506 (tacrolimus) and cyclosporin. HspSS 
belongs to the family of FKSOS-binding proteins (FKBPs) and is also known as 
FKBP52 (Yem et al., 1992, Davies and Sanchez, 2005). HspSS has peptidyl-prolyl cis- 
trans isomerase (PPIase) activity (also known as rota ma se activity), which is a 
chaperoning function that catalyzes the conversion of prolyl-peptide bonds from 
trans- to cis-proline, often a rate-limiting step in protein folding (Schiene and Fischer, 
2000). FKSOS reduces PPIase activity by binding the smaller immunophilin FKBP12, a 
complex that inhibits the phosphatase enzyme calcineurin, an important signalling 
molecule required for T-lymphocyte signal transduction and activation (Liu et al., 
1991). However, the role of hspSS in binding with FKSOS is unclear, as the 
interaction does not inhibit calcineurin (Lebeau et al., 1994).
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The structure of hsp56 is composed of four distinct domains. Domains I and II 
contain a functional site for PPIase activity and a PPIase-like region (Chambraud et 
a!., 1993). Domain III harbours three tetracopeptide repeat (TPR) elements that 
mediate interactions with other TPR containing proteins. A putative binding site for 
calmodulin is found in domain IV (Davies and Sanchez, 2005). Expression studies in 
the rat have demonstrated that hsp56 is highly expressed in thymus, liver, and 
spleen, with low levels in lung and muscle (Ruff et al., 1992). Hsp56 is located in the 
cytoplasm and the nucleus (Ruff et al., 1992, Czar et al., 1994).
Hsp56 is a component of steroid receptor complexes, where it interacts with the heat 
shock protein hsp90 via tetracopeptide repeat domains shared by the two proteins. 
Hsp90 associates with steroid receptors and keeps them in the inactive form in the 
cytoplasm until stimulation of the receptor by the corresponding steroid. Upon 
steroid and receptor interaction, hsp90 dissociates from the receptor enabling the 
receptor to translocate to the nucleus and activate gene transcription. Steroid 
receptor complexes consist of a receptor monomer, an hsp90 dimer, the co­
chaperone p23, and one of four cochaperones that contain a TPR domain. The TPR 
cochaperones include two FKBP family members, hsp56/FKBP52 and FKBP51, a 
member of the cyclosporin-binding immunophilin cyclophilin 40 (CyP40) or the 
protein phosphatase PP5 (Tranguch et al., 2005).
Hsp56 was first discovered as a component of the progesterone receptor (PR) 
complex (Nakao et al., 1985, Sanchez et al., 1990) In addition, hsp56 has also been 
found to be in steroid complexes for the oestrogen (ER), androgen (AR) and 
glucocorticoid receptors (Renoir et al., 1990, Tai et al., 1986). Possibly the most 
important physiological role played by hsp56 is in mediating steroid hormone 
signalling in reproduction. Progesterone and oestrogen are the primary regulators of 
uterus preparation for embryo implantation, a process dependent on hsp56. Female 
transgenic mice deficient in the hsp56 gene, FKBP^ '^, have complete implantation 
failure due to lack of attainment of uterine receptivity (Tranguch et al., 2005). Male 
FKBP^ '^ mice have several defects in tissues that are consistent with androgen 
insensitivity (Cheung-Flynn et al., 2005).
In addition to binding FK506 and its role in steroid receptor signalling hsp56 has now 
been implicated in mediating the hypertrophic response induced by CT-1. Railson
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and colleagues demonstrated that hsp56 is induced by CT-1 and mediates its 
hypertrophic effect (Railson et al., 2001). Increased synthesis of hsp56 mRNA and 
protein was detected in NRCM cells treated with CT-1. Moreover, over-expression of 
hsp56 in NRCM cells, achieved by transformation with a viral or plasmid expression 
vector for hsp56, was sufficient for inducing hypertrophy as determined by an 
increase in cell size and protein to DNA ratio. In NRCM cells transfected with the 
plasmid expression vector for hsp56, the hypertrophic effect was abrogated with an 
hsp56 antisense expression construct. The hypertrophic effect of hsp56 is the first 
time such an effect for a heat shock protein had been demonstrated. The effect was 
also specific to hsp56 as no hypertrophy was observed in cells in which hsp27, hsp70 
or hsp90 was over-expressed.
Jamshidi and colleagues demonstrated that the hypertrophic effect of hsp56 is 
dependent on several well-characterized signal transduction pathways (Jamshidi et 
al., 2004). Pharmacological inhibition of the JAK/STAT, PI3K/Akt or MEK signalling 
pathways abrogated the hypertrophic effect induced by hsp56 over-expression in 
NRCM cells, as determined by an increase in cell size and activity of a luciferase 
reporter of the ANF promoter that was co-transfected with hsp56.
CT-1 mRNA expression has been shown to be induced by Urocortin, a peptide related 
to corticotrophin releasing hormone that has cardioprotective and hypertrophic 
effects. The role of Urocortin in cardioprotection from I/R-injury will be discussed 
further.
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Figure 1.8 The cardiotrophin-1 (CT-1) signalling pathway. Binding of CT-1 to 
its receptor, a heterodimer of leukaemia inhibitory factor (LIF) and gplSO subunits, 
induces cardioprotective and hypertrophic signalling pathways in cardiac myocytes. 
Cardioprotective pathways of CT-1 signal via the ERK and PI3-K/Akt signalling 
pathways, which are inhibited by the pharmacological agents PD98059 and 
LY294002, respectively. CT-1 mediated cardioprotection is also dependent on the 
induction of hsp70 and hsp90 accumulation. CT-1 induces hypertrophy, including 
induction of mRNA synthesis of hypertrophic molecules such as ANF, and is 
dependent on its ability to induce hsp56. The hsp56 protein is known to associate 
with steroid receptor complexes although it is not known if this Is important for CT-1 
mediated effects
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1.10 Urocortin
Urocortin (Ucn) is a secreted peptide that induces the expression of IL-6 related 
cytokines, including CT-1 in NRCM cells (Janjua et al., 2003, Kageyama et al., 2006). 
Ucn belongs to a small family of peptides that are structurally related to mammalian 
corticotrophin releasing hormone (CRH), the principal mediator of the hypothalamic- 
pituitary-adrenal axis and stress response in mammals (De Souza, 1995, Vale et al., 
1981). The other mammalian members of the CRH family identified are two peptides 
highly related to Ucn, Urocortin II (UcnII)/Stresscopin-related peptide (SRP) and 
Urocortin III (UcnIII)/Stresscopin (SCR) (Hsu and Hsueh, 2001, Donaldson et al., 
1996, Lewis et al., 2001, Reyes et al., 2001). Non-mammalian species of CRH-related 
peptides had been identified earlier, urotensin derived from fish, sauvagine from frog 
and insect diuretic hormones (Bern and Lederis, 1969, Erspamer et al., 1980).
The Ucn gene consists of 2 exons with all coding information in the second exon 
(Zhao 1998). CRH peptides are synthesised as precursor molecules, termed 
prohormones or proenzymes, before being enzymatically cleaved by proenzyme 
convertases (PCs) to produce an active peptide. For example, the CRH prohormone 
of 181-amino acids is converted by PC2 to produce the active 41-amino acid peptide 
(Miller et al., 2003). Ucn is synthesised as a 122-amino acid precursor molecule 
containing an N-terminal methionine and consensus signal peptide before being 
cleaved to produce a 40-amino acid active peptide (Vaughan et al., 1995). CRH 
peptides share a 13 amino acid motif (PPLSIDLTFHLLR) near the N-terminus, with a 
completely conserved GK sequence immediately prior to the stop codon. Ucn shares 
45% homology with CRH and 63% homology with urotensin at the amino acid level 
(Vaughan et al., 1995). CRH family members are evolutionary conserved; homology 
between human and mouse is 100% for CRH and 95% for Ucn (Coste et al., 2002).
Ucn was the second mammalian member of the CRH family discovered when it was 
identified by screening a rat midbrain cDNA library with a probe derived from 
urotensin (Vaughan et al., 1995). Histological analysis of the midbrain region 
demonstrated that Ucn is highly expressed in the Edinger-Westphal nucleus and the 
lateral superior olive, both of which do not express CRH (Vaughan et al., 1995). 
Although originally identified in the brain, Ucn has been found to be expressed in the 
placenta, lymphocytes and the heart (Petraglia et al., 1996, Bamberger et al., 1998,
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Okosi et al., 1998). Synthetic Ucn stimulates adrenocorticotrophin (ACTH) secretion 
from rat pituitary cells in primary culture and in vivo 'm rat (Vaughan et al., 1995).
Cell signalling by the CRH family is mediated by binding two types of G-protein 
coupled seven transmembrane receptor, CRH-Rl and CRH-R2, which are coupled to 
adenylate cyclase (Lawrence and Latchman, 2006). Alternative RNA splicing gives 
rise to subtypes of CRH receptors. To date, there are eight CRH-Rl and four CRH-R2 
isoforms identified (Lawrence and Latchman, 2006). In C0SM6 cells transiently 
transfected with expression constructs for CRH-Rl and CRH-R2 receptors, it was 
demonstrated that CRH-R2 receptors bind Ucn with higher affinity than CRH-Rl and 
Ucn was ten fold more potent at inducing intracellular cAMP in cells expressing CRH- 
R2 (Vaughan et al., 1995). In the same study, Ucn binding to CRH-R2 was forty 
times stronger than CRH. CRH-Rl shows no appreciable binding to UCN II or III but 
binds UCN and CRH with similar potency (Hsu and Hsueh, 2001, Donaldson et al., 
1996, Lewis et al., 2001, Reyes et al., 2001).
CRH-Rl receptors are generally found in the CNS whereas CRH-R2 receptors are 
more widespread in the periphery and discretely located in the CNS. Although this 
distinctly different distribution is true for rodents, it is not so well defined in humans 
(Coste et al., 2002). In rodents, CRH-Rl receptors are highly expressed on ACTH 
containing cells of the anterior pituitary and are responsible for mediating pituitary- 
adrenal activation. They are also found in brain regions including the cerebral cortex, 
cerebellum, hippocampus, brain stem and hypothalamus.
Endogenous inhibition of CRH and Ucn signalling is mediated by CRH binding protein 
(CRH-BP). CRH-BP is a 37 kDa secreted glycoprotein that is known to bind CRH and 
Ucn with high affinity, thus preventing them from stimulating CRH receptors 
(Westphal and Seasholtz, 2006). Molecules that inhibit CRH have been developed for 
potential clinical use in treating undesirable effects of CRH on the nervous system, 
such as depression and anxiety (Lawrence and Latchman, 2006). These molecules 
tend to be antagonists of CRH receptors and can be used experimentally to elucidate 
the roles that CRH family members play in disease pathways. For example, the 
synthetic peptides, alpha helical CRH (ahCRH) and astressin, are non-selective CRH 
receptor antagonists. However, selective inhibition of CRH receptor can be achieved 
with R278995 and CRA0405, which are antagonists of the CRH-Rl and CRH-R2 
receptors respectively (Lawrence and Latchman, 2006).
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CRH-R2 receptors are the only type of CRH receptor found in the heart, the alpha 
form in man and the beta form in the rat (Chen et al., 1993, Stenzel et al., 1995, 
Perrin et al., 1995, Kishimoto et al., 1995). CRM has been shown to stimulate 
adenylate cyclase activity in cardiac myocytes (Heldwein et al., 1996). Given that 
CRH-R2 receptors are the only CRH receptor found In the heart and that Ucn has a 
higher affinity for this receptor than CRH, it suggests Ucn may have important 
physiological effects in the heart and has led to the idea that CRH-R2 may be a 
natural receptor for Ucn (Latchman, 2001b).
The CRH family of peptides have effects on the nervous, cardiovascular and immune 
systems. Injection of Ucn can produce enhanced anxiety and activity as well as an 
appetite suppressing effect in the mouse and rat that is more potent than CRH 
(Spina et al., 1996). The distribution of CRH receptors in different sites of the brain 
suggests the effects of Ucn on anxiety are mediated via CRH-Rl and appetite via 
CRH-R2 (Lovenberg et al., 1995). CRH stimulates T and B cell proliferation in vitro, 
when applied exogenously CRH and Ucn can reduce inflammation (Turnbull et al., 
1996).
CRH peptides mediate central and peripheral regulation of cardiovascular function. 
Intracerebroventicular (ICV) administration of CRH elicits cardiovascular responses 
similar to effects of stress, increasing heart rate, cardiac output, and mean arterial 
pressure, which depend on an intact sympathetic nervous system (Fisher et al., 
1983). However, intravenous (IV) delivery was shown to induce a marked decrease 
in mean arterial pressure accompanied by reflex tachycardia due to vasodilation in 
specific beds (Lenz et al., 1985). Direct peripheral actions were subsequently 
demonstrated in isolated heart preparations. Perfusion of CRH in the isolated heart 
resulted in a sustained increase in coronary blood flow, a positive inotropic effect, 
and rapid release of ANF (Grunt et al., 1992, Grunt et al., 1993). IV administration of 
Ucn also induced a reduction in mean arterial pressure and increased cardiac 
contractility in rodents, although it is possible that the decrease in blood pressure 
contributed to the increase in cardiac contractility (Vaughan et al., 1995, Parkes et 
al., 1997, Terui et al., 2001). However, Ucn induced an increase in cardiac in 
contractility in sheep, in addition to increased cardiac output and coronary flow, and 
this was not accompanied with hypotension (Parkes et al., 1997). The expression of 
Ucn II and III mRNA in certain brain regions and the finding that delivery of Ucn II in 
the CNS activates several brain regions important in autonomic function suggests
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these peptides may mediate central regulation of cardiovascular function (Coste et 
al., 2002).
CRH and Ucn mRNAs are expressed in the rodent heart and Ucn protein has been 
detected in all four chambers of the human heart (Muglia et al., 1994, Okosi et al., 
1998, Kageyama et al., 2000, Nishikimi et al., 2000, Kimura et al., 2002). Ucn II has 
been shown to be highly expressed in the human and mouse heart whereas Ucn III 
is virtually absent in the mouse heart (Hsu and Hsueh, 2001, Lewis et al., 2001). 
Interestingly, this pattern of Ucn II and Ucn III mRNA expression is reversed in 
cardiac myocytes from rat, with expression of Ucn III mRNA but no Ucn II mRNA 
observed (Chanalaris et al., 2003).
Studies in transgenic mice deficient in CRH-R2 demonstrate the importance of this 
receptor in mediating the regulation of cardiovascular function by the CRH family of 
peptides. CRH-RZ '^ mice have increased arterial pressure compared to wild type 
mice, which is not lowered with systemic administration of Ucn (Coste et al., 2000). 
It has been postulated that Ucn affects arterial pressure through activation of CRH- 
R2 in vascular beds because the rapid fall in peripheral resistance is the primary 
cause of hypotension associated with CRH peptides in rodents (Coste et al., 2002). 
This is indeed possible, as CRH-R2 expression has been reported in cardiac arterioles 
and in a vascular smooth muscle cell line (Chalmers et al., 1995, Perrin et al., 1995, 
Kageyama et al., 2000).
1.10.1 Urocortin protects from I/R injury
Ucn has been shown to be a cardioprotective agent, reducing the effects of I/R
induced death or injury. Ucn mRNA expression increases in NRCM cells following
heat shock or ischaemia (Okosi et al., 1998, Brar et al., 1999). Treatment with Ucn
protected NRCM cells from a subsequent dose of simulated lethal ischaemia as
measured by the uptake of trypan blue and LDH release (Okosi et al., 1998). The
protective effect of exogenous Ucn in NRCM cells was shown to be superior to that of
CRH and urotensin (Brar et al., 1999). Furthermore, Ucn is released into the culture
medium of NRCM cells following ischaemia (Brar et al., 1999). When another culture
of NRCM cells were incubated in this conditioned medium they were protected from
ischaemia (as measured by trypan blue uptake and LDH release), an effect that was
abolished with ahCRH (Brar et al., 1999). These findings demonstrate that stress
induced production of Ucn protects NRCM cells in an autocrine/paracrine manner.
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Furthermore, the cardioprotective effect of Ucn may, at least in part, be dependent 
on its ability to induce the expression of CT-1.
The induction of the Ucn gene in ischaemia may be mediated by the transcription 
factors C/EBP, NF-IL6/NF-IL6p and NF-k^. MAP kinase signalling pathways are 
activated in ischaemia and NF-IL6 and NF-ILôp are substrates of MAP kinase 
phosphorylation (Nakajima et al., 1993).The expression and activity of NF-IL6, NF- 
IL6p and the p65 subunit of NF-xp are induced by hypoxia or ischaemia (Van et al., 
1997, Brar et al., 1999). Moreover, the Ucn gene contains a consensus site for C/EBP 
transcription factors and the CRH gene has been shown to be transcriptionally 
regulated by NF-IL6 and NF-IL6P in neuronal and lymphoblastoid cells (Stephanou et 
al., 1997).
Like CT-1, Ucn protects NRCM cells and the intact heart from simulated I/R injury 
when given at re perfusion (Brar et al., 2000). Whereas previous experiments in 
NRCM cells had demonstrated Ucn protected against total cell death, in this study 
Brar and colleagues used TUNEL and annexin V assays in NRCM cells to show that 
Ucn was specifically inhibiting apoptosis, which was contributing to cell death 
following simulated I/R (Brar et al., 2000). Ucn was also shown to protective when 
given at reperfusion in an in vivo rat model of I/R (Schulman et al., 2002). In order 
to demonstrate that reduced infarct sizes in the in vivo rat model was not a 
secondary effect of the reduction in arterial pressure induced by Ucn, glyceryl 
trinitrate (GTN) was infused to mimic the hypotensive effect of Ucn. Infusion of GTN 
did not reduce infarct sizes.
The protective effect of Ucn in the Langendorff perfused rat heart has also been 
measured in terms of improved functional recovery following I/R. Scarabelli and 
colleagues observed improvements of developed pressure (DP) and diastolic pressure 
(dP) ranging from partial to complete recovery depending on when Ucn was 
delivered (Scarabelli et al., 2002). Ucn delivery prior to ischaemia and during 
reperfusion resulted in complete recovery of DP and dP. However, when given only 
prior to ischaemia there was normalization of DP and partial restoration of dP. When 
given at reperfusion there was progressive but partial recovery of DP and dP. 
Improvements in cardiac function were accompanied by reduced necrotic and 
apoptotic cell death, as determined by reduced CPK release and caspase-3 activity. 
This reduction in cell death was observed whether Ucn was delivered prior to
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ischaemia or at reperfusion. However, improvements in ATP and creatine phosphate 
stores were observed when Ucn was given prior to ischaemia but not when given 
only at reperfusion.
Cardiopulmonary bypass, cardioplegic arrest and subsequent reperfusion expose the 
heart to an iatrogenic (meaning caused by medical treatment) I/R injury (IRI) 
(Scarabelli et al., 2004). Different cardioplegic techniques (crystalloid, cold blood and 
warm blood cardioplegia) have been developed to prevent this injury (Mauney and 
Kron, 1995). However, protection is inadequate, especially in surgical procedures 
requiring prolonged cardiac arrest (Scarabelli et al., 2004). Cardiac myocyte survival 
in human heart biopsies subjected to IRI is associated with Ucn expression 
(Scarabelli et al., 2004). Only viable cells expressed Ucn whereas it was not detected 
in TUNEL positive cardiac myocytes. This study suggests that Ucn improves cardiac 
myocyte survival following I/R injury.
1.10.2 Cardioprotective signalling pathways of Urocortin
Members of the CRH family activate p42/p44 MARK enzymes (Figure 1.9). For 
example, CRH has been shown to activate p42/p44 MARK in the Chinese hamster 
ovary (CHO) cell line transfected with CRH-Rl and CRH-R2 receptors (Rossant et al., 
1999). Ucn was shown to activate p42/p44- but not p38- or JNK- MARK in NRCM 
cells (Brar et al., 2000). Ucn induced activation of p42/p44 MARK is necessary for 
mediating its protective effect. Blocking p42/p44 MARK activation with the MEK 
inhibitor RD98059 or dominant negative mutants of p42/p44 MARK resulted in loss of 
the protective effect of Ucn in NRCM cells following I/R, even when Ucn was given at 
reperfusion (Brar et al., 2000). Similar results have been demonstrated in the 
Langendorff perfused and in vivo rat heart. Schulman and colleagues demonstrated 
that administering Ucn for the first 20 minutes of reperfusion in the Langendorff 
perfused rat heart was cardioprotective (Schulman et al., 2002). However, when 
RD98059 was also added with Ucn in the first 20 minutes of reperfusion the 
cardioprotective effect was abolished. In the same study, using an In vivo rat model 
of I/R, Ucn delivered just before reperfusion was cardioprotective. However, when 
RD98059 was injected intravenously 3 minutes prior to reperfusion, the 
cardioprotective effect of Ucn was inhibited.
Activation of the p42/p44 MARK pathway is necessary for the increased expression of 
hsp90 observed in NRCM cells treated with Ucn (Brar et al., 2002a). Increased
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expression of hsp90 following Ucn treatment Is not a result of Increased 
transcription, as the Increase was not blocked by actlnomycin D, an Inhibitor of 
transcription. However, Increased synthesis of proteins Is necessary for 
cardioprotection mediated by Ucn. Cycloheximlde, a translational Inhibitor blocks Ucn 
mediated protection from Ischaemia Induced death In NRCM cells (Brar et al., 
2002a). Thus, Increased hsp90 expression may be a result of Increased hsp90 mRNA 
stability and/or modified transport to the cytoplasm. However, the role of hsp90 In 
Ucn signalling Is unclear, as earlier studies have seemingly dismissed a protective 
role for hsp90 In I/R-lnjury (Heads et al., 1995, Gumming et al., 1996). These studies 
do not satisfactorily preclude hsp90 as a protective agent from I/R-lnjury, whether by 
Its over-expresslon or as a mediator of Ucn Induced protection. For Instance, there Is 
more than one Isoform of hsp90 and those studies that found hsp90 was not 
protective used over-expresslon of the beta Isoform (hsp90p). Expression of the 
alpha Isoform (hsp90a) has been shown to be Induced In reperfused hearts and 
might potentially be protective from I/R-lnjury (NIshlzawa et al., 1996). Possibly, 
hsp90 does not protect from I/R-lnjury when over-expressed. However, Ucn may 
Induce other proteins that are required for hsp90 mediated protection, an effect that 
may not be observed by hsp90 over-expresslon alone.
Phosphorylation of Akt Is observed In cardiac myocytes treated with Ucn In a PI3K 
dependent manner. Ucn Induced phosphorylation of Akt In NRCM cells was Inhibited 
with the PI3K Inhibitors, Wortmannin and LY294002 (Brar et al., 2002b). This was 
the first study to demonstrate that a peptide of the CRH family can Induce Akt via 
the PI3K pathway. Moreover, Wortmannin and LY294002 attenuated the reduction In 
I/R-lnduced necrotic and apoptotic death observed In NRCM and ARVC cells treated 
with Ucn. Inhibition of PI3K and Akt by over-expresslon of dominant-negative 
mutants of these two kinases In NRCM cells also resulted In the loss of Ucn mediated 
cardioprotection from I/R-lnduced death.
The findings of some studies suggest that the mechanism by which Ucn elicits 
cardioprotection Is one similar to that of Ischaemic preconditioning (IPC). This Idea Is 
supported by those studies demonstrating that Ucn Is cardioprotective In cultured 
myocytes when Ischaemia Is simulated either Immediately or when delayed after Ucn 
treatment, thus mimicking the effects of Immediate and delayed IPC respectively. 
The cardioprotective effect of Ucn In the Langendorff perfusion model can only be 
Investigated when Ischaemia Is simulated shortly after Ucn treatment as the heart
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retains function when perfused ex vivo for only a few hours. As there are no such 
reports In vivo, what Is known about the cardioprotective of Ucn treatment when 
ischaemia is delayed is based on studies in cultured cardiac myocytes.
Lawrence and colleagues used Affymetrix gene chips to screen genes whose 
expression is modulated by Ucn in NRCM cells and found significant increases in two 
mediators of preconditioning that are involved in cardioprotection; PKCe and the Katp 
channel subunit potassium inward rectifying (Kir) 6.1 (Kir6.1) (Lawrence et al., 2002, 
Lawrence et al., 2005). Increases in mRNA levels following Ucn treatment correlated 
with increases in the corresponding proteins in NRCM cells and the Langendorff 
perfused rat heart.
A number of studies have implicated Katp channels in mediating survival pathways in 
I/R-injury, in particular preconditioning (Scarabelli et al., 2002, Takano et al., 2000, 
Takashi et al., 1999). The Kirô.l subunit is located predominantly in the inner 
mitochondrial membrane (Suzuki et al., 1997). Simulated I/R also induces the 
expression of Kir6.1 in NRCM cells and the Langendorff perfused rat heart, however, 
treatment with ahCRH blocked either Ucn or I/R induced expression of Kirô.l 
(Lawrence et al., 2002, Lawrence et al., 2005). Chromakalim, a Katp channel opener, 
provided cardioprotection that was similar to Ucn, whereas the protective effect of 
Ucn was blocked with Tolbutamide, an inhibitor of Katp channel opening (Lawrence et 
al., 2002, Lawrence et al., 2005) . Although Tolbutamide is generally considered to 
be a sarcolemmal Katp blocker, interference of K atp mitochondrial channels has been 
reported and it is generally believed that it is opening of the mitochondrial channel 
that is responsible for the protective effect of preconditioning (Takano et al., 2000). 
Therefore, Lawrence and colleagues used 5-HD to specifically inhibit mitochondrial 
K atp Channels and found that this inhibited Ucn mediated protection. Furthermore, 
inhibition of Kirô.l with a dominant negative mutant enhanced I/R induced death 
(Lawrence et al., 2002, Lawrence et al., 2005).
Translocation of PKCe from a cytosolic fraction to a membrane rich fraction rich in 
mitochondria was observed in NRCM cells and the Langendorff perfused heart 
exposed to Ucn for 10 minutes, an effect that was blocked by ahCRH and a specific 
inhibitor peptide of PKCe (Lawrence et al., 2005). Specific localisation of PKCe in the 
mitochondria was demonstrated by immunoflourescence in NRCM cells showing co­
localisation of PKCe and the mitochondrial specific marker dye, Mitotracker.
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Moreover, preventing mitochondrial translocation of PKCe resulted in loss of the 
protective effect of Ucn from I/R-injury (Lawrence et al., 2005).
Gordon and colleagues demonstrated that Ucn protected ARCM cells from simulated 
ischaemia when Ucn was present during the ischaemic episode, as determined by 
release of LDH and CK enzymes into the culture medium (Gordon et al., 2003). The 
cardioprotective effect of Ucn was comparable with adenosine, which is thought to 
be a trigger for PKC activation and the classical preconditioning cascade. ARCM cells 
were treated with Ucn for 5 minutes with 10 minutes of recovery or 20 minutes with 
20 hours of recovery prior to ischaemia. These treatment protocols were designed to 
mimic classical and delayed preconditioning and both were found to be protective. 
Moreover, the PKC inhibitor chelerythrine and the Kat? channel blocker 5-HD were 
able to attenuate the cardioprotective effect of Ucn.
In the Affymetrix gene chip study conducted by Lawrence and colleagues, the 
expression of some genes decreased with Ucn treatment, notably the gene for the 
calcium insensitive phospholipase 2 (iPLAz) enzyme (Lawrence et al., 2003). This was 
confirmed by RT-PCR and a decrease in the corresponding protein was also observed 
by Western blotting. Interestingly, simulated I/R-injury also induced a decrease in 
iPLAz. Moreover, the I/R induced decrease in iPLAz was abrogated in the presence of 
ahCRH, suggesting that the release of Ucn following I/R is responsible for the 
reduction in iPLAz. There was a concomitant reduction in the iPLA2 substrate 
lysophosphatidylcholine (LPC) in Ucn treated cells with lower levels of IPLA2. 
However, I/R caused a large increase in LPC concentration, which was significantly 
lowered by Ucn treatment. Thus, as IPLA2 expression decreases in I/R, there is most 
likely an increase in its activity for the resulting increase in LPC accumulation. LPC 
accumulation is toxic for the cell. Bromoenol lactone (BEL) is an inhibitor of LPC and 
was shown to inhibit cell death of NRCM cells and improve the functional recovery of 
the Langendorff perfused rat heart following simulated I/R-injury. The protective 
effect of BEL was not additive when given in combination with Ucn, suggesting that 
the two agents protected via a common mechanism.
The roles played by PKCe, Kirô.l and iPLA2 in Ucn mediated protection involve 
interaction with mitochondria and prevention of mitochondrial damage. The Kirô.l 
subunit has been shown to be the diazoxide (a potassium channel opening drug) 
sensitive and mitochondrially localised form (Gross and Fryer, 1999, Cui et al., 2001).
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The IPLA2 substrate LPC can modulate Katp channels and PKCe, and PKCe can 
Interact with Katp channels and IPLA2 (Eddlestone, 1995, Steer et al., 2002). PKCe 
translocates to mitochondrial membranes and interact with mitochondrial proteins 
including MPTP (Baines et al., 2003). The loss of AWm in NRCM cells following I/R, as 
measured by a reduction in TMRM, was abrogated by Ucn, the Katp channel opener 
chromakalim or the LPC inhibitor BEL (Lawrence et al., 2004). Ucn mediated 
protection was abrogated by a PKCe inhibitor peptide and the inhibitor peptide or the 
Katp  channel blocker 5-HD caused greater damage than I/R alone (Lawrence et al.,
2004). Furthermore, partial restoration of ATP and CK levels at the end of both 
ischaemia and reperfusion suggests Urocortin acts on the mitochondria to maintain 
the respiratory transport chain, thus preventing mitochondrial injury (Scarabelli et al., 
2002).
In addition to being a cardioprotective agent, Ucn is also a hypertrophic one. 
Hypertrophy is associated with peptides such as Ucn, which are potent stimulants of 
contractile function and that signal through cAMP (Miyakoda 1987). Experiments in 
NRCM cells have demonstrated that Ucn stimulates release of AN F and BNP (Ikeda et 
al., 1998). Moreover, LVH is associated with higher expression of Ucn mRNA and Ucn 
treatment also induces an increase in ARVC cell size and NRCM cell size with an 
accompanying increase in the protein to DNA ratio (Nishikimi et al., 2000, Railson et 
al., 2002). Ucn induces an increase in intracellular cAMP with concomitant increases 
in collagen DNA synthesis in fibroblasts (Nishikimi et al., 2000). Thus, Ucn may be 
involved in processes such as scar formation and collagen deposition that occur 
during ventricular remodelling of the failing heart.
The ability to induce hypertrophy seemingly precludes Ucn or similarly acting 
molecules from clinical use. However, it has been demonstrated that the signalling 
pathways that mediate the hypertrophic effect of Ucn are distinct from the ones that 
are involved in its cardioprotective effect. Blocking the p42/p44 MAPK pathway 
inhibits Ucn mediated protection but not Ucn induced hypertrophy (Railson et al., 
2002,). Furthermore, Ucn induced hypertrophy requires activation of the 
transcriptional coactivator p300, although its role in Ucn mediated protection is not 
known (Railson et al., 2002, Davidson et al., 2005). The results from these studies 
suggest that analogues of Ucn, or similarly acting molecules, that lack its ability to 
stimulate the hypertrophic signalling pathway could be synthesised and used in 
therapy of I/R-injury.
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Figure 1.9 The cardioprotective signalling pathways of Urocortin (Ucn). Ucn
binds the corticotrophin receptor 2a (CRH-R2a) in the heart and stimulates signalling 
pathways that mediate protection from I/R injury. Cardioprotection is mediated by 
the ERK and PI3-K/Akt signalling pathways. Ucn mediated protection also involves 
protection of the mitochondria through activation of PKCe, increasing Kirô.l, 
decreasing iPLAz and the inhibition of mitochondrial permeability transition pore 
(MPTP) from opening.
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1.11 Conclusion and aims of thesis
In conclusion, it appears that components of the IFNy and CT-1 signalling pathways 
play an important role in regulating I/R-injury and hypertrophy. Therefore, these 
components represent potential therapeutic targets for minimising the extent of 
injury caused by I/R-injury and the progression of hypertrophy to heart failure. 
However, the exact molecular mechanisms involved in these pathways are not fuiiy 
understood (Figure 1.10).
The IFNy mediator, STATl, induces apoptotic cell death in cardiac myocytes exposed 
to I/R although the relative contribution of the intrinsic and extrinsic apoptotic 
pathways in STATl induced apoptosis is not known. Therefore, transgenic mice with 
Inactivated intrinsic or extrinsic apoptotic signalling pathways would be model 
animals for investigating the relative contributions of these pathways in STATl 
mediated apoptosis induced by I/R. Therefore, the first aim of this thesis is:
1. To produce transgenic mice that have inactivated extrinsic or intrinsic 
apoptotic signalling by over-expression of flice-like inhibitory protein (FLIP) or 
caspase-9s (C9s), which are inhibitors of caspase-8 (extrinsic pathway) and 
caspase-9 (intrinsic) pathway respectively.
The effect of gene induction by STATl largely depends on its role as a transcription 
factor. However, truncated STATl proteins, including those consisting of just the 
transactivation domain have been shown to induce ceil death. In this regard, STATl 
has been shown to induce transcription by functioning as a transcriptional co­
activator for other transcription factors. One such factor, p53, associates with STATl 
and this interaction has been shown to be necessary for the induction of p53 target 
genes. A commercially available strain of STATl deficient mice is IFNy insensitive but 
hearts from these mice are more sensitive to I/R injury compared to those from wild 
types. However, these mice express a truncated STATl protein lacking the N- 
terminal domain (1-135 amino acids). Therefore, the second aim of this thesis is:
2. To test if the increased sensitivity of hearts from Statl'^' mice to I/R injury is 
dependent on an interaction between p53 and the truncated STATl protein 
expressed in these mice, and to identify other proteins regulated in the 
process using a proteomic approach.
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The hypertrophic effect of CT-1 has been shown to be dependent on its ability to 
induce expression of hsp56. Over-expression of hsp56 in NRCM cells has been shown 
to be sufficient for the induction of hypertrophy. Thus, hsp56 may be a mediator of 
pathological hypertrophy. However, the effect of hsp56 induction in the adult 
mammalian heart is not known. Therefore the third aim of this thesis:
3. To assess the hypertrophic effect of hsp56 in the adult heart by generating 
transgenic mice that over-express hsp56.
The expression of CT-1 has been shown to be induced by another, further upstream, 
cardioprotective peptide. This peptide, Ucn, protects from I/R-injury in the heart via 
multiple signalling pathways. Ucn mediated protection has been shown to involve 
protection of the mitochondria and inhibition of the MPTP in NRCM cells. However, 
the effect of Ucn on MPTP opening in the adult mammalian heart is not known. 
Therefore, the fourth aim of this thesis is:
4. To assess the role of the MPTP in Ucn mediated protection from I/R injury 
and cell death in the Langendorff perfused adult rat heart and isolated ARVC 
cells.
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Figure 1.10 The regulation of cardiac injury, cardioprotection and 
hypertrophy by IFNy, Ucn and CT-1 signalling pathways. The role of 
STATl/p53, MPTP and hsp56 In these pathways is unclear. The aims of thesis will 
attempt to elucidate these mechanisms.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 Materials
2.1.1 Chemicals and reagents
All chemicals used in this project were supplied by BDH, Lutterworth, Leicestershire, 
UK with the following exceptions:
Alcohols (Hayman Ltd, Witham, Essex, UK)
Dimethyl Sulfoxide (DMSO) (#0-5879, Sigma, Poole, UK)
Trypan Blue solution (0.4%) (#78154, Sigma, Poole, UK)
5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside in dimethylformamide (X-gal)
All solid chemicals were dissolved in ddH20, adjusted to the correct pH with 0.1 M 
HCL, glacial acetic acid or O.IM NaOH and autoclaved or filter sterilised with 0.22 \xm 
syringe driven filter units (Millipore, Bedford, MA, USA) unless otherwise stated. 
Deoxynucleoside Triphosphates (dNTPs)- 100 mM (pH 7.5) set of dATP, dCTP, dGTP 
and dTTP (Promega, Southampton, UK) were stored at -20 °C.
Deoxycholate (DOC) (#D-5670, Sigma, Poole, UK)
Dithiothreitol (DTT) (#D-9779, Sigma, Poole, UK)
Nonidet P-40 (NP-40) (#13021, Sigma, Poole, UK)
Protease inhibitor cocktail tablets (#11-836-153-001, Roche, Germany)
Bovine serum albumin (BSA) (#A7030, Sigma, Poole, UK)
Urocortin (#U6631, Sigma, Poole, UK)
Interleukin-6 (#19646, Sigma, Poole, UK)
2.1.2 General materials and equipment
15 ml and 50 ml sterile tubes (#910157, Helena Biosciences, Sunderland, U.K)
Bijou tubes (#39740, Bibby Sterilin Ltd, Staffordshire, U.K)
1.5 ml and 0.5 ml microfuge tubes (Anachem, Luton, Bedfordshire, U.K)
1.7 ml siliconised microfuge tubes (#73406, Sigma, Poole, U.K)
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Centrifuges: (Kendro Laboratory Products Ltd, Herts, U.K)
Sorvail Blofuge Pico (and refrigerated version Fresco),
Sorvall RT-7 Plus and RC26 Plus
PGR Cycler Machine (Eppendorf Mastercycler, Hamburg, Germany)
Centricon-YM30 centrifugal concentrators (Amicon Bioseparations, Millipore, UK) 
Spectrophotometer (BioRad laboratories, CA, USA)
2.1.3 Enzymes
Asel (#R0526, New England Biolabs (NEB), Hertfordshire, UK)
Bgill (#R6081, Promega, Southampton, UK)
PstI (#R6111, Promega, Southampton, UK)
PvuII (#R6331, Promega, Southampton, UK)
BamHI (NEB, Hertfordshire, UK)
EcoRI (#R6017, Promega, Southampton, UK)
Proteinase K (#P-6556, Sigma, Poole, UK)
Taq DNA Polymerase (#M1665, Promega, Southampton, UK)
All enzymes were stored at -20°C.
2.1.4 Reaction buffers
a) Buffer E- for restriction enzyme BamHI
- 60 mM Tris-HCI (pH 7.5)
-1  M NaCI
- 60 mM MgClz 
-10 mM DTT
(Promega, Southampton, UK)
b) Buffer H- for restriction enzyme EcoRI
- 900 mM Tris-HCI (pH 7.5)
- 500 mM NaCI
- 100 mM MgClz
(Promega, Southampton, UK)
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c) Buffer K- for restriction enzyme Asel 
-100 mM Tris-HCI (pH 7.4)
-1.5 M KCI 
-100 mM MgCb
(Promega, Southampton, UK)
d) Thermophilic DNA Polymerase lOx Buffer B supplied with separate MgClz
(Promega, Southampton, UK)
- 20 mM Tris-HCI (pH 8.0 at 25°C)
-100 mM KCI
-0.1 mM EDTA
- 1 mM DTT
- 50% glycerol
- 0.5% Tween 20
- 0.5% NP-40
e) Super Script II 5x First strand cDNA synthesis buffer (Invitrogen, UK)
-250 mM Tris-HCI (pH 8.3 at room temperature)
- 375 mM KCI
-15 mM MgCb 
-0.1 M DTT
All reaction buffers were stored at -20 ®C.
2.1.5 Antibodies
Primary antibodies used in this study are shown in Table 2.1. Secondary peroxidase- 
conjugated goat immunoglobulins were from Dako (Glostrup, Denmark). Secondary 
Alexa Fluor fluorescent antibodies were from Invitrogen.
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Primary Antibody Manufacturer Catalogue Number
p-Actin (1-19) Santa Cruz SC-1616
Caspase-9 short (Ab-1) Oncogene PC475
Desmin (Y-20) Santa Cruz SC-7559
FÜP Alexis ALX-804-428
p-Galactosidase Abeam ab616
GAPDH Chemicon AB1932
hsp56 (N-17) Santa Cruz SC-1803
Interleukin-6 (M-19) Santa Cruz SC-1265
p53^ ^^  phospho Calbiochem PC386
STATl (E-23) Santa Cruz SC-346
STAT1^°^ phospho Zymed 33-3400
Tet Repressor Mo Bi Tec TET03
Table 2.1 Primary antibodies
2.1.6 Agarose gei electrophoresis materials and buffers
Agarose and low melting point agarose were supplied by Gibco BRL, Life 
Technologies, Paisley, Scotland, UK.
Molecular weight markers:
- 2-Log DNA Mw marker (New England Biolabs, UK)
Loading Buffer:
- 25 mg xylene cyanole, 30% glycerol
2.1.7 General buffers and solutions
a) Tris Acetate EDTA (TAE buffer)
A stock solution of 50 times working strength TAE buffer was made by dissolving the 
following components in IL of distilled water:
- 242 g/LTris base
- 57.1 ml glacial acetic acid
- 100 ml 0.5M EDTA (pH 8.0)
Dilution to a working strength gave a final concentration of 40 mM Tris acetate and 1 
mM EDTA.
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b) Tris-EDTA (TE buffer) (pH 7.5)
-10 mM Tris-HCI (pH 7.5)
- 1 mM EDTA
c) Phosphate buffered saline (PBS) (pH 7.4)
One PBS tablet (Gibco, Paisley, UK) was added per 500 ml distilled water.
To make PBS/0.1% Tween, 1 ml "Tween 20" detergent was added to IL PBS.
2.1.8 Specific buffers and solutions
a) Plasmid DNA purification from bacterial cultures
The following buffers were supplied with Qiagen (Crawley, West Sussex, UK) plasmid 
purification kits:
- Buffer PI (Resuspension Buffer)
- Buffer P2 (Lysis Buffer)
- Buffer P3 (Neutralisation Buffer)
- Buffer QBT (Equilibration Buffer)
Buffer QC (Wash Buffer)
- Buffer QF (Elution Buffer for maxiprep kit)
- Buffer N3 (Neutralisation Buffer)
- Buffer EB (Elution buffer for miniprep kit)
50 mM Tris-HCI (pH 8.0) 
10 mM EDTA 
100 pg/ml RNase A 
200 mM NaOH 
1% SDS
3 mM potassium acetate (pH 5.5) 
750 mM NaCI 
50 mM MOPS (pH 7.0) 
15% isopropanol 
0.15% Triton ®X-100 
1 M NaCI 
50 mM MOPS (pH 7.0) 
15% isopropanol 
1.25 M NaCI 
50mM MOPS (pH 7.0) 
15% isopropanol 
3 mM potassium acetate (pH 5.5) 
10 mM Tris-HCI (pH 8.5)
b) Buffers for production of competent DH5a E.co/i cells:
Transformation buffer 1: 10 mM MES (pH 5.8) 
100 mM RbCb 
10 mM CaClz
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50 mM MnClz
Transformation buffer 2: 10 mM PIPES (pH 6.5)
75 mM CaClz 
10 mM RbClz 
15% v/v glycerol
c) Tail digestion buffer
-100 mM Tris pH 8 
-5 mM EDTA pH 8 
-200 mM NaCI 
-0.2% SDS
-0.5 mg/ml proteinase K
Peroxidase-Conjugated Goat Anti-Mouse Immunoglobulins (P0447, Dako, Glostrup, 
Denmark)
2.1.9 Bacterial Strains
- E co//of Strain DH5a was supplied by GIbco, Paisley, U.K.
2.1.10 Bacterial growth media
Media were made In ddHzO and sterilised by autoclavlng.
Lurla-BertanI (LB) medium:
-1%  (w/v) Bacto-tryptone (Duchefa, Haarlem, The Netherlands)
- 0.5% (w/v) Bacto-yeast extract (Duchefa, Haarlem, The Netherlands)
-1%  (w/v) Sodium chloride
The pH was adjusted to pH 7.0 using NaOH.
For LB agar plates 1,5% (w/v) agar (Duchefa, Haarlem, The Netherlands) was added to the 
LB medium.
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2.1.11 Growth media and solutions for maintenance of eukaryotic celis
-Dulbecco's Modified Eagie Medium (DMEM) (41966-029, Invitrogen, Paisley, UK)
Supplemented with:
10% (v/v) Foetal bovine serum (PBS) (10099-133, Invitrogen, Paisley, UK)
580 jjg/mi L-giutamine (25030-024, Invitrogen, Paisley, UK)
lOOOOU/mi peniciilin/lOOOOU/mi streptomycin (15140-122, Invitrogen, Paisley, UK)
- Hank's Balanced Sait solution, containing no magnesium and no calcium (HBSS)
(14175- 053, Invitrogen, Paisley, UK)
- Trypsin-EDTA (Ix) in HBSS w/o CA&MG, liquid - 0.25% Trypsin ImM EDTA*4Na
(25200-056, Invitrogen, Paisley, UK)
2.1.12 Plasmid expression constructs
The plasmid expression vectors used in this study are shown in Table 2.2. The pBIG- 
C9s expression vector was constructed by Dr. A Stephanou (Stephanou et ai., 2002) 
(figure 2.1). The C9s cDNA insert was sub-cioned from the pcDNA3-C9s expression 
construct generated by Dr. D Seoi (Seoi and Biiiiar, 1999). Human C9s was obtained 
by PCR from a human liver cDNA library using the following primers: forward primer 
5-ATGGACGAAGCGGATCGGCGGC-3' and reverse primer 5'- 
TTATGATü I I I I  AAAGAAAAü I I I I 11C-3'. The product was then cloned into pcDNA3 
(Seoi and Biiiiar, 1999).
Dr D Fauikes constructed the pCAGGs-hsp56 expression vector (figure 2.2). Human 
hsp56 was PCR cloned using the following primers: forward primer 5'- 
GGCTCTAGAGCCGCCATGACAGCCGAGGAGATG-3' and reverse primer 5'- 
CCGCTCGAGCrATGCTTCTGTCTCCAC-3. The PCR was performed with Advantage 
polymerase mix (Ciontech) and cloned in the pGEM-T-easy vector. The hsp56 cDNA 
was cloned into pCAGGs using /Votf/X/7o/excision into Xhol cut vector.
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Figure 2.1. The pBIG-C9s and pBIG-FLIP expression vectors. The pBlG 
expression vector contains a bi-directional Tet responsive element (TRE) fused to 
minimal CMV promoters. These promote expression of the adjoining lacZ gene and 
inserted cDNA of C9s or FLIP, downstream of which are poly-adenylation signals. The 
vector also contains the ampicillin resistance gene that encodes for the protein beta- 
lactamase.
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Figure 2.2. The pCAGGs-hsp56 expression vector. The pCAGGs-hsp56 
expression vector contains a chicken p-actin promoter that promotes expression of 
the inserted hsp56 cDNA, downstream of which is a poly-adenylation signal. The 
vector also contains the ampicillin resistance gene that encodes for the protein beta- 
lactamase.
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Expression Vector Source Catalogue Number
pTet-Off BD Biosciences K1620-A
pBIG BD Biosciences 6150-1
pCAGGs NIH Aids Research 10463
pBIG-C9s A. Stephanou (UCL) N/A
pBIG-FLIP P. Townsend (UCL) N/A
pCAGGS-hsp56 D. Faulkes (UCL) N/A
Table 2.2 Plasmid expression vectors 
2.1.13 Primers
Gene sequences were obtained from the National Centre for Biotechnology 
Information database, h ttp ://w w w .n cb i.n lm .n ih .Q o v / (Table 2.3). Oligonucleotide 
primers were designed using Primer Select software (Power Macintosh 3.11 ©1994- 
1997, DNASTAR inc) and were synthesized by MWG-biotech (Germany).
Oligonucleotide primers used in the genotyping of mice mutant for Trp53 (p5314F, 
p53E5R and OPT-21) or Statl (STATIF, STATIR, STATIKOF and STATlKOR) were 
designed by Taconic (USA). Primers used in the genotyping of aMHC-tTA transgenic 
mice were designed by the Jackson Laboratory (USA).
Primer pairs used in real-time RT-PCR (Table 2.3) were designed so that they 
spanned at least one intron in order to avoid amplification of contaminating genomic 
DNA or would amplify differentially sized genomic products that could be 
distinguished from cDNA amplification products. The exon and intron boundaries of 
sequences were determined using the UCSC Genome Bioinformatics database, 
h ttp ://Q en o m e.u csc .ed u /.
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Gene Gene Symbol Species Accession Number
p-ActIn Actb Mus musculus NM_007393
Atrial natriuretic 
factor (ANF)
Nppa Mas musculus K02781
Brain natriuretic 
peptide (BNP)
Nppb Mus musculus NM_008726
(MHC) Class II 
transactivator
C2ta Mus musculus NM_007575
Caspase-9 short 
(C9s) isoform
CASP9 Homo sapiens AFl10376
FBJ osteosarcoma 
oncogene (c-fos)
Fos Mus musculus NM_010234
FLICE-like inhibitory 
protein long (FLIP- 
L) isoform
CFLAR Homo sapiens U97074
Glyceraldehyde-3-
phosphate
dehydrogenase
(GAPDH)
Gapdh Mus musculus M32599
Heat shock protein 
56 (hspSG)
FKBP4 Homo sapiens NM_002014
Serum/glucocorticoid 
regulated kinase
Sgk Mus musculus NM_011361
Interleukin 6 (IL-6) 116 Mus musculus NM_031168
Interferon regulatory 
factor 1 (IRF-1) Ir f l Mus musculus NM_008390
p2-microglobulin B2m Mus musculus NM_009735
Beta myosin heavy 
chain (p-MHC) Myh7 Mus musculus NM_08G728
p53 Trp53 Mus musculus X01237
Table 2.3 NCBI gene accession numbers
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Primer Name Primer Sequence 5 -3'
Annealing 
Temperature and 
Am pi icon Size
p5314F ACA CAC CTG TAG CTC CAG CAC 60 X
p53E5R AGC GTC TCA CGA CCT CCG TC WT 520 bp
OPT-21 GTG TTC CGG CTG TCA GCG CA KO 730 bp
STATIF CTA CCA GAG TAT CTG CCT AGA C 60
STATIR CCT CTC AAC e r r  CCT GAC ACC 325 bp
STAT1565F GGA GTG TTTTCT AAG GCA G 57 X
Meraz 37 R GCA TCG CCT TCT ATC GCC 450 bp
C9s F GTC AGG CTC TTC CTT TGT TC 58 "C
C9sR GGT CTTTCT GCT CGA CAT CA 225 bp
FUP F GGG CCA GCG ATG AAG AAT GTG G 58 "C
FLIPR GGA TGG TGA GCT GTG AGA CTG C 135 bp
oIMROOlS CAA ATG TTG CTT GTC TGG TG 60 "C
OIMR0016 GTC AGT CGA GTG CAC AGT TT 450 bp
OIMR0856 CGC TGT GGG GCA TTT TAC TTT AG 60 "C
OIMR0857 CAT GTC CAG ATC GAA ATC GTC 200 bp
hsp56 F GCC TAC GGT TCA GCA GGC A 58 "C
hsp56 R TCA TCT CCC AAG ACT CCT TG 451 bp
Table 2.4 Oligonucleotide primers for genotyping
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Primer Name Primer Sequence 5'-3'
Annealing 
Temperature and 
Amplicon Size
p-Actin F AGA TCA CCC AGA TCA TGT TTG AG 60 °C
p-Actin R AGG TCC AGA CGC AGG ATG 187 bp
ANF F AGG CCA TAT TGG AGC AAA TCC T 66 °C
ANFR TGC TTC CTC AGT CTG CTC ACT C 151 bp
BNP F CTG TTT CTG CTT TTC CTT TAT CTG 67 °C
BNP R CTG GGC CAT TTC CTC CGA CTT T 138bp
Cllta F GAC AGC CAG CCA GGA CTT CT 61 °C
Cllta R GGG GCC CAA CGC AAA CTC 341bp
c-fos F GCG CAG AGC ATC GGC AGA AG 68 °C
c-fos R GAG AAG GGG CAG GGT GAA GG 375bp
GAPDH F AAT GTG TCC GTC GTG GAT CTG A 67 °C
GAPDH R GAT GCC TGC TTC ACC ACC TTC T 83bp
IL-6 F GAA CAA CGA TGA TGC ACT TGC AG 60 °C
IL-6 R CCT TAG CCA CTC CTT CTG TGA C 328bp
IRF-1 F CAC GGC TGG GAC ATC AAC AAG 68 °C
IRF-1 R GTC CGG GCT AAC ATC TCC ACA C 299bp
P-MHC F GCC GCG CCA GTA CTT CAT AGG T 69 °C
P-MHC R ACT TGC CCA GGT GGT TGT CGT A 326bp
p2-micro F TGC TGT CTC CAT GTT TGA TGT ATC T 60 *C
p2-micro R TCT CTG CTC CCC ACC TCT AAG T 187bp
Sgk F GGC CTG CCC CCG TTT TAT 61 °C
Sgk R GTC ACT GGG CCC ACT CAC ATT T 267bp
Table 2.5 Oligonucleotide primers for real time PCR
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2.2 Animals
This study was performed in accordance with the United Kingdom, Home Office 
Animals (Scientific Procedures) Act 1986.
2.2.1 Transgenic mice
Mutant Trp53 (B6.1 2 9 - N12) and Statl (129S6/SvEvTac-Sfai '^”^'^^ gene 
targeted knockout mice were purchased from Taconic (USA). aMHC-tTA (FVB/N- 
TgN(aMAyC-frA)6Smbf) transgenic mice were purchased from the Jackson 
Laboratory (USA).
2.3 Langendorff perfusion o f the isolated adult mouse heart
Langendorff perfusion of mouse hearts was performed using a commercial 
Langendorff system (#ML870B2, ADInstruments). Male mice (aged 10-12 weeks) 
were anaesthetised (sodium pentobarbitone, 60 mg/kg intraperitoneal injection) and 
heparinized (25 lU intra peritonea I injection). Once an adequate level of anaesthesia 
had been achieved, the chest was opened and the heart of the mouse was rapidly 
removed, placed in ice-cold (4 °C) Krebs-Henseieit buffer and the aorta was 
canulated. Hearts were then perfused with a modified Krebs-Henseleit buffer (NaCI 
118 mM; NaHCOs 24 mM; KCI 4 mM; NaH2P0 4  1 mM; CaClz 2.5 mM; MgClz 1.2 mM; 
EDTA 0.5 mM; glucose 10 mM; gassed with 95% 02/5% C02at 37 °C and a constant 
pressure of 100 mmHg. In this modified Krebs-Henseleit buffer EDTA was added in 
order to lower the final calcium concentration to the physiological range of 1.5 mM. 
Temperature was measured by the placement of a fine thermocouple wire in the left 
ventricle. Monitoring of perfusion pressure, left ventricular developed pressure 
(LVDP) and heart rate was performed with a water-filled balloon inserted into the left 
ventricle.
For the normoxic control, isolated mouse hearts were perfused for 95 minutes under 
normoxic conditions. For the ischaemia/reperfusion treatments, mouse hearts were 
subjected to 35 minutes of global ischaemia by stopping the flow of buffer and
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immersing the heart in buffer at 37 °C followed by 45 minutes of reperfusion initiated 
by returning the flow of buffer. At the end of each experimental protocol, the infarct 
size was assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining. 2 ml of a 1% 
solution of TTC was perfused through the heart followed by immersing the heart in 
TTC solution at 37 °C for 1 minute. Hearts were frozen at -20 °C and sectioned into
1.5 mm slices. These slices were laid out and compressed between thin glass plates 
0.5 mm apart. The sections were scanned, enlarged, and infarct size assessed using 
computerised planimetry (Planimetry+, Boreal Software, Norway).
2.4 Langendorff perfusion o f the isolated adult rat heart
Hearts were removed from male Sprague-Dawley rats (250-260 g), placed in ice-cold 
(4 °C) Krebs-Henseleit buffer and the aorta was canulated. The heart was perfused 
with Krebs-Henseleit buffer (NaCI 118.0 mM; NaHCOa 25 mM; KCI 4.8 mM; NaH2P0 4
1.2 mM; CaCb 1.2 mM; MgS0 4  1.2 mM; EDTA 0.5mM; glucose 11 mM; gassed with 
95% 0 2 / 5 % CO2 at 37 ®C) at a constant flow of 12 ml/min. Monitoring of developed 
pressure (LVDP) was performed with a water-filled balloon inserted into the left 
ventricle set to give and initial end-diastolic pressure (EDP) of 2.5-5 mmHg. After a 
15-minute stabilisation period of perfusion, hearts were perfused for 30 minutes in 
the presence or absence of 10 nM Ucn in re-circulation mode. Global isothermic 
ischaemia was induced by halting perfusion and immersing the heart in perfusion 
buffer at 37 °C. For non-ischaemic controls the perfusion was not interrupted. After 
30 minutes of ischaemia, perfusion was restarted (in the presence or absence of 
Ucn) and continued for 30 minutes. Samples of perfusate were collected prior to 
ischaemia, every minute for the first five minutes of reperfusion and at every 5 
minutes of reperfusion for the spectrophometric determination of lactate 
dehydrogenase (LDH) activity.
2.5 Measurement o f mitochondrial permeability transition pore 
opening in situ using [^H]-2-deoxyglucose entrapment
Following the 15-minute stabilisation period of perfusion, hearts were perfused in 
recirculating mode in Krebs-Henseleit buffer containing 0.5 mM [^H]-2-deoxyglucose
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([^H]"DOG) (0.1 piCi/ml) for 30 minutes. Perfusion was then returned to non­
circulating mode with normal Krebs-Henseleit buffer for 15 minutes to wash out 
extracellular [^H]-DOG. The buffer was then halted to initiate isothermic (37 °C) 
ischaemia. After 30 minutes of ischaemia, hearts were reperfused for 30 minutes in 
presence or absence of 10 nM Ucn prior to mitochondrial preparation and 
determination of [^H]-DOG and citrate synthase activity.
At the end of re perfusion the ventricles were rapidly cut away, weighed, and 
homogenized with a Polytron homogenizer at setting 3 for 5s in 5 ml of ice-cold 
sucrose buffer (300 mM sucrose, 10 mM Tris-HCI, 2 mM EGTA, pH 7.4) and then 
made up to 40 ml with buffer containing 5 mg/ml BSA. The homogenate was 
centrifuged at 10 000 x g for 5 minutes. The pellet was resuspended in 6 ml sucrose 
buffer containing 20% (w/v) Percoll and centrifuged at 12 000 x g for 10 minutes to 
yield a purified mitochondrial pellet. The pellet was washed once in 40 ml of BSA- 
free sucrose buffer followed by centrifugation at 12 000 x g and finally resuspended 
in 0.5 ml of sucrose buffer. A 100 pi sample of the suspension was retained for assay 
of citrate synthase to correct for mitochondrial recovery. An equal volume of 
perchloric acid (PCA) was added to release the entrapped [^H]. The homogenate was 
centrifuged at 12 000 x g for 2 minutes and the supernatant was assayed for 
radioactivity in 10 ml scintillant (Packard Emulsifier-Safe).
2.6 Cell culture
All protocols were carried out in sterile conditions using a laminar flow cabinet 
(Heraeus) and cells were maintained at 37 °C and 5% CO2 in a humidified 
HeraCELL™ (Heraeus). Mammalian cell lines were cultured in growth medium 
(Dulbecco's Modified Eagle Medium containing 10% foetal bovine serum, penicillin 
and streptomycin) in tissue culture plastic ware (Nunc).
2.6.1 Cell Harvesting
Adherent cells were washed once with Hanks Buffered Saline Solution (HBSS) and 
harvested by incubating in Trypsin for 2-5 minutes. The trypsin was inactivated by
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addition of growth medium and cells were gently pipetted to detach clumped cells. 
Cells were passaged when cultures reached 70-80% confluence.
2.6.2 Cryopreservation of Cells
Stocks of mammalian cells were stored in 1.8 ml cryovials under liquid nitrogen. Cell 
suspensions were centrifuged at 1000 x g for 5 minutes. The supernatant was 
discarded and the cell pellet was re-suspended in growth medium supplemented with 
20% FBS and 10% DM SO. Cell suspensions were transferred to cryovials and placed 
in liquid nitrogen storage.
2.6.3 Thawing of Cells
Mammalian cell line stocks stored in cryovials were thawed at 37 °C in a water bath. 
The cells were washed once by adding the suspension to 10 ml of growth medium 
and were centrifuged at 1000 x g for 5 minutes. The cell pellet was re-suspended In 
growth medium and the suspension transferred by pipette to tissue culture flasks.
2.6.4 Determination of cell number
Viable cells were quantified using the Trypan Blue exclusion assay. 200 pil of cell 
suspension was added to 500 pil of Trypan Blue and 300 pil of HBSS in a bijou and 
was mixed by inverting. 20 \i\ was pipetted onto a haemocytometer overlaid with a 
coverslip and the number of non-Trypan blue containing cells were counted under 
light microscopy.
2.6.5 Determination of cell growth
Cellular growth rates were measured using the CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay kit (G3582, Promega). Cells were seeded at a density of 
1x10  ^cells per well (100 pil volume) in 96-well plates. The day of plating was termed 
day 0 (zero). The quantity of cells was determined on subsequent days according to
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manufacturer's Instructions. Absorbance was measured at 492 nm by a Gen I os 
microplate reader (Tecan, UK).
2.7 Primary culture o f adult rat cardiac myocytes
Adult rat ventricular cells (ARVC) were isolated by perfusion of the heart with 
collagenase. Hearts from 250-300 g male Sprague-Dawley rats, that were freshly 
culled, were excised and placed in ice-cold Krebs-Henseleit buffer (130 mM NaCI, 5.4 
mM KCI, 3.5 mM MgCI, 750 i^M CaCb, 0.4 mM NaH2P0 4 , 5 mM HEPES and lOmM 
glucose) containing 10.5U/ml heparin. The aorta was canulated and the heart was 
perfused with Krebs-Henseleit buffer for 1 minute followed by Ca^^-free Krebs- 
Henseleit buffer containing 100 \xM EGTA for 3 minutes. Hearts were then perfused 
with Krebs-Henseleit buffer containing 350U/ml collagenase and 180 fxM CaCb for 15 
min. During collagenase perfusion the waste pipe was closed to allow the heart to 
become immersed in the perfusate inside a water jacket and the collagenase buffer 
was re-circulated. All buffers were oxygenated prior and during perfusion, 
maintained at 37 °C and hearts were perfused at 2 ml/min.
The heart was then cut into fine pieces with a scalpel and was incubated in shake 
solution (13.5 ml re-circulated collagenase buffer and 1.5 ml of 10% BSA) for 5 
minutes with gentle shaking. The dissociated cells were filtered through muslin into a 
fresh tube. The cells were spun at 1000 rpm for 1 minute and the supernatant was 
discarded. The cell pellet was washed with 10 ml of restore buffer (10 parts Krebs- 
Henseleit buffer to 1 part 10% BSA and 180 ^M CaClz) and spun at 1000 rpm for 1 
minute. The supernatant was discarded and the cells were re-suspended in medium 
199 containing 5 mM creatine, 2 mM carnitine, 5 mM taurine, 0.8 mM EGTA. Cells 
were then plated on laminin (L-2020, Sigma) coated culture dishes. After 1 hour the 
media was replaced and non-adhered cells were discarded.
2.8 Primary culture o f neonatal rat or mouse cardiac myocytes
Hearts were excised from 2-day old Sprague Dawley rats or mice and incubated in
Krebs-Henseleit bicarbonate buffer. Once all hearts were excised the isolation of
myocytes was continued in sterile conditions in a laminar flow cabinet. Hearts were
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trisected and transferred to a 25 cm  ^ culture flask. The Krebs-Henseleit buffer was 
removed by pipette and discarded and hearts were washed once with 7 ml of Krebs- 
Henseleit buffer. Cells were enzymatically dissociated by incubating in 7 ml of 
oxygenated digestion buffer (0.1% (% ) Collagenase in Krebs-Henseleit) at 37 ®C in a 
humidified incubator maintained at 5% CO2 for 15 minutes. The cell suspension was 
transferred to 15 ml tube, 2 ml of foetal bovine serum (FBS) was added to terminate 
the reaction and cells were centrifuged at 1000 x g for 5 minutes. The supernatant 
was discarded and the cell pellet was re-suspended in 4 ml of FBS. Hearts were 
incubated in fresh digestion buffer and the enzymatic dissociation of cardiac cells 
was repeated 8 times. The cell suspensions were pooled in a 50 ml tube and 
centrifuged at 1000 x g for 5 minutes. The supernatant was discarded and the cell 
pellet was re-suspended in plating medium (DMEM, 15% FBS, penicillin and 
streptomycin) and transferred to a culture flask. The cell suspension was pre-plated 
for 1 hour in a humidified incubator (37 ®C /5% CO2) to remove non-myocytes from 
the suspension. The enriched myocyte suspension was counted and plated onto 
tissue culture plates pre-coated with 1% gelatin in PBS. On the following morning 
the plating medium was removed from myocyte-attached cultures and replaced with 
maintenance medium (DMEM, 1% FBS, penicillin and streptomycin) in order to 
minimize fibroblast growth.
2.9 Primary culture o f mouse embryonic fibroblasts
Mouse embryonic fibroblast (MEF) cells were isolated from embryos aged day 13.5 
days post coitum (dpc). Embryos were isolated, washed in PBS, and the head and 
visceral organs were removed. The carcasses were washed in PBS and then minced 
into fine pieces in 2 ml Trypsin-EDTA followed by incubation at 37 °C for 30 minutes. 
The carcasses were then vigorously mixed by pipette to dissociate the cells. A 10 ml 
volume of DMEM containing 10% FBS was added. The large debris was allowed to 
settle and the supernatant was then plated to culture dishes. After 1 hour non­
adhered cells were washed off and the cells were cultured in growth medium.
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2.10 Simulated ischaemia/reperfusion in cultured cells
simulated ischaemia was performed in cells using an ischaemic chamber supplied 
with carbon dioxide/argon (95%/5%) and maintained at 37 °C. Cells were washed 
with HBSS and incubated in 137 mM NaCI, 12 mM KCI, 0.49 mM MgClz, 0.9 mM 
CaCb, 4 mM HEPES, 10 mM deoxyglucose and 20 mM Na lactate (pH 6.2) during 
simulated ischaemia. Cells were removed from the chamber and reperfusion was 
simulated by replacing the ischaemic buffer with maintenance media and incubating 
the cells in normal conditions. Non-ischaemic control cells were incubated in 137 mM 
NaCI, 3.8 mM KCI, 0.49 mM MgCb, 0.9 mM CaCb, 4 mM HEPES, 10 mM glucose and 
20 mM Na lactate (pH 7.4) for an equal length of time to the ischaemic treated cells. 
The cultures were incubated in an incubator with normal conditions (37 °C and 5% 
CO2) and the ischaemic control buffer was replaced with maintenance media in 
synchronisation with ischaemic cells.
2.11 Measurement o f MPTP opening in adult rat cardiac myocytes 
using Tetramethyl rhodamine methyl ester (TMRM) fluorescent 
dyes
MPTP opening in isolated adult rat cardiac myocytes was assessed using TMRM, a 
cell permeable, voltage-sensitive dye that accumulates in energized but not 
depolarised mitochondria. Cytofluorimetric analysis was performed using an Epics XL 
flow cytometer (Beckman Coulter, UK) equipped with a 488 nm argon ion-laser. The 
TMRM signal was analysed in the FL2 channel, which was equipped with a bandpass 
filter 575 ± 20 nm. Data were acquired on a logarithmic scale. Arithmetic mean 
values of the median fluorescent intensities were determined for TMRM.
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2.72 Immunocytochemistry
Cells were cultured on round 13 mm coversllps. Cells were washed with PBS and 
then fixed in 4% RFA or ice-cold methanol for 10 minutes. Cells were washed in PBS 
and PFA fixed cells were permeabilised in 0.1% NP-40 in PBS for 10 minutes. Cells 
were then blocked in 3% BSA in PBS for 1 hour. The blocking solution was discarded 
and the cells were incubated in primary antibody at concentrations of 1:5 to 1:500 in 
1% BSA for 1 hour or overnight at 4 °C. The primary antibody was washed off five 
times with PBS. The cells were then incubated with the fluorescent tagged secondary 
antibody in 1% BSA at a concentration of 1:1000. The secondary antibody was 
washed off by rinsing the cells five times with PBS. The coverslips were then 
mounted onto glass slides with fluorescent mounting medium (#302380, Da ko).
2.13 Histology
Mouse hearts were perfused with Krebs-Henseleit buffer for 5 minutes to wash out 
the blood. Hearts were fixed in 4% formalin overnight at room temperature. Hearts 
were then dehydrated in the following graded series of ethanol (2  hours for each); 
50%, 70%, 80, 90%, 96% and 100%. Hearts were then incubated in butanol at 
room temperature overnight. Hearts were then transferred to glass scintillation vials 
and incubated in a 1:1 ratio of butanol:molten pastiHated wax at 60 °C for 20 
minutes. The butanol/wax mix was discarded and replaced with 100% molten wax 
for four hours followed by replacement with fresh wax and incubation overnight. 
Hearts were then embedded in fresh wax in disposable plastic sectioning blocks with 
mount and allowed to set at room temperature.
Wax embedded hearts were sliced into 8  pim sections with a rotary microtome 
(Leica-microsystems). Sections were placed in a water bath heated to 42 °C and then 
mounted onto TESPA coated glass slides. Slides were stood upright to remove excess 
water and then dried at 42 °C for 1 hour. Sections were de-waxed by five minute 
incubations in the following order; 2 x Histoclear (HS-200, National Diagnostics), 2 x 
100% ethanol, 95% ethanol, 80% ethanol and 70% ethanol.
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Sections were stained in Haematoxylin for 10 minutes. The slides were removed and 
dipped twice in dHzO. Sections were then stained in Eosin (#AS025, Raymond-A- 
Lamb) for 5 minutes followed by dipping twice in dHzO. Slides were left to dry 
overnight at room temperature. Coverslips were then mounted using DPX mount for 
microscopy (#36029, BDH).
2.14 Quantification of nucleic acid concentration
The concentration of double stranded DNA (dsDNA) was quantified in two ways; 
either by running the linearized DNA samples alongside molecular weight markers of 
known DNA concentration on an agarose gel and comparing the intensity of the 
bands or by using ultraviolet (UV) absorbance spectrophotometry. The amount of UV 
light absorbed by a solution of nucleic acid is directly proportional to the amount of 
nucleic acid in the sample. Absorbance was measured at 260 nm, at which 
wavelength an absorbance (A260) of 1.0 corresponds to 50 of dsDNA per ml or 40 
\xQ of RNA per ml.
UV absorbance was also measured at the wavelength 280 nm in order to check the 
purity of the nucieic acid preparation. The ratio of the absorbance at 260 nm and 
280 nm (A260/A280) of a pure sample of nucleic acid would be 1.9-2.1. A ratio of less 
than 1.8 indicated that the preparation was contaminated with protein. The integrity 
RNA was checked by separating 1 jig of RNA and observing 28S and 18S ribosomal 
RNA.
2.15 DNA cloning in bacterial cells
2.15.1 Production of Heat Shock Competent DHSa Strain E.coli Cells
A culture of DHSa-strain Eco//was then grown overnight in a shaking incubator (250 
rpm) at 37 °C. 100 \i\ of this overnight cuiture were added to 100 ml LB medium in a
2.5 L sterile (autoclaved) conical flask and then returned to the shaking incubator 
(250 rpm) for approximately three hours.
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After 2 hours and then every 30 minutes after that, the growth of the cell culture 
was checked by measuring absorbance at 600 nm. The 100 ml culture was removed 
from the incubator when the culture was in the exponential log phase of the growth 
curve (i.e. clouds of bacteria swirling in the medium were just visible when held up 
to the light and when the absorbance reading of the culture when measured on the 
spectrometer at 600 nm was between 0.3 and 0.8).
The culture was then divided between two 50 ml sterile tubes, placed on ice for five 
minutes and centrifuged at 3000 rpm for 10 minutes in a Sorvall RT-7 Plus at 4 °C. 
The supernatant was discarded and the pellet in each tube was resuspended in 20 
ml ice-cold transformation buffer 1 and incubated on ice for 5 minutes. Each tube 
was again centrifuged at 3000 rpm for 10 minutes at 4 °C and the supernatant 
discarded. Each pellet was then resuspended in 1 ml of transformation buffer 2 and 
incubated on ice for 15 minutes. 100 \i\ of this suspension were then aliquoted into 
pre-chilled 1.5 ml microcentrifuge tubes and stored at -80®C or used directly for 
transformations.
2.15.2 Transformation of heat shock competent E.coli cells
In a 1.5 ml microfuge tube, 100 pi of heat shock competent DH5a strain Eco//cells 
were thawed on ice and 50-100 ng of plasmid DNA was added, mixed by gently 
stirring with a pipette tip and incubated on ice for 30 minutes. Cells were heat 
shocked by incubating at 42 °C for 1 minute in a water bath and further incubated on 
ice for 2 minutes. 900 pi of LB medium was added to the cells and were incubated at 
37 °C for 1 hour. Cells were centrifuged at 3000 x g for 10 minutes, the supernatant 
was poured off and the cells were re-suspended in the residual supernatant. The re­
suspended cells were then pipetted onto selective LB agar plates containing 
appropriate antibiotic. A glass Pasteur pipette was sterilised by passing through a 
flame and used to the spread the cells over the surface and the plates were 
incubated at 37 °C overnight. The following day antibiotic resistant clones were 
picked, grown LB with appropriate antibiotic.
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2.15.3 Purification of plasmid DNA
Large-scale extraction to produce 100-500 \ig of DNA per preparation was carried 
out using the Qiagen Plasmid Maxi purification buffers and protocol. A single colony 
of plasmid transformed clones was picked from a freshly prepared LB/Ampicillin plate 
to inoculate a starter culture of 5 ml LB/Ampicillin medium. This culture was 
incubated for approximately eight hours at 37 °C with vigorous shaking at 300 rpm. 1 
ml of the starter culture was then diluted into 500 ml of LB/Ampicillin medium and 
incubated at 37 °C for 16 hours overnight with vigorous shaking at 300 rpm. On the 
following day, bacterial cells were harvested by centrifugation at 9000 rpm in a 
Sorvall RC26 Plus (SLA 3000 rotor) for 15 minutes at 4 °C. Supernatant was 
discarded and the bacterial pellet resuspended in 10 mi of ice cold buffer PI and 10 
ml of buffer P2 was added. After mixing and incubation at RT for 5 minutes 10 ml of 
chilled buffer P3 was added. The mixture was kept on ice for 20 minutes then 
centrifuged at 12000 rpm in a Sorvall RC26 Plus (SS-34 rotor) for 30 minutes at 4 °C. 
Supernatant containing plasmid DNA was promptly removed and re-centrifuged for 
15 minutes at 4 °C. A Qiagen tip 500, containing DNA binding resin, was equilibrated 
by the addition and free gravity flow of 10 ml Buffer QBT. Supernatant was then 
applied to the Qiagen tip and allowed to enter and bind DNA to the resin by free 
gravity flow while all other components pass through. The DNA was then washed by 
passing 30 ml of buffer QC through the tip twice and eluted with 15 ml of buffer QF. 
To precipitate the DNA 10.5 ml (0.7 volumes) of RT isopropanol was added to the 
eluted DNA, mixed and then centrifuged at 3000 rpm (in a Sorvall RT7 Plus) for 45 
minutes at 4 °C. Following which supernatant was carefully decanted and the DNA 
pellet washed with 5 ml of RT 70% ethanol and centrifuged at 3000 rpm (in a Sorvall 
RT7 Plus) for 15 minutes at 4 °C. The supernatant was discarded, the pellet dried 
under a vacuum for 2-5 minutes and then redissolved in 1 ml of autoclaved water.
2.15.4 Separation of DNA fragments by agarose gel electrophoresis
DNA were separated by agarose gel electrophoresis. Agarose was mixed in TAB 
buffer and boiled in a microwave oven until dissolved and was left to cool at 55 °C. 3 
\i\ of 1 0  mg/ml ethidium bromide was added to 1 0 0  ml of boiled agarose and then 
poured and left to solidify in a casting gel tray with the open ends closed off by tape.
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20-well or 14-well gel combs were inserted. Once the gel solidified the tape and 
combs were removed. The tray with the gel was then placed in an electrophoresis 
tank and TAE buffer was poured into the tank until the gel was covered. 
Bromophenol Blue loading buffer was added to the DNA sample and the sample was 
pipetted into the well. 0.5 jxg 2-Log DNA ladder was loaded adjacent to samples so 
that the molecular weight of DNA fragments could be determined. Electrophoresis of 
DNA was carried out at 100mA until resolution of DNA fragments was sufficient. DNA 
fragments were visualized on a long wave UV transilluminator and photographed 
using the Syngene doc system.
2.15.5 Purification of DNA from agarose gels
DNA was purified from agarose gel using the QIAquick gel extraction (Qiagen, 
Crawley, West Sussex, UK) kit. An excised band of DNA of up to 0.4 g was placed in 
a 1.5 ml microfuge tube and 1 ml of buffer QG added. The mixture was then 
incubated at 55 °C for 10 minutes until all agarose had dissolved. 700 \i\ of this 
solution was then added to a spin column placed in a collection tube and centrifuged 
at 13000 rpm for 10 seconds. The flow through was discarded from the collection 
tube and the procedure repeated until all of the initial mixture had been passed 
through the spin column. A further 500 pil of buffer QG was added to each spin 
column and centrifuged at ISOOOrpm for 10 seconds. After discarding the flow 
through, the column was washed twice with 500 pil of buffer PE and centrifuged as 
above. Each column was then placed into a fresh 1.5 ml microfuge tube and dried 
under a lamp for 5 minutes. Elution of DNA from each column was performed by 
addition of 50 pil of solution EB (lOmM Tris-HCI pH 8.5), allowing the column to 
stand for 1 minute followed by centrifugation as above. The product was then stored 
at-20°C.
2.16 Transgenesis by pronuclear injection
Ttie expression constructs pBIG-C9s, pBIG-FLIP and pCAGGS-Hsp56 were linearized 
and dialyzed against injection buffer (7.5mM Tris pH7.4 and 0.02mM EDTA) prior to 
pronuclear injection by the Institute of Child Health (ICH) transgenic facility. 
Expression constructs were injected in the male pronucleus of fertilized eggs from
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FVB/N Strain mice and were re-implanted into the FVB/N foster mothers after 1-2 
days culture. For injections by the Karolinska Institute, expression constructs were 
sent in non-linearized form and restriction digestions were performed as part of the 
service.
2.17 Genotyping by polymerase chain reaction (PCR)
2.17.1 Purification of genomic DNA from tail biopsies
Tail biopsies were digested in 700 pi of tail digestion buffer overnight at 55 °C. An 
equal volume of Tris equilibrated phenol was added to the digested tail, mixed by 
inverting the tube vigorously and centrifuged at 13000 rpm in a micro centrifuge for 
5 minutes. The upper aqueous phase was removed by pipetting to a clean 1.5 ml 
microfuge tube. An equal volume of chloroform: isoamylalchohol (24:1) was added, 
mixed and centrifuged as before. The upper aqueous phase was removed to a clean 
tube and DNA was precipitated by adding an equal volume of isopropanol and mixed 
gently until a DNA precipitate was visible. The precipitated DNA was pelleted by 
centrifugation at 13000 rpm for 10 minutes at 4 °C and the supernatant was 
discarded. The DNA pellet was washed with 700 pi of 70% (v/v) ethanol and 
centrifuged at 13000 rpm for 5 minutes. The ethanol was discarded and the DNA 
pellet was left to air dry. Once dry, the DNA was re-suspended in 300 pi of TE buffer.
2.17.2 Mouse genotyping by Polymerase Chain Reaction (PCR)
The genotypes of mice for aMHC-tTA, pBIG-C9s, pBIG-FLIP, pCAGGs-hsp56 
transgenes and Trp53 and Statl alleles were determined by PCR. Primer pair 
sequences, annealing temperatures and amplicon sizes are shown in Table 2.4. A 
region of the aMHC-tTA transgene was amplified with primers oIMR0015 and 
OIMR0016 in duplex with primers oIMR0856 and oIMR0857 for an internal DNA 
control. Regions of STATl^ '^*’ and STATl'^ ' alleles were amplified in separate 
reactions using specific wild type (STATIF and STATIR) and knockout (STAT1565F 
and STAT1852R) primer pairs. Regions of Trp53^ '^*' and TrpSJ '^ alleles were amplified
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in a single reaction using a common forward oligonucleotide primer (p5314F) with 
specific wild-type (p53E5R) and knockout (OPT-21) reverse primers.
1 \i\ of mouse genomic DNA was assayed per reaction in a total volume of 25 pil 
containing Ix  PCR buffer, 2 mM MgCb, 0.2 mM dNTPs, and 1 unit Tag polymerase. 
Primer pairs were used at a final concentration of 1 pM each with the following 
exceptions. Trp53 primers were used at the following concentrations: 0.5 pM 
p5314F, 1 pM p53E5R and 0.5 pM OPT-21. Primers OIMR0015 and 0 IMROOI6  were 
used at 1.05 pM and primers oIMR0856 and oIMR0857 were used at 1.66 pM. A 
master mix of PCR buffer, MgCb, dNTPs, primers and Tag polymerase in ddHzO was 
prepared in a 1.5 ml microfuge tube. 24 pi aliguots of the master mix were 
transferred to 0.2 ml PCR tubes and 1 pi of DNA was added. The tubes were then 
placed into a PCR machine and the cycling parameters were used as follows:
Initial dénaturation at 95 °C for 3 minutes
Then 35 cycles as follows:
Dénaturation - 95 °C for 1 minute 
Annealing - 60 ®C for 1 minute 
Extension - 72 ®C for 1 minute
Final extension at 72 °C for 5 minute
The reaction was then held at 4 °C until samples were removed.
2.18 Southern Blotting
2.18.1 Restriction endonuclease digestion, electrophoresis and 
denaturing of DNA
10 pg of mouse genomic DNA was restriction digested overnight at 37 °C in an 
incubator. Each sample was digested in a volume made up to 80 pi with ddHzO 
containing Ix  restriction enzyme buffer, 1 mg/ml BSA, and 1 pi of restriction enzyme.
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40 \i\ of restriction digested DNA was separated by electrophoresis in a 20 x 20 cm 
1% agarose gel overnight at 35 V. DNA was depurinated by incubating the gel in 500 
ml of 0.25 M HCI for 10 minutes and gently agitated on a shaker. The gel was 
washed once with ddHzO and the gel was denatured in 500 ml of denaturing buffer 
(0.5 M NaOH, 1.5 M NaCI) for 20 minutes while shaking. The reaction was then 
neutralised by incubating the gel in neutralising buffer (0.5 M Tris, 1.5M NaCI) for 20 
minutes.
2.18.2 Transfer of DNA to nylon membrane
DNA was transferred from the gel to a nylon membrane, Hybond N'^  (Amersham), by 
capillary action. A flat and solid support for the gel was placed in the centre of a tray 
that acted as a reservoir and was filled with 500 ml of 20x SSC so that the support 
was not submerged. A piece of Whatmann 3MM filter paper was cut to a length so 
that it covered the support and hung over at two ends reaching the bottom of the 
reservoir so that it would function as a wick. The filter paper was saturated with 20x 
SSC and the gel was placed on top. The gel and reservoir was covered with a piece 
of cling film. The cling film covering the gel was cut away with a scalpel so that the 
cling film covered only a few millimetres of the edges of the gel and the reservoir. 
Hybond-N nitrocellulose membrane was cut to the dimensions of the gel, soaked in 
2x SSC and positioned on the gel. Two pieces of 3MM filter paper were pre-wet in 2x 
SSC and placed on top of the blot and covered by four more pieces of dry 3MM filer 
paper. Absorbent paper towels were then placed on top of the 3MM filter paper and 
a solid weight of approximately 500 g was placed on top so that the towels were 
compressed. Blotting was carried out overnight. On the following the day the DNA 
was cross-linked to the membrane by exposing it to 1.2 Joules of UV light. The 
membrane was then pre-hybridised in 20 ml of hybridisation buffer in a glass 
hybridisation bottle beaker whilst rotating in an oven at 65 °C for 1 hour.
2.18.3 ^^P-labelling of DNA probes
DNA probes were radiolabelled by random primer extension with ^^P-labelled dCTP 
(Amersham, PB10205) using DNA labelling beads (Amersham, 27-9240-01). The DNA 
labelling bead was dissolved in its tube with 10 \i\ of ddHzO. The DNA probe was
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denatured by boiling at 100 ®C on a hot plate for 5 minutes, pulse centrifuged and 
incubated on ice for 2 minutes. 50 ng of denatured DNA was added to the dissolved 
bead and 5 1^ (l.SSMBq) of ^^P-labelled dCTP was then added. The reaction was 
made up to 50 1^ with ddHzO and mixed. The primer extension was carried out at 37 
°C for 1 hour in a water bath. The probe was then purified from unincorporated ^^ P- 
labelled dCTP, random primers and dNTPs by affinity column chromatography. 150 pil 
of ddHzO was added to the probe and then added to the column and centrifuged at 
1000 X g for 2 minutes. The eluate was collected in a 1.5 ml microfuge tube and 2 \i\ 
was transferred to another microfuge tube and the radioactivity was measured in a 
scintillation counter. Probes measuring less than 15000 counts per second were not 
used.
2.18.4 Hybridisation of DNA probes to membrane and detection
Boiling for 5 minutes denatured the radiolabelled probe and 50 i^l was added to 20 
ml hybridising buffer. The pre-hybridising buffer was discarded and replaced by 20 
ml of hybridising buffer containing the radiolabelled probe. The membrane was 
incubated with the probe overnight at 65 °C. The probe was discarded and the 
membrane was washed by incubating the membrane in 0.5 M phosphate buffer 
containing 0.5% SDS for 10 minutes at 42 °C. The wash solution was discarded and 
the membrane was then washed in 0.25 M phosphate buffer containing 0.5% SDS 
for 10 minutes at 42 °C. Membranes with hybridised radiolabelled DNA fragments 
were visualised by exposing the membrane to Kodak auto-radiographic film or 
phosphor imager plates for quantitation.
2.19 Quantification of mRNA expression
2.19.1 RNA extraction
RNA was extracted from cells or tissue using Trizol (#15596-026, Invitrogen). Cell
monolayers were washed once with PBS. For cells cultured in 6-well plates (3 mm),
750 pi of Trizol was added to the cells and the plates were rotated on an orbital
shaker at 60 rpm for 10 minutes at room temperature. The homogenate was then
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collected by pipette and transferred to 1.5 ml microfuge tube. For tissue, 100-200 
mg was frozen in liquid nitrogen and was crushed with a pestle and mortar. The 
crushed tissue was transferred to a dounce glass homogeniser and was homogenised 
in 1 ml of Trizol at room temperature. The homogenate was then collected by pipette 
and transferred to a 1.5 ml microfuge tube. The RNA extraction procedure for cells 
or tissue continued as follows. 200 pil of chloroform was added to the Trizol 
homogenate and the tubes were shaken vigorously for 15 seconds. The samples 
were incubated at room temperature for 15 minutes and were then spun at 12 000 
rpm for 5 minutes at room temperature. The aqueous phase was transferred to a 
clean 1.5 ml microfuge tube by pipette and 500 [i\ of isopropanol was added. The 
samples were incubated at room temperature for 10 minutes and were then spun at 
12 000 rpm for 15 minutes at 4 ®C. The supernatant was removed, leaving the RNA 
pellet in the tube. The RNA was washed with 1 ml of absolute alcohol and was spun 
at 4000 rpm for 5 minutes. TTie alcohol was removed and the RNA was left to air dry 
at room temperature with the lids open. The RNA was then re-suspended in 20 pil of 
ddHzO.
2.19.2 First strand cDNA synthesis
First-strand cDNA was reverse transcribed from messenger RNA (mRNA) by Super 
Script II (SSII) reverse transcriptase (RT) using a first-strand cDNA synthesis kit from 
Invitrogen (18064-022) and random hexamer primers. 1 pig of total RNA was primed 
with 250 ng of random hexamer primer in a reaction made up to 11 pil with ddHzO. 
The RNA was denatured by incubation at 72 °C for 10 minutes followed by 
immediately placing on ice. The contents were collected by brief centrifugation and 
then 8 pil of the following premix was added: 4 pil of 5x buffer, 2 pil 0.1 M DTT, 1 pil 
10 mM dNTPs and 1 pil RNaseOut (40U/pil) (Invitrogen, 10777-019).
The contents of the tube were mixed gently by pipette and were incubated at room 
temperature for 2 minutes. 1 pil (200 units) of SSII RT was then added and the 
reaction was mixed gently by pipette followed by incubation at room temperature for 
10 minutes. First-strand cDNA was then synthesised by incubating the reaction at 42 
°C for 60 minutes. Incubating at 72 °C for 10 minutes inactivated the reaction. The 
cDNA sample was diluted with ddHzO to 100 pil prior to use in real-time PCR.
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2.19.3 Quantitative real-time PCR
Gene expression was measured quantitatively by real-time PCR. Real-time PCR was 
performed using SYBR I green technology on the DNA engine Opticon system (MJ 
research). The following premix was prepared (for PCR primer pairs see Table 2.5): 
10 pil 2x SYBR green mix, 0.75 pil each primer (20 piM) and 3.5 \i\ ddHzO. 5 \i\ of 
cDNA was added and the tubes were briefly vortexed and pulse centrifuged. Real­
time PCR was then performed using the following parameters: SYBR green activation 
step, 94 °C for 3 min; 50 cycles of; denaturing, 94 °C for 30 seconds; annealing (see 
table for annealing temperature) for 30 seconds; extension, 72 °C for 30 seconds.
Real-time PCR quantification of two or three of the following reference genes was 
performed to normalize for differences in template concentration: p-Actin, Gapdh and 
p2-microglobulin. Relative expression was quantified using the 2(-Delta Delta C(T)) 
(AACT) method described by Livak and Schmittgen (Livak and Schmittgen, 2001). 
Primer pair efficiencies were assessed by performing PCR on serial dilutions of cDNA 
template.
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2.20 Protein extraction and quantification
2.20.1 Protein extraction from heart for one-dimensional electrophoresis
Whole mouse heart was frozen in liquid nitrogen and crushed to a fine powder using 
a pre-chilled pestle and mortar. The crushed tissue was then transferred using a 
scalpel blade to a pre-chilled 1.5 ml microcentrifuge tube. The tissue was then lysed 
in 1 ml of radioimmunoprecipitation (RIPA) buffer (0.75 M NaCI, 5% (7v) NP40, 
2.5% (7v) deoxycholate, 0.5% (7v) SDS, 0.25 M Tris-HCI pH 8.0, 10 mM Dithio-L- 
threitol (DTT) containing protease inhibitors) and incubated on ice for 20 minutes. 
The lysate was then centrifuged at 13000 x g for 5 minutes at 4 °C. The supernatant 
was transferred to a clean 1.5 ml microfuge tube and was stored at -80 °C until use.
2.20.2 Protein assay of lysates prepared for one-dimensional 
electrophoresis
Protein concentration was determined by the bicinchoninic acid (BCA) protein assay 
(#23255, Pierce). A standard curve between 0-50 pig of bovine serum albumin (BSA) 
was prepared and 2 pil of protein lysates were assayed. BCA solution was prepared 
by mixing 50 parts of reagent A with 1 part reagent B. 200 pil of BCA solution was 
mixed with the protein standards and lysates and were incubated at 37 °C for 30 
minutes. Absorbance was measured at 560 nm by a Genios microplate reader 
(Tecan, UK). Protein concentration was determined by extrapolating the O.D of the 
protein lysate with the BSA standard curve.
2.20.3 Protein extraction from heart for two-dimensional electrophoresis
Whole mouse heart was frozen in liquid nitrogen and crushed to a fine powder using 
a pestle and mortar. The crushed tissue was then transferred using a scalpel blade to 
a 1.7 ml siliconised microcentrifuge tube. The tissue was then lysed in 1 ml of lysis 
buffer (8M Urea, 0.2 % DTT, 0.5% CHAPS containing protease inhibitors) and 
passed through a 21-gauge needle five times. Lysis was continued at room 
temperature for 20 minutes and the lysate was then centrifuged at 13000 x g for 5
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minutes at room temperature. The supernatant was transferred to a clean 1.7 ml 
siliconised microfuge tube and was stored at -80 °C until use.
2.20.4 Protein assay of lysates prepared for two-dimensional 
electrophoresis
The 2-D Quant Kit (Amersham) was used to determine protein concentration of 
lysates prepared for 2-DE. 2 pil of protein lysates that were to be assayed were 
pipetted to 1.5 ml microfuge tubes. 500 pil of precipitant was added to each tube and 
mixed using a vortex. 500 \i\ of co-precipitant was then added, mixed and 
centrifuged at 13 000 x g for 5 minutes. The supernatant was discarded, the tubes 
were centrifuged briefly and the remaining supernatant was removed using a Gilson 
pipette. 100 \i\ of copper solution and 400 1^ of ddHzO was added to each tube, 
mixed using a vortex and incubated at room temperature for 20 minutes. The 
absorbance was measured at 480 nm and protein concentration was determined by 
comparing the O.D of the protein lysate with a BSA standard curve.
2.21 One-dimensional SDS-PAGE and Western blotting
2.21.1 SDS-PAGE
Protein extracts were separated according to their molecular weight by SDS- 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). SDS-PAGE gels were cast in 8 x 7 
cm plates with 1.5 mM thick spacers. The resolving gel was prepared containing 12% 
acrylamide, 0.375 M Tris pH 8.8, 0.1% SDS, 0.1% ammonium persulfate (APS) and 4 
\i\ TEMED (per 10 ml of gel mix). The mix was poured into the plates until it reached 
1.5 cm below the small plate. Gels were overlaid with butan-2-ol and left to 
polymerise for at least 1 hour. The butan-2-ol was poured off and the gel surface 
was washed 4-5 times with ddHzO. The stacking gel was then prepared containing 
5% acrylamide, 125 mM Tris pH 6.8, 0.1% SDS, 0.1% APS and 10 pil of TEMED (per 
10 ml of gel mix) and poured on top of the resolving gel and a comb was inserted 
and left to polymerize for at least 45 minutes
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Following polymerization the comb was removed and the plates were attached to the 
Mini-Protean electrophoresis system (Bio-Rad). The cathodic chamber was filled to 
the top with running buffer and the tank comprising the anodic end was filled with 
300 ml of running buffer. The wells were flushed out with running buffer using a 20 
ml syringe and 21-guage needle to remove any non-polymerised acrylamide. Protein 
samples were then loaded into the wells using a Gilson pipette. 10 pil of pre-stained 
molecular weight protein standard (New England Biolabs, #P7708) was also run. 
Electrophoresis was carried out at 150 V until sufficient separation of the pre-stained 
standard was achieved.
2.21.2 Western Blotting
Proteins separated by SDS-PAGE were transferred to Hybond-C nitrocellulose 
membrane (Amersham) using the Mini-Protean transfer system (Bio-Rad). Firstly, the 
stacking gel was detached from the resolving gel and discarded. The resolving gel 
was removed from the glass plates and incubated in transfer buffer. Hybond-C and 2 
pieces of 3MM filter paper were cut to the size of the resolving gel and were wetted 
in transfer buffer. The Hybond-C membrane was placed on top of the gel and 
sandwiched by 3MM filter paper and on the outside by sponges. Firstly, the 3MM 
filter paper was laid on top of a sponge followed by the gel. Then, 3MM filter paper 
was placed on the gel and bubbles between the gel and membrane were smoothed 
out using a glass Pasteur pipette. A piece of 3MM filter paper was then placed on the 
membrane followed by sponge and the 'sandwich' was enclosed in a transfer 
cassette. The cassette was fitted into the transfer tank and electrophoresis was 
carried out at 100 V for 1 hour.
The membrane was removed and incubated in 5% C/v) non-fat milk in Tris-buffered 
saline (TBS) for 1 hour. The membrane was then incubated with primary antibody 
(1:500-1:2500) dissolved in 5% C/v) non-fat milk/TBS overnight at 4 °C. The 
membrane was then washed in 0.1% Tween-20 in TBS for 5 minutes 3 times. The 
membrane was then incubated with a horseradish peroxidase (HRP) conjugated 
secondary antibody (1:2000) in 5% C/v) non-fat milk/TBS for 30 minutes and then 
washed in 0.1% Tween-20 in TBS for 5 minutes 3 times.
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HRP conjugated antibodies bound to protein were visualized using enhanced 
chemllumlnescence (ECL) (Amersham). Excess TBS/Tween-20 was removed from the 
membrane and was placed on cling film. The ECL reagent was pipetted onto the 
membrane Incubated for 2 minutes. Excess ECL reagent was removed and the 
membrane was wrapped In cling film. The membrane was exposed to x-omat x-ray 
film and developed.
2.22 Two-dimensional electrophoresis
2.22.1 First Dimension - Isoelectric Focusing (lEF)
Proteins were separated on the basis of their Isoelectric point using Immoblllne 
DryStrIp gel strips (Amersham), which contain an Immobilised pH gradient (IPG), and 
an Ettan IPGphor II (Amersham) Isoelectric focusing system. Proteins were applied 
to the IPG strips by passive rehydration In an Immoblllne DryStrIp reswelling tray 
(Amersham). Passive rehydratlon buffer was added to 100-400 pig of protein to a 
total of 340 pil In a siliconised microfuge tube and was pipetted Into the slot of the 
tray. IPG strips were then loaded Into the wells, covered with mineral oil and left to 
rehydrate for 20 hours. IPG strips were then placed on the Ettan IPGphor II manifold 
ceramic tray. Paper wicks (Amersham) were saturated with 150 pil of ddHzO water 
and were placed In contact with the acrylamide at each end of the IPG strips. The 
electrodes were connected and the tray was covered with 108 ml of mineral oil. 
Proteins were then focused using the following programme.
Step 1 Gradient 
Step 2 Step and Hold 
Step 3 Gradient 
Step 4 Gradient 
Step 5 Step and Hold
0-300 V 
300 V
300-1000 V 
1000-8000 V 
8000 V
30 minutes 
4hours 
6 hours 
4 hours
To a total of 81 kV hours
IPG strips were stored In 10 ml pipettes wrapped In cling film at -80 °C until use.
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2.22.2 Resolubilisation of proteins foliowing lEF
Focused proteins were resolubilised and carboamidomethylated prior to SDS-PAGE. 
Proteins were denatured by incubating the strip for 15 minutes at room temperature 
in 6 M Urea, 50 mM Tris-HCI pH 8.8, 30% (7v) glycerol, 2% (7v) SDS and 1% (7v) 
DTT. The solution was discarded and replaced with 50 mM Tris-HCI pH 8.8, 30% (7v) 
glycerol, 2% (7v) SDS and 2.5% (7v) iodoacetamide with a trace of bromophenol 
blue and incubated at room temperature for 15 minutes.
2.22.3 Second Dimension -  SDS-PAGE
Following lEF and protein resolubilisation, proteins were then separated on the basis 
of their molecular weight by SDS-PAGE using the Ettan Dalts/x electrophoresis 
system (Amersham). Using the Ettan gel-casting chamber, 12% acrylamide/bis- 
acrylamide gels were cast in 25.5 x 20.5 cm gel plates with 1 mM thick spacers. 500 
ml of gel mix was prepared containing 12% acrylamide, 0.375 M Tris pH 8.8, 25 
sodium thiosulphate, 500 \i\ of 10% (7v) APS and 50 pil of TEMED. The gel was 
poured into the chamber until it reached 1 cm below the top of the smaller plate and 
the gels were immediately overlaid with butan-2-ol and left to polymerise for two 
hours. The butan-2-ol was poured off and tops of the gels were thoroughly washed 
with ddHzO to remove any traces of butan-2-ol. Gels were either used immediately or 
were overlaid with 0.375 M Tris pH 8.8, wrapped in cling film, stored overnight at 4 
°C and used the following day.
Following resolubilisation of proteins each IPG strip placed at the surface of a gel. 
The Ettan electrophoresis tank was filled with Ix running buffer and the gels were 
loaded into the tank and the upper chamber that creates the cathodic chamber was 
attached and filled with Ix running buffer. Electrophoresis was carried out at 80 V for 
1 hour followed by 250 V until the line of bromophenol blue exited the gels. Gels 
were removed from the plates and placed into fixative solution (50% methanol and 
10% acetic acid).
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2.22.4 Silver Staining
Proteins were visualized by staining with silver nitrate. Gels were transferred from 
fixative solution and incubated in sensitising solution (30% ethanol, 6.8% ('^ /v) 
sodium acetate and 0.1% C/v) sodium thiosulphate) and gently rotated on a bench 
top shaker for 30 minutes. Sensitising solution was discarded and gels were washed 
three times with ddHzO for 5 minutes while shaking. Gels were then incubated in 
staining solution (2.5% C/w) silver nitrate and 0.1 ml of 37% formaldehyde in 250 ml 
ddHzO) for 30 minutes while shaking. Gels were then washed twice with ddHzO for 1 
minute followed by incubation in developing solution (2.5% sodium carbonate and 
0.05 ml formaldehyde in 250 ml ddHzO). Gels were developed until protein spots 
were seen and incubating the gels in 5% acetic acid terminated the process. Gels 
were bag sealed and scanned using a GS-800 Densitometer (Bio-Rad).
Silver stained 2D gels were scanned and the expression profiles of cardiac proteomes 
were compared using ImageMaster™ 2D Platinum software (Amersham). 
ImageMasterTM detected silver stained protein spots with the minimum for 
parameters of spot detection being set as follows: minimum area of 2, smoothness 
of 5 and saliency of 150. Proteins were selected by ImageMaster^^ and were 
matched between gels by choosing proteins as landmarks. Expression analysis using 
ImageMaster™ identified differences in expression of proteins by comparing the ratio 
of percentage volume density of gel of proteins between the cardiac proteomes of 
wild-type, Trp5J '^, STATl'^' and TrpSJ^'/STATl'^' mice. ImageMaster^^ selected 
proteins that had an average ratio of more than 2 and did not have overlapping class 
intervals as significant changes. ImageMaster™ regarded proteins with the largest 
gap between class intervals as the most significant. Manual analysis of 2D gels 
verified proteins that were identified by ImageMaster^ as authentic protein spots.
2.23 Identification o f proteins by peptide mass fingerprinting (PMF)
2.23.1 In-gel cysteine residue derivatisation
Protein spots were excised from gels using a scalpel and were transferred to a 1.5 ml 
siliconised microfuge tube. The gel piece was then washed 3 times with 100 mM
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ammonium bicarbonate pH 7.8. The gel piece was then partially dehydrated in 500 \i\ 
of acetonitrile whilst rotating on a wheel for 20 minutes. The acetonitrile was 
discarded and the gel piece was dehydrated compietely by centrifugal evaporation at 
37 °C. The gel piece was then washed 5 times with 100 mM ammonium bicarbonate 
pH 7.8 to remove excess iodoacetamide. Gel pieces were either used immediately or 
stored at -80 °C until use.
2.23.2 In-gel trypsin digestion
60 \i\ of 12.5 ng ml'  ^Trypsin in 50 mM ammonium bicarbonate pH 7.8 was added to 
the dehydrated gel piece and incubated overnight at 37 °C.
2.23.3 Extraction of peptides
Peptides were released from the gel matrix following in-gel trypsin digestion with 500 
pil of 50% C/v) acetonitrile containing 0.1% TFA for 60 minutes whilst mixing on a 
wheel. The acetonitrile/TFA containing peptides was transferred to a fresh siliconised 
microfuge tube and the acetonitrile was removed by centrifugal evaporation at 37 °C. 
Hydrophobic peptides were then released from the gel piece by incubating in 300 pil 
of 4 M Urea whilst mixing on a wheel for 30 minutes. The 4 M urea solution, 
containing peptides, was transferred to the tube containing the dried peptides 
extracted with acetonitrile in the previous step and were resolubilised by vortexing 
for 60 seconds.
2.23.4 De-salting peptide samples
Peptide samples were de-salted using Zip-Tip C-18 micro columns (Millipore, 
ZTC185024). Zip-Tip micro columns were conditioned by aspirating 20 ml of 50% 
(7v) acetonitrile containing 0.1% (7v) TFA 5 times followed by 0.1% TFA 5 times. 20 
ml of peptide sample was then aspirated 10 times and peptides bound to the tip 
were washed 5 times by aspirating 20 ml of 0.1% (7v) TFA. Peptides were eluted 
with 20 ml of 50% acetonitrile containing 0.1% TFA and transferred to a fresh
121
Chapte." Two____________________________________________________________________________ Materials and Methods
siliconised microfuge tube Peptides were dried by centrifugal evaporation and were 
resolubilised in 20 ml of 0.1% (7v) TFA.
2.23.5 Preparation of MALDI-TOF matrix
20 mg of a-cyano-4-hydroxycinnamic acid (#70990, Fluka) was dissolved in 1 ml of a 
1:1 solution of acetonitrile: ethanol. 300 ml of this solution was added to 300 ml of 
50 mM Fucose (Blochemika). 4.5 ml of this solution was added to a mix of 1.5 ml of 
peptide sample and 1.5 ml each of the standards ACTH and Angiotensin II. 1.5 ml of 
this peptide and matrix/Fucose mix was spotted onto the reservoir of the MALDI-TOF 
plate.
2.23.6 MALDI-TOF mass spectrometry
Mass spectrometry was carried out on a MALDI TOF MS instrument, fitted with a 
reflectron and a 337 nm U.V laser (TOF Spec E. MicroMass, Manchester, UK). Peptide 
analyses were performed in positive ion mode with the following voltages, source 20 
kV, extraction 19.95 kV, focus 16.5 kV, reflectron 25kV and a pulse voltage of 2.9 kV. 
Spectra were acquired by averaging over a period of 5 scans of highest signal. Data 
were acquired in reflectron mode, operating over a mass range of 6000 m/z with 
matrix suppression set out at 650 Da and analyzed using Mass Lynx software 
(MicroMass, UK) (figure 2.3).
2.24 Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) detection of interleukin-6 (IL-6) was 
performed using the READY-SET-GO! Mouse IL-6 ELISA kit (88-7064-88, Bioscience). 
Mouse cardiac protein lysates were diluted in PBS and concentrated with Centricon- 
YM30 centrifugal concentrators (Amicon Bioseparations, Millipore, UK) to remove 
ELISA inhibiting components present in the protein extraction buffer. The medium of 
cultured MEF cells was used directly in the ELISA. The ELISA procedure was 
performed according to manufacturer's instructions. Absorbance was measured at 
450 nm using a Genios microplate reader (Tecan, UK).
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2.25 X-Gal Staining
The substrate 5-bromo-4-chloro-3-indolyl-6-D-galactoside (X-gal) was used to detect 
expression of the p-galactosldase protein in cell cultures and hearts. Cells were fixed 
on the plate in 4% paraformaldehyde (PFA) in PBS for 20 minutes. Hearts were fixed 
in 2% PFA in PBS containing 2 mM MgCb for 20 minutes. Cells were washed in PBS 
and hearts were washed in PBS containing 2 mM MgCb. The staining solution (Ix  
PBS, 20 mM K3Fe(CN)e, 20 mM K4Fe(CN)6, 2mM MgCb, 0.01% DOC, 0.4 mg/ml X-gal 
(0.02% NP-40 for hearts)) was then added to cells or hearts were incubated at 37 °C 
until the stain developed.
2.26 Statistical analysis
Statistical tests were performed using Graphpad Prism 4.0 software.
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Figure 2.3. Peptide mass fingerprinting by MALDI-TOF. Shown is a peptide mass fingerprint of trypsin digested bovine serum 
albumin (BSA). BSA was trypsin digested and the masses of the digested peptides were measured by MALDI-TOF. Peptides of known 
mass from human angiotensin II = 1046.2) and adrenocorticotrophic hormone (ACTH) (%  = 2466.6) were included in the BSA 
peptide mix and used as standards to measure BSA peptides.
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CHAPTER THREE
Generation of transgenic mice with inactivated caspase-8 or 
caspase-9 signalling
3 .1 1ntroduction and aims of this chapter
Apoptosis contributes to cell death In ischaemla/reperfusion (I/R) in the heart 
(reviewed by MacLellan and Schneider, 1997). Apoptotic death proceeds by two 
distinct signalling pathways, the death receptor and mitochondrial pathways, which 
are mediated by initiator caspases -8 and -9 respectively. These two pathways are 
regulated by other proteins that promote or inhibit the apoptotic process. The 
transcription factor, signal transducer and activator of transcription 1 (STATl), is a 
pro-apoptotic member of the ST AT family and the primary mediator of interferon 
gamma (IFNy) response. STATl has also been shown to be a mediator of apoptotic 
cell death induced by I/R (Stephanou et al., 2000). However, it is not known what 
contribution the caspase-8 and caspase-9 pathways have in STATl mediated I/R- 
injury.
Transgenic mice that are deficient in caspase-8 or caspase-9 activation would enable 
the relative contribution of the death receptor and mitochondrial pathways in STATl 
mediated I/R-injury to be determined. Specific inhibition of caspase-8 and caspase-9 
has been achieved in isolated cells by over-expression of flice-like inhibitory protein 
(FLIP) or caspase-9 short (C9s) respectively (Stephanou et al., 2001, Stephanou et 
al., 2002).
The major aim of the work presented here was is generate transgenic mice, that 
over-express FLIP or C9s using the pronuclear injection method. Transgenic mouse 
production by pronuclear injection of DNA is a routine technique in many transgenic 
facilities (reviewed by Bianco et al., 2003). Constructs are injected into the 
pronucleus of a one-cell fertilized mouse embryo where the DNA randomly integrates 
into the mouse genome in the form of head-to-tail concatemers, resulting in multiple 
copies of the transgene inserting into a single site (Bianco et al., 2003). Caspase-8 
knockout mice have an embryonic lethal phenotype with impaired heart muscle 
development and caspase-9 knockout mice have a perinatal lethal phenotype (Kuida
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et al., 1998, Varfolomeev et al., 1998). Transgenic mice that over-express FLIP or 
C9s may have the same lethai phenotype as caspase-8 and caspase-9 knockout 
mice. Therefore, the tetracycline transactivator (tTA) system was used so that 
transgene expression couid be temporaliy regulated.
3.2 Generation o f Tet responder transgenic mice for C9s or FLIP 
over-expression
The Tet-inducible system is a binary system that involves two distinct transgenic 
mice; a Tet mouse and a Tet-responder mouse. The Tet mouse is a transgenic 
mouse expressing the tTA protein and the Tet-responder mouse is a transgenic 
mouse with a transgene that is transcriptionaliy regulated by the tTA protein (see 
figure 1.3). Progeny from these mice that have inherited both transgenes (compound 
transgenics) will express the Tet-responsive gene in tissues that the tTA protein is 
expressed. Expression is inducible with the addition or removal of tetracyclines, 
depending on whether the Tet mouse is Tet-on or Tet-off, respectively. The pBIG 
plasmid is an expression vector in which expression of an inserted transgene is 
induced by tTA. The pBIG plasmid also contains a bi-directional promoter, which is 
linked to the inserted transgene and the p-galactosidase reporter gene, lacZ. The 
lacZ reporter gene is used in the pBIG vector for easy identification of transgene 
expression. Thus, tTA induces the expression of both p-galactosidase and the 
inserted transgene.
Therefore, pBIG expression vectors containing C9s (pBIG-C9s) (Figure 3.1) or FLIP 
(pBIG-FLIP) (Figure 3.2) transgenes, which have been previously generated, 
linearized and prepared for pronuclear injection in our laboratory, were used in the 
generation of tTA responder transgenic mice.
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Figure 3.1 Linearization of the pBIG-C9s expression vector. A) Restriction 
map of the circular pBIG-C9s expression vector. B) The pBIG-C9s vector, linearized 
by Ase/digestion, was used in transgenesis.
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Figure 3.2 Linearization of the pBIG-FLIP expression vector. A) Restriction 
map of the circular pBIG-FLIP expression vector. B) The pBIG-FLIP vector, linearized 
by Bg///digestion, was used in transgenesis.
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3.2.1 Mouse pronuclear injection with pBIG-C9s and pBIG-FLIP using the 
Institute of Child Health (ICH) transgenesis service
Our institute, the Institute of the Child Health (ICH), has its own relatively new 
transgenic facility and service and was therefore used for the generation of pBIG-C9s 
and pBIG-FLIP transgenic mice. Pronuclear injection was undertaken in the FVB/N 
mouse strain, as this is the preferred strain used by the ICH service. The FVB/N 
strain is commonly used because FVB/N zygotes have a large male pronucleus, which 
enables easy microinjection of DNA. Furthermore, the Tet mouse used here was also 
in the FVB/N strain. Thus, there no genetic variability would be introduced when 
crossing the Tet responder mice with the Tet mice.
Pronuclear injection of pBIG-C9s in fertilized FVB/N embryos and subsequent embryo 
transfer to pseudo pregnant female mice resulted in 42 live births. DNA was 
extracted from tail biopsies and was screened by PCR for the integration of pBIG- 
C9s. However, pBIG-C9s was not detected in the genomic DNA of any of the 42 
potential pBIG-C9s founder mice (Figure 3.3 A). The pBIG-C9s construct was used as 
a positive control in the PCR and amplification of the target sequence demonstrated 
that the PCR screen worked successfully (Figure 3.3 A, Lane 14). Furthermore, the 
quality of the mouse DNA template was checked to be sufficient for PCR by 
amplifying a region of the mouse p-actin gene. (Figure 3.3 B).
The DNA template used in PCR amplification can be a source of variation in the 
reaction, leading to possible false positive or negative results. Genomic DNA isolated 
from mouse-tail biopsies, which here has been purified differently to plasmid DNA, 
may contain impurities that may inhibit the reaction. Furthermore, due to the vastly 
different number of DNA sequences between plasmid and mouse genome, primers 
are more likely to anneal with non-target sequences in genomic DNA compared to 
plasmid DNA. Therefore, using purified plasmid DNA alone may not necessarily be 
considered as a sufficient control for the comparison of amplification of sequences 
from genomic DNA. Therefore, further validation of the PCR screen was required. To 
this end, the target sequence was amplified using pBIG-C9s diluted in mouse 
genomic DNA. The plasmid was serially diluted in mouse genomic DNA to 
concentrations of lower than 1 plasmid copy per cell of genomic DNA. The target 
sequence and was amplified by PCR at the all the concentrations tested, including 
the lowest of 1 x 10 ® (Figure 3.4). Therefore, the mouse genomic DNA samples were
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not Inhibiting the PCR amplification of pBIG-C9s, suggesting that the potential pBIG- 
C9s founder mice were indeed negative.
Southern blot screening of potential pBIG-C9s founder transgenics also did not 
detect the transgene. The same validation procedure of detecting pBIG-C9s when 
diluted in mouse genomic DNA used for PCR was also applied Southern blotting. The 
pBIG-C9s plasmid was detected in all the dilutions tested (Figure 3.5). Therefore, 
based on the PCR and Southern blot evidence, the conclusion made was that the 
pBIG-C9s transgene did not integrate into the DNA of any of the 42 potential 
founders.
Similarly, the ICH transgenic service failed to produce any mice from pronuclear 
injection of pBIG-FLIP in FVB/N strain zygotes. Further pBIG-FLIP DNA was prepared, 
separately to the first, and was provided to the ICH service. However, no potential 
founder mice were produced. This failure was not limited to pronuclear injections 
with the pBIG-FUP construct as other service users also experienced similar 
problems. Technical difficulties and signs of animal stress, such as mice neglecting 
their pups, were cited by the ICH transgenic service. Therefore, it was not possible 
to attribute toxicity of pBIG-FLIP in pronuclear injection as the reason for failure to 
produce potential founder mice. Therefore, we opted to outsource the generation of 
pBIG-C9s and pBIG-FLIP transgenic mice to an established provider.
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Figure 3.3 PCR genotyping of potential pBIG-C9s founder mice generated
by the ICH service. PCR products of (A) pBIG-C9s transgene and (B) genomic DNA 
control (reference gene) were separated by 2% agarose gel electrophoresis. Lane 1; 
DNA Mw marker; lanes 2-11; pBIG-C9s founders 1-10; lane 12; non-transgenic 
mouse; lane 13; water; lane 14; pBIG-C9s plasmid.
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Figure 3.4 PCR of pBIG-C9s plasmid serially diluted in mouse genomic
DNA. The pBIG-C9s plasmid was serially diluted in mouse genomic DNA and was 
amplified by PCR. PCR products were separated by 2% agarose gel electrophoresis. 
Lane 1; DNA Mw marker; lanes 2-6; pBIG-C9s serial dilution in mouse genomic DNA; 
lane 2; 1 x 10'^ ; lane 3; 1 x 10"^ ; lane 4; 1 x 10'^ ; lane 5; 1 x 10’®; lane 6; 1 x 10'^ ; 
lane 7; mouse genomic DNA only; lane 8; water; lane 9; undiluted plasmid.
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Figure 3.5 Southern blot of pBIG-C9s plasmid serially diluted in mouse 
genomic DNA. The pBIG-C9s plasmid was serially diluted in EcoRl restriction 
digested mouse genomic DNA and separated by 1% TAB agarose gel electrophoresis. 
Separated DNA was transferred to Hybond-N  ^nitrocellulose membrane and a [^ ^P]- 
dCTP radiolabelled fragment of pBIG-C9s was hybridised to the membrane. Three 
distinct bands were observed, representing different supercoiled forms of the pBIG- 
C9s plasmid. Lanes 1-6; pBIG-C9s serially diluted in mouse genomic DNA; Lane 1; 1 
X 10' ;^ lane 2; 1 x 10"^ ; lane 3; 1 x 10' ;^ lane 4; 1 x 10*®; lane 5; 1 x 10' ;^ lane 6; 1 x 
10'®; lane 7; mouse genomic DNA only.
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3.2.2 Mouse pronuclear Injection using the Karolinska Institute 
transgenesis service
Pronuclear injection of pBIG-C9s and pBIG-FLIP DNA in FVB/N mouse strain zygotes 
was undertaken by the Karolinska Institute (KI) transgenesis service. As a result, 88 
pBIG-C9s and 73 pBIG-FLIP potential transgenic mice were born. DNA was extracted 
from tail biopsies of potential pBIG-C9s and pBIG-FLIP transgenic mice and was 
screened by PCR for potential transgene integration. The pBIG-C9s transgene was 
detected in the DNA of 25 of the 88 potential pBIG-C9s transgenic founder mice, by 
PCR amplification of a 220bp sequence of the transgene (Figure 3.6 A). The pBIG- 
FUP transgene was detected in the DNA of 11 of the 73 potential pBIG-FLIP 
transgenic founder mice by PCR amplification of a 150 bp sequence of the transgene 
(Figure 3.6 B). The success rate of transgenics generated from pronuclear injection 
was 28% for pBIG-C9s and 15% for pBIG-FLIP (Table 3.1).
Expression
construct
Number of 
potential founders
Number of 
transgenics
Percentage of 
transgenics
pBIG-C9s 88 25 28%
pBIG-FLIP 73 11 15%
Table 3.1. Quantity and percentage of transgenics identified in potential pBIG- 
C9s and pBlG-FLIP founders generated by the KI transgenic service.
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Figure 3.6 PCR genotyping of potential pBIG-C9s and pBIG-FLIP 
transgenic founders generated by the KI transgenic service. PCR products of 
(A) potential pBIG-C9s founders and (B) potential pBIG-FLIP founders were 
separated by 2% TAE agarose gel electrophoresis. (A) Lane 1; Upper and lower; 
DNA Mw marker; lanes 2-14 top and 2-8 bottom; pBIG-C9s founders 74-93; lane 10 
bottom; water; lane 13 bottom; pBIG-C9s plasmid. (B) Lane 1 Top and bottom; DNA 
Mw marker; lanes 2-14 top and 2-8 bottom; pBIG-FLIP founders 1-20; lane 10 
bottom; water; lane 13 bottom; pBIG-FUP plasmid.
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3.2.3 Southern blot detection of pBIG-C9s or pBIG-FLIP transgenic mice
The presence of pBIG-C9s or pBIG-FLIP in the DNA of those mice identified by PCR 
was confirmed by Southern blotting. p^P]-dCTP radiolabelled fragments of the pBIG- 
C9s or pBIG-FLIP expression vector were used as probes and were hybridised to 
nitrocellulose membranes on which the potential founder transgenic genomic DNA, 
restriction digested with EcoRl, had been transferred.
Hybridisation of the pBIG-C9s probe detected a prominent band of 2.6 kb in the DNA 
of all animals that had been identified as transgenic for pBIG-C9s by PCR (Figure 
3.7). The 2.6 kb band observed was the expected size of a DNA fragment if a head- 
to-tail concatemer of pBIG-C9s has integrated in the mouse genome. Pronuclear 
injection normally results in concatemers of the transgene integrating at a single 
random site. Potential founders (160 and 161) identified as non-transgenic by PCR 
were used as negative controls in Southern blotting and the 2.6 kb band observed in 
transgenics was not present in either. Hybridisation of the pBIG-FLIP probe 
detected a prominent bad of 3.3 kb in the DNA of all animals that had been identified 
as transgenic for pBIG-FLIP by PCR (Figure 3.8). The 3.3 kb band was the expected 
size of a DNA fragment if a head-to-tail concatemer of pBIG-FLIP had integrated and 
was not observed in non-transgenic animals (1 and 2).
The intensity of the 2.6 kb or 3.3 kb band present in the transgenics is an indication 
of transgene copy number. However, relative copy number was determined 
quantitatively by phosphor imaging of membranes with hybridised [^^P]-dCTP 
radiolabelled probes. The 2.6 kb band for pBIG-C9s or 3.3 kb band pBIG-FLIP that 
was observed in all transgenics is representative of a concatemer of the transgene. 
Therefore, a minimum of two copies of the transgene is present in all transgenics. To 
determine relative copy number, the lowest value recorded for a pBIG-C9s transgenic 
was designated as having two copies of the transgene, and based on this value the 
copy number of all other pBIG-C9s transgenics was determined. Quantification of 
pBIG-GUP transgenics was determined in an identical manner. The transgene copy 
number for pBIG-C9s and pBIG-FLIP transgenics are shown in Table 3.2.
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Figure 3.7 Southern blot detection of pBlG-C9s transgenic founder mice. (A
and B) Mouse genomic DNA of pBIG-C9s founders were restriction digested with 
EcoRl and separated by 1% TAE agarose gel electrophoresis. Separated DNA was 
transferred to Hybond-N  ^ nitrocellulose membrane and a pP]-dCTP radiolabelled 
fragment of pBIG-C9s {PstI digested) was hybridised to the membrane. 160 and 161 
are non-transgenic DNA controls. A band of 2.6 kb was observed in transgenic mice 
that represents head-to-tail concatemers of the inserted transgene. C) Schematic 
detailing how the 2.6 Kb band is derived as a result of integration of concatemers.
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Figure 3.8 Southern blot detection of pBIG-FLIP founder transgenic mice.
A) Mouse genomic DNA of pBIG-FLIP founders was restriction digestion with EcoRl 
and separated by 1% TAE agarose gel electrophoresis. Separated DNA was 
transferred to Hybond-N  ^ nitrocellulose membrane and a [^^P]-dCTP radiolabelled 
fragment of pBIG-FLIP (PCR amplified) was hybridised to the membrane. Animals 1 
and 2 are non-transgenic controls. A band of approximately 3.3 kb was observed in 
transgenic mice that represents head-to-tail concatemers of the inserted transgene.
B) Schematic detailing how the 3.3 Kb band is derived as a result of integration of 
concatemers.
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Transgene Copy number pBIG-C9s founders pBIG-FLIP founders
Low (2-10) 75, 79, 96, 105, 110, 120, 
126, 138, 145, 153, 157
28, 35, 36, 42, 51, 63
Medium (11-20) 92, 98, 107, 111, 114, 
121, 125, 132, 133, 136
56
High (21 and above) 98, 100, 106, 140, 16, 40, 69, 71
Table 3.2 Relative copy number of pBIG-C9s and pBIG-FLlP transgenic mice 
determined by phosphor imaging of southern blots with radiolabelled probes.
3.2.4 Generation of pBIG-C9s and pBIG-FLIP F1 progeny
The pBIG-C9s and pBIG-FLIP transgenic founders were imported from the Karoiinska 
Institute in Sweden and quarantined at the Royai Veterinary Coiiege (RVC) in 
London. The quarantine period was for six months. Therefore, at the RVC, transgenic 
founders were mated with FVB/N strain wiid types to ensure transgenic iines were 
derived from as many founders as possibie during this time. Transgenic progeny 
were then transferred to the ICH animai facility. There were 13 pBIG-C9s and 3 
pBIG-FLIP transgenic founders that generated offspring. The remainder of the 
founders had died, either prior to being imported to the RVC or within the RVC, or 
failed to produce litters for unknown reasons.
Ail the transgenic founders that produced offspring transmitted the transgene. 
However, transmission of the transgene from transgenic founder to progeny varied 
between 17% and 75%. The expected Mendeiian ratio for transgene transmission 
would be 50%. A ratio higher than this is likely to reflect too small a sample size (the 
number of progeny screened) thereby giving an artificially high value. This same 
reason may also explain a low ratio. However, lower ratios may be a sign of 
mosaicism. Transgenic mice that are described as mosaics do not contain the 
transgene in all the ceils of the body. Mosaic mice are generated if the microinjected 
DNA has integrated into the zygote after the single ceil stage. Thus, if not ail the sex 
cells contain the transgene then transmission will be lower than 50%. However, in ail 
subsequent generations normal Mendeiian inheritance of transgenes was observed.
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3.2 Tet transgenic mice
The Tet transgenic mice used here, aMHC-tTA, express the tTA protein under control 
of the alpha myosin heavy chain (aMHC) promoter. The transcriptional activity of the 
tTA protein in aMHC-tTA is inhibited by tetracyclines and thus these mice are Tet-off 
mice. Expression of aMHC in the adult mouse is restricted to the heart, specifically 
cardiac myocytes. Therefore, when aMHC-tTA transgenic mice are crossed with Tet 
responder mice, the expression of Tet responsive genes in compound transgenics will 
also be restricted to cardiac myocytes. The aMHC-tTA transgenic mice were obtained 
from Jackson Laboratories and were crossed with FVB/N strain wild types, which was 
done to establish a colony of aMHC-tTA transgenics. The aMHC-tTA transgene in 
these mice is present as a single allele and thus are described as hemizygous. 
Therefore, it is necessary to screen aMHC-tTA transgenic progeny for the presence 
of the transgene. Progeny of aMHC-tTA mice were genotyped by PCR and aMHC-tTA 
transgenic mice were identified (Figure 3.9).
Neonatal mouse cardiac myocyte (NMCM) cells were isolated from aMHC-tTA 
transgenic mice and transfected with the pBIG expression vector to confirm they 
produced functional tTA protein. This was assayed by detecting the expression of p- 
galactosidase, the product of the Tet responsive reporter gene harboured by the 
pBIG vector, lacZ. Expression of p-galactosidase was determined by X-gal staining 
and Western blotting (Figure 3.10). X-gal (5-bromo-4-chloro-3-indolyl-b-D- 
galactopyranoside) is a glycoside that is cleaved by p-galactosidase to yield galactose 
and 5-bromo-4-chloro-3-hydroxyindole, which is then is oxidized into 5,5'-dibromo- 
4,4'-dichloro-indigo, an insoluble blue product. Blue cardiac myocytes were observed 
following X-gal staining and p-galactosidase expression was also detected by 
Western blotting. Only a few myocytes observed in Figure 3.10 are blue, which is a 
reflection of the low transfection efficiency achieved by calcium phosphate mediated 
transfection in primary cardiac myocyte cultures that is routinely experienced in our 
laboratory. Nevertheless, this experiment demonstrates that NMCM cells isolated 
from aMHC-tTA transgenic mice express functional tTA that can induce expression of 
genes in the pBIG vector.
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Figure 3.9 PCR genotyping of aMHC-tTA transgenic mice. PCR products from 
aMHC-tTA screening of litters derived form aMHC-tTA and wild type FVB/N matings 
were separated by 2% agarose gel electrophoresis. Duplex PCR was performed for 
amplification of the transgene (450 bp) and a genomic DNA control (200 bp). Lane 
1; DNA Mw marker; lanes 2-15; progeny of an aMHC-tTA transgenic and FVB/N wild 
type parent; lane 16; water; lane 17; aMHC-tTA parent; lane 18; water; Ianel9; wild 
type FVN/N parent.
142
Chapter Phree Results
B
Lane
1 2  3 4
Size (kPa)
175 —
83 —
■p-galactosidase
47— p-actin
Figure 3.10 Induction of Tet responsive genes in cardiac myocytes isolated 
from aMHC-tTA transgenic mice. Neonatal mouse cardiac myocyte (NMCM) cells 
were Isolated from aMHC-tTA transgenic mice and transfected with pBIG expression 
vectors and tTA activity was determined by Induction of p-galactosldase. (A) Light 
microscopic Image of X-gal stained culture of aMHC-tTA NMCM cells transfected with 
the pBIG expression vector (magnification x25). Arrows Indicate blue cells that are 
expressing the pBIG reporter, p-galactosldase. (B) Western blot of cell extracts form 
aMHC-tTA NMCM cells transfected with pBIG-C9s construct or a C9s expression 
construct that lacks the lacZ gene. Blots were probed with antl-p-galactosldase or 
antl-p-actin antibodies. Lane 1; Protein Mw marker; lane 2; non-transfected cells; 
lane 3; CMV-C9s; lane 4; pBIG-C9s.
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3.3 Generation o f aMHC-tTA/pBlG-C9s and aMHC-tTA/pBIG-FLIP 
compound transgenic mice
The pBIG-C9s and pBIG-FUP transgenic founders were crossed with aMHC-tTA 
transgenics to generate aMHC-tTA/pBIG-C9s and aMHC-tTA/pBIG-FLIP compound 
transgenics. Transgenic mice deficient in caspase-8 or caspase-9 die prematurely. 
Thus, inhibition of caspase-8 by over-expression of FLIP or inhibition of caspase-9 
with C9s may also result in premature death. With the tTA system employed, 
temporal regulation of transgene expression with tetracyclines would enable any 
lethal embryonic or neonatal phenotype to be overcome. However, the outcome of 
C9s or FLIP over-expression is not known. Therefore, when initial generation of 
compound transgenics began, tetracyclines were not administered to mice during 
pregnancy.
At the time of weaning, three weeks of age, the progeny were genotyped by PCR for 
the presence of aMHC-tTA and the Tet responder transgene (Figure 3.11). The 
genotyping results of a litter of eight mice generated from an aMHC-tTA and pBIG- 
C9s cross are shown in Figure 3.11. The PCR products of mice that have been 
genotyped are separated in lanes 2-9 and their genotypes are summarised in the 
table. There is one (lane 7) aMHC-tTA/pBIG-C9s compound transgenic present in 
this litter. The expected frequency of compound transgenics in a litter from a cross of 
hemizygous parents is 25%. The expected frequency was observed for all Tet 
responder transgenic lines crossed with aMHC-tTA mice. Therefore, in the absence 
of tetracyclines, aMHC-tTA/pBIG-C9s and aMHC-tTA/pBIG-FLIP compound 
transgenics do not result in embryonic or perinatal death.
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Figure 3.11. Genotyping of compound transgenic mice. PCR genotyping of 
aMHC-tTA and pBIG-C9s screening of progeny derived from an aMHC-tTA and pBIG- 
C9s parent. PCR products from amplification of pBIG-C9s and aMHC-tTA and 
genomic controls were separated by 2% agarose gel electrophoresis. Lane 1; DNA 
Mw Marker; lanes 2-9; progeny from aMHC-tTA and pBIG-C9s parents; lane 10; 
pBIG-C9s or aMHC-tTA parent; lane 11; water. The genotypes of mice are 
summarized in the table. One aMHC-tTA/pBIG-C9s compound transgenic was 
identified in this litter (lane 7).
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3.3.1 LacZ reporter expression in compound transgenics
Identification of compound transgenic lines that express the transgene construct was 
determined by the induction of the pBIG reporter gene, lacZ. The expression of the 
lacZ reporter product, p-galactosidase, was assayed in the hearts of compound 
transgenic mice, p-galactosidase expression was detected in the hearts of aMHC- 
tTA/pBIG-C9s compound transgenics in 2 out of 3 lines tested by X-gal staining and 
Western blotting (Figure 3.12). The level Of p-galactosidase expression observed in 
aMHC-tTA/pBIG-C9s line 145 was higher compared to line 121. p-galactosidase 
expression was not detected in aMHC-tTA/pBIG-C9s line 75. However, p- 
galactosidase was not expressed in any of the 3 lines of aMHC-tTA/pBIG-FLIP 
compound transgenics (Figure 3.13). Failure of transgene expression is expected in 
some transgenic lines generated by pronuclear injection. However, as only three 
pBIG-FLIP transgenic lines were generated from the original eleven pBIG-FUP 
transgenic founders, the chances of generating an expressing aMHC-tTA/pBIG-FLIP 
line were reduced.
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Figure 3.12. Identification of pBIG-C9s expressing transgenic lines.
Transgene expression in aMHC-tJA/pBIG-C9s compound transgenic lines 75, 121 
and 145 was determined by detection of p-galactosidase expression. (A) Digital 
image of hearts stained with X-gal. Hearts expressing p-galactosidase appear blue. 
(B) Western blot of cardiac protein probed with anti-p-galactosidase antibody. 
Protein extract from ROSA26, a p-galactosidase expressing mouse, was used as a 
positive control. Expression of p-galactosidase was detected by X-gal staining and 
Western blotting in hearts from lines 121 and 145 but not 75.
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Figure 3.13. Identification of pBIG-FLIP expressing transgenic lines.
Transgene expression in aMHC-tTA/pBIG-FLIP compound transgenic lines 51, 56 and 
69 was determined by detection of p-galactosidase expression. (A) Digital image of 
hearts stained with X-gal. A hearts from the p-galactosidase expressing ROSA26 
mouse was used a positive control (B) Western blot of cardiac protein probed with 
anti-p-galactosidase antibody. Expression of p-galactosidase was not detected by X- 
gal staining or Western blotting in hearts of any aMHC-tTA/pBIG-FLIP transgenic 
lines.
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3.3.2 C9s expression screening in aMHC-tTA/pBIG-9s compound 
transgenics that express p-galactosidase
The aMHC-tTA/pBIG-C9s compound transgenic lines that express p-galactosidase, 
lines 121 and 145, were screened for the expression of C9s by Western blotting 
(Figure 3.14). Expression of C9s was not detected by Western blotting in either line 
121 or 145. As p-galactosidase is expressed in these mice, it suggests that there is 
low affinity of the anti-C9s antibody for C9s used in Western blotting. However, the 
anti-C9s antibody did detect C9s in a stable cell line expressing tTA, MCF-7-tTA, that 
were transiently transfected with a C9s expression for containing a CMV promoter 
but not when transfected with the pBIG-C9s construct.
The MCF-7-tTA cell line was tested for the expression of tTA and the expression of p- 
galactosidase when transfected with pBIG-C9s (Figure 3.15). Expression of tTA was 
detected in MCF-7-tTA cells and p-galactosidase was also detected when MCF-7-tTA 
cells were transiently transfected with pBIG-C9s, demonstrating that the stable line 
was expressing functional tTA that could induce Tet responsive genes in pBIG-C9s. 
The expression of C9s may be stronger with the CMV promoter compared to the Tet 
responsive promoter in the pBIG vector, explaining why C9s was not detected in 
MCF-7-tTA cells transiently transfected with the pBIG-C9s construct.
3.4 Incorrect orientation o f C9s cDNA in the pBIG-C9s construct
The inability to detect C9s in aMHC-tTA/pBIG-C9s compound transgenic lines or in 
the MCF7-tTA cell line transiently transfected with pBIG-C9s may possibly be due to 
low antibody affinity for C9s. However, as anti-C9s antibody does detect C9s in cells 
transiently transfected with a C9s expression construct with a CMV promoter but not 
the pBIG-C9s construct suggests there may be an error with the pBIG-C9s construct. 
Therefore, the pBIG-C9s construct used in transgenesis was sequenced. Analysis of 
the sequence revealed that the C9s sequence is in reverse orientation in the pBIG 
vector (Figure 3.16). Therefore, C9s could not possibly be expressed with the pBIG- 
C9s construct that we were given and that was used to generate the pBIG-C9s 
transgenic mice.
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Figure 3.14. Probing C9s expression in p-galactosidase expressing oMHC- 
tTA/pBIG-C9s transgenic lines. Western blot of cardiac protein from transgenic 
lines aMHC-tTA/pBIG-C9s 121 and 145 probed with anti-C9s antibody. Protein 
extract from MCF7-tTA cells transiently transfected with pBIG-C9s or CMV-C9S 
expression constructs were used as positive controls. A prominent band of 30 kDa 
representing C9s was observed in MCF7-tTA cells transiently transfected with CMV- 
C9s. However, a band of 30 kDa was not observed in aMHC-tTA/pBIG-C9s mice.
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Figure 3.15 Induction of Tet responsive genes in MCF7-tTA stable cell line.
Western blot of MCF7-tTA cells transfected with pBIG, pBIG-C9s or CMV-9s 
constructs. Blots were probed with anti-C9s, anti-p-galactosidase, anti-tJA or anti-p- 
actin antibodies. The expression of tTA was detected in the MCF7-tTA cells and 
expression of p-galactosidase was induced when transfected with pBIG or pBIG-C9s. 
C9s expression was only observed in cells transfected with the CMV-C9s construct.
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Sail Restriction site C9s Initiation codon
Figure 3.16 Sequencing of pBIG-C9s expression vector. The pBIG-C9s construct was sequenced using an oligonucleotide 
designed for a sequence in the pBIG vector that is 3' to the C9s insert and the Sail restricton site in the multiple cloning site (MCS) 
of the vector. The C9s initiation codon is boxed and the arrow depicts the direction of transcription. C9s is in reverse orientation.
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3.5 Discussion
The data presented here describes the generation and identification of aMHC- 
tTA/pBIG-C9s and aMHC-tTA/pBIG-FLIP transgenic mice. Pronuclear injection of 
pBIG-C9s and pBIG-FLIP DNA was undertaken by two separate transgenic services, 
the Institute of Chiid Heaith (ICH) and Karoiinska Institute (KI) services. The ICH 
service generated 42 potentiai pBIG-C9s founders but no potentiai pBIG-FLIP 
founders were generated. The 42 potentiai pBIG-C9s founders were screened for the 
presence of the transgene and were identified as non-transgenic by PCR and 
Southern blotting. The failure to produce any transgenic mice by the ICH service was 
also experienced by other service users. At the time, noise and vibration due to 
building work in the Institute was suspected to be the cause of animal stress 
observed in mouse colonies in the ICH animal facility. Animal stress can affect 
breeding and may have been the reason why no potentiai pBIG-FLIP transgenic mice 
were generated, although fewer embryos injected with pBIG-FLIP were attempted 
compared to pBIG-C9s.
There are limitations to PCR and Southern blotting screening such as the generation 
of false positive and negative results in genotyping. Thus, consideration was given to 
the potentiai for false negative identification of the potentiai pBIG-C9s founders 
generated by the ICH service. Therefore, positive and negative controls were used in 
the screening. Furthermore, the pBIG-C9s plasmid that was used as a positive 
control was diluted in mouse genomic DNA and the target sequence was amplified to 
ensure that the transgene sequence could be amplified in the presence of genomic 
DNA. Although this does not replicate the exact conditions of amplifying the 
transgene if it were integrated in genomic DNA, it does to some extent validate the 
screening protocols used.
The KI transgenic service generated 88 potential pBIG-C9s and 73 potential pBIG- 
FLIP transgenic founders. Of these, there were 25 pBIG-C9s and 11 pBIG-FLIP 
transgenic founders identified by PCR and ail confirmed by Southern blotting. The 
transgenic founders were imported to the Royal Veterinary College (RVC) and bred 
with wild type mice. However, during this period the some of the transgenic founders 
had died, possibly due to the stresses suffered during transportation. Nevertheless, 
the progeny derived from transgenic founders were then crossed with aMHC-tTA 
transgenic mice to generate compound transgenics.
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There were two of the three aMHC-tIA/pBIG-C9s transgenic lines that expressed p- 
galactosidase. However, none of the three aMHC-tTA/pBIG-FLIP transgenic lines that 
were generated expressed p-galactosidase. The location of DNA integration of 
transgenes by pronuclear injection is random. The nature of random integration of 
the transgene can have detrimental effects on expression. Heterochromatin is 
densely packed DNA and a region of little transcriptional activity (Bianco et al., 
2003). Thus, integration of transgenes into this region may result in the transgene 
not being expressed. Furthermore, integration into close proximity to the regulatory 
elements of another gene can have subtle or dramatic effects on the expression level 
or expression profile of the transgene (Bianco et al., 2003). This phenomenon has 
been termed the "position effect" (reviewed by Sigmund, 1993). The position effect 
may explain why no aMHC-tTA/pBIG-FLIP transgenic lines expressed the transgene.
The relative transgene copy number in pBIG-C9s and pBIG-FLIP transgenics was 
determined by phosphor imaging of hybridised p^P]-radiolabelled probes in Southern 
blotting. The copy number of the two aMHC-tTA/pBIG-C9s expressing lines, 121 and 
145, did not correlate with expression of the /acZtransgene product, p-galactosidase. 
The transgene copy number of line 121 was double that of line 145 but p- 
galactosidase expression was higher in line 145, as determined by X-gal staining and 
Western blotting. The lack of correlation between transgene copy number and 
expression is well documented. In 99% of transgene constructs, especially those 
containing simple promoter-cDNA fusions, copy number is not proportional to 
transgene expression (Bianco et al., 2003).
The level of transgene expression is of much importance in production of transgenic 
mouse disease models. For example, in mouse models for dominantly inherited 
diseases such as Huntington's disease, the desired level of mutant protein expression 
would be on a par with the normal expression levels of that protein. An alternative 
transgenic approach may be adopted to avoid some of the problems faced with 
transgenic over-expression using plasmid based constructs. Transgenic animals can 
be produced using yeast artificial chromosome (YAC) and bacterial artificial 
chromosome (BAG) vectors, as alternatives to plasmid based vectors. YAC and BAG 
vectors are much larger than plasmids and allow large sequences to be inserted. 
Therefore, the whole sequence of a gene Including regulatory elements can be used 
to generate a transgenic mouse instead of only the cDNA sequence. The whole gene 
is more likely to express normal levels of the protein with normal temporal and
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spatial expression. Thus, YAC and BAG based vectors can be used to overcome the 
position effect, including copy number dependent expression (Sinn et al., 1999). 
However, the interests of our study were in assessing the relative contribution of 
caspase-8 and caspase-9 in STATl mediated I/R-injury by specific inhibition by FLIP 
or C9s over-expression respectively. Therefore, the use of plasmid based vectors for 
over-expression was an appropriate choice. Furthermore, the tTA transgenic system 
also allows the expression of the transgene to be regulated temporally, and therefore 
was an appropriate system to use given that inhibition of caspase-8 or caspase-9 
may result in developmental defects.
Producing transgenic mice is an expensive and time consuming procedure and does 
not always result in expression of transgenes integrated as a result of pronuclear 
injection. However, transgenic mice are a fundamental tool in the study of 
cardiovascular diseases and dissection of the signalling pathways involved. 
Transgenic mice have been used to highlight the importance of particular genes in 
I/R induced apoptosis. For example, hearts from mice over-expressing caspase-3 are 
more susceptible to I/R induced apoptosis (Condorelli et al., 2001).
The discovery that the C9s cDNA sequence in the pBIG-C9s construct was in reverse 
orientation meant that expression of C9s could not be derived from this vector and 
the pBIG-C9s transgenic mice generated were in effect redundant. Nevertheless, the 
results described in this chapter demonstrate that Tet responsive transgenic over­
expressing mice were successfully generated, as demonstrated by p-galactosidase 
expression. Therefore, using the tTA system is a viable option for the cardiac over­
expression of transgenes.
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CHAPTER FOUR
Regulation of cardiac I/R injury and the cardiac proteome by 
STAT1 and p53
4 .1 1ntroduction and aims of this chapter
The transcription factor STATl has been demonstrated to contribute to apoptosis of 
isolated neonatal rat cardiac myocyte (NRCM) cells following simulated I/R injury 
(Stephanou et al,, 2000). It has also been found that different N-terminal truncated 
STATl mutants that retain the transactivation domain in the C-terminus, including 
those lacking part or all of the DNA-binding domain, were sufficient for stress 
induced apoptosis (Janjua et al., 2002). Moreover, cardiac myocytes and intact 
hearts from Statl'^' mice, which express a C-terminal STATl fragment, were more 
sensitive to simulated I/R injury compared to hearts from wild type mice (Stephanou 
et al., 2002).
The transcriptional effect of STATl on most genes is through direct binding of the 
gene promoter. However, STATl is increasingly recognised to activate transcription 
by acting as a co-activator for other transcription factors. In this regard, STATl has 
been shown to associate with the transcription factor p53 in mouse embryonic 
fibroblast (MEF) cells and it was demonstrated that this association is required for 
maximal induction of p53 responsive genes (Townsend et al., 2004). Furthermore, 
p53 has also been shown to contribute to apoptosis in NRCM cells and in the 
Langendorff perfused rat heart following simulated I/R-injury (Long et al., 1997, 
Matsusaka et al., 2006).
The hypothesis being tested in this chapter is that the enhanced sensitivity of cardiac 
myocytes and hearts from Statl'^' mice to I/R injury occurs through an association of 
the truncated C-terminal STATl protein expressed in these mice and p53, resulting in 
enhanced p53 induced apoptosis. The main aim of this chapter is to investigate this 
hypothesis using neonatal mouse cardiac myocyte (NMCM) cells isolated from wild 
type, Statr^', Trp5J '^, and Trp5J''IStatï'' mice.
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The second aim of this chapter is to use a proteomic approach to identify 
differentially expressed proteins in adult hearts from these gene knockout mice. This 
will further our knowledge of the proteins regulated by STATl and/or p53 and 
identify new candidate proteins that may mediate STATl and/or p53 induced 
apoptosis in cardiac I/R-injury.
4.2 Generation o f mice deficient in p53 and STAT1
Statr^' and Trp5J^' mice were purchased from Taconic and were crossed to produce 
offspring that were heterozygous knockout for each gene {Trp53'^ ^'/Statl^ ^'). 
Compound heterozygous mice were crossed and the offspring generated were 
genotyped by PCR (Figure 4.1). There are nine possible genotypes for offspring 
generated from compound heterozygous crosses and one in sixteen were expected 
be wild-type, TrpSJ '^, Statl'^' or TrpSJ^'/Statl'^ '. There were no apparent anomalies 
between the actual and expected ratio of genotypes of mice born.
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Trp53 KO 
Trp53WT
Statl WT
Statl KO
Lane 2 3 4 5 6 7 8 9
T r p 5 3 +/+ +/- -/- +/- +/+ +/- +/+ +/+
S t a t l +/+ -/- -/- +/+ +/- +/- -/- +/-
Figure 4.1 PCR genotyping of T r p 5 3  and S t a t l  knockouts. Mice progeny of 
compound heterozygous parents {Trp53*^'/Statl*^') were genotyped by PCR. PCR 
products from (A) Trp53 and (B) Statl genotyping were separated by 2% agarose 
gel electrophoresis and visualized under UV light. (A) The PCR products of 77p55 wild 
type (500 bp) and knockout (750 bp) allele screening were amplified in a single 
reaction by 'duplex' PCR. (B) Statl wild type and knockout alleles were screened for 
in separate reactions. (C) The genotypes of mice in lanes 2-9 are summarized. Lane 
1; DNA Mw marker; lanes 2-9; progeny of Trp53^ '^/Statl'^ '^^ arer\Xs) lane 10; water.
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4.3 Analysis o f p53 and STAT1 protein expression in knockout 
mice
TrpSJ '^ and StatT^' mice were tested for the expression of p53 and ST ATI in the 
heart (Figure 4.2). Statl'^' mice lack a 91 kDa protein product observed in wild type 
mice that represents STATla. The expected STATl truncated protein of 72 kDa in 
Statr^' mice was observed. A band representing p53 was not observed in cardiac 
protein lysates from Trp5J^' or wild type mice (Figure 4.2 B). A positive control for 
p53, protein lysate from cells over-expressing p53, was used to show that the 
protocol was sufficient for the detection of p53. Two other anti-p53 antibodies were 
used and neither detected p53.
As p53 expression could not be detected in the hearts of any mice tested, possibly 
because in basal conditions p53 is targeted for degradation. Therefore, the 
mice that were identified by PCR were verified for deficiency in p53 protein in 
isolated mouse embryonic fibroblast (MEF) cells. Furthermore, as basal p53 is 
targeted for degradation, the expression of p53 was chemically induced in MEF cells 
so that the quantity of p53 was sufficient for it to be detected by Western blotting. 
MEF cells from mice of wild type, Trp5J^', Statl'^' and TrpSJ^'/Statl'^ ' genotypes 
were isolated and cultured. MEF cells from wild type and Statl'^' mice ceased to 
proliferate after approximately 10 days in culture. However, MEF cells from TrpSJ '^ 
and TrpSJ^yStatr^' mice continued to proliferate. Therefore, p53 expression was 
tested in these cells and immortalized wild types MEF cells used in our laboratory, 
that express p53, were used as a positive control for p53. Wild type, TrpSJ '^ and 
TrpSJ^'/Statr^' MEF cells were treated with etoposide, a chemical that induces DNA- 
damage and expression of p53.
A band of 53 kDa was present in protein lysates from etoposide treated MEF cells 
from wild type mice but not in etoposide treated MEF cells from Trp5J^' or Trp5J^' 
/Statr^' mice (Figure 4.3). STATl alpha and beta isoforms were observed in TrpSJ '^ 
mice but not in TrpSJ^'/Statl'^ ' mice (Figure 4.3). These experiments demonstrate 
that Trp5J^' mice are deficient in p53 expression.
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Figure 4.2 Western blot of STATI and p53 expression in hearts from (A) 
S t a t r ^ '  and (B) T r p S J ^ ' mice. Cardiac protein samples from a wild type (lanel) 
and a Statl'^' or pJJ' '^Clane 2) mouse were separated by 12% SDS-PAGE. (A) Statl'^' 
mice lack the 91 kDa STATla protein but express the truncated 72 kDa STATl 
protein. (B) No bands for p53 are present in wild type or Trp5J '^ samples. A protein 
lysate from cells over-expressing p53 was used as a positive control (lane 3).
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Figure 4.3 Western blot of p53 and STATI expression in etoposide treated 
MEF cells. MEF cells from (A) Trp5J '^ and (B) TrpSJ^'IStatr^'mce were treated with 
a vehicle control or etoposide (labelled C or E, respectively). MEF cells from two 
animals of each genotype were tested (labelled 1 and 2), in duplicate, and were 
compared with MEF cells from wild type mice. MEF cells were tested for the 
expression of p53 and STATl. No protein bands were observed in Trp5J^'or Trp5J '^ 
IStatr^' MEF cells following control or etoposide treatments. A band of 53 kDa was 
observed in wild type MEF cells. Bands of sizes corresponding to ST ATI a and p 
isoforms were observed in wild type and Trp5J^' MEF cells but not in TrpSJ^'IStatl'^ ' 
MEF cells.
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4.4 Poor health o f Trp53'^VStatT^'mice precludes the use o f NMCM 
cells as a practical approach
TrpSJ^'/Statr^' mice were susceptible to the spontaneous development of a variety 
of tumours including lung, mammary and stomach tumours. The majority of Trp5J^' 
IStatr^' mice that were generated either died or were culled because of sick health 
between three and six months of age (Table 4.1). Some mice either died or were 
culled at less than three months of age and only one mouse lived for more than 6 
months. Trp5J^' mice also developed tumours but generally survived beyond six 
months. The high incidence of tumours observed In Trp5J^' and Trp5J^'/Statr^' mice 
was not observed in wild type or Statl'^' mice.
Age at death Less than 3 months 3-6 months More than 6 months
Number of mice 4 27 1
Table 4.1 Age at death of T r p S J ^ ' / S t a t l '^ ' mice. The ages of 32 T r p S J ^ ' / S t a t l '^ '  
mice of when they died or were culled because of sick health.
The consequence of the ill health caused by the tumours was that it was very 
difficult to generate litters from TrpSJ^'IStatl'^ ' parents. Crosses of TrpSJ^’/Statl'^' 
mice were attempted over a course of three months involving the use of at least 20 
male and 20 female TrpSJ^'/Statl'^ ' mice. However, only two litters were ever 
produced from crosses of TrpSJ^'/Statl'^ ' mice. These crosses were set up 
concurrently with successful crosses generating pure litters of Statl'^', Trp5J^' and 
wild type mice.
The implication, for this study, of the poor success rate for generating litters from 
TrpSJ^yStatr^' crosses was that the isolation and culture of NMCM cells from Trp5J^' 
IStatr^' was impractical as myocytes could only be isolated from individual neonates, 
which would not provide a sufficient quantity of cells. The first aim of this chapter 
was to ascertain whether the increased sensitivity of hearts from StatT^' mice to I/R- 
injury was dependent on p53. These experiments would have been performed in 
cardiac myocytes, isolated and cultured by a method routinely used in our 
laboratory, from pooled neonatal hearts of wild type, Trp5J '^, Statl'^' or Trp5J^' 
/Statr^' mice. This was dependant on crosses of TrpSJ^'/Statr^' mice to generate
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pure litters of homozygous TrpSJ^'/Statl'^ ' neonatal mice. Therefore, this approach 
was not practical for testing the hypothesis in question.
4.5 Proteomic approach to identification of proteins regulated by 
p53 and/or STAT1 in the mouse heart
Both p53 and STATl have been implicated in apoptosis signalling in response to I/R. 
Although p53 and STATl mediated effects occur in response to stress, they have 
also been shown to be involved in the constitutive expression of some genes. The 
second aim of this chapter was the identify proteins regulated in a manner 
dependent on p53 and/or STATl. This was achieved by means of proteomic 
screening of cardiac protein samples from wild type, Trp5J'', Statl'^' and TrpSJ '^ 
JStatr^' mice.
Cardiac protein samples were separated by 2D-PAGE using broad range pH 3-10 IPG 
acrylamide strips and 12% SDS-PAGE gels (Figure 4.4). Good resolution of proteins 
on the basis of molecular weight was achieved, however, there was horizontal 
streaking between pH 7-10. Poor resolution of basic proteins in isoelectric focusing 
had been previously experienced in our laboratory. Therefore, further analyses of 
cardiac proteomes were continued using IPG acrylamide strips of ranges between pH 
4-7.
Cardiac protein samples from 8-10 week old wild type, Trp5J'', StatT^' and Trp5J^' 
IStatr^' male mice were separated using IPG acrylamide strips of narrow-range pH 
4-7 (figure 4.5) and micro-range pH 5.5-6.7 (figure 4.6). 2D-PAGE gel comparisons 
using ImageMaster™ analysis software revealed few differences between the 
experimental groups. The protein most differentially expressed was the spot labelled 
1269 (figure 4.7). The expression of spot 1269 was relatively high in the cardiac 
proteome of Trp5J'' mice compared to all other groups, the lowest expression being 
in the wild type group. As protein 1269 was the most differentially expressed spot 
between any of the groups, it was thus a candidate for identification by peptide mass 
fingerprinting (PMF). Spot 1269 was observed to be a distinct spot with a pi close to 
7.0 and was considered to be sufficiently abundant for potential identification by 
(PMF) (Figure 4.8).
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Figure 4.4 Mouse cardiac protein separated by 2D-PAGE using broad range pH 3-10 IPG acrylamide strips. Horizontal
streaking of cardiac protein from wild type (A) and Trp53-^- null (B) mice was observed when separated using pH 3-10 acrylamide strips.
100 \xg of protein was ran on 12 % SDS-PAGE gels and were stained with silver nitrate.
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Figure 4.5 Mouse cardiac protein separated by 2D-PAGE using broad range pH 4-7 IPG acrylamide strips. Cardiac protein
from wild type (A) and Trp53-/- null (B) mice was separated using pH 4-7 acrylamide strips. 100 pg of protein was ran on 12% SDS-PAGE
gels and were stained with silver nitrate.
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Figure 4.6 Mouse cardiac protein separated by 2D-PAGE using micro range pH 5.5>6.7 IPG acrylamide strips. Cardiac protein
from wild type (A) and Trp53-/- null (B) mice was separated using pH 5.5-6.7 acrylamide strips. 100 jxg of protein was ran on 12% SDS-
PAGE gels and were stained with silver nitrate.
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Figure 4.7 Differential expression of spot 1269 identified using 
ImageMaster^” analysis software. (A) Histogram of spot volume density (SVD) 
of spot 1269 in cardiac proteomes of wild type (a-c), Trp5J '^ (d-f), Statl'^' (g-i) and 
Trp5J^'/Statr^'(j-\) mice. The SVD is a percentage of total gel volume. Blue lines 
represent the class means of three animals and the red lines represent the class 
interval. (B) Table of the mean SVD for each class.
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Figure 4.8 Spot 1269 identified as differentially expressed between groups using ImageMaster. Shown are cardiac protein
from wild type (A) and Trp53-^- (B) mice separated using narrow range pH 4-7 acrylamide strips. 100 pg of protein was ran on 12% SDS-
PAGE gels and were stained with silver nitrate.
4.6 Peptide mass fingerprinting of spot 1269
A moderate quantity of protein was loaded on the analytical gels that were run for 
proteome profiling. The reason for this is that for expression analysis only distinct 
spots can be analyzed; overlapping spots due to a high abundance of protein are 
difficult to distinguish and analyze. However, once a protein is selected for PMF, a 
preparative 2D-PAGE gel is run with an increased amount of the protein sample so 
that there is more of the selected protein to excise. Therefore, a preparative 2D- 
PAGE gel for PMF of proteins was run for identification of spot 1269 using a Trp5J^' 
cardiac protein sample (Figure 4.9). Spot 1269 was excised, as were additional 
proteins labelled spot A and B. Limiting factors in peptide mass fingerprinting include 
protein size and abundance. Therefore, spots A and B were excised because they are 
highly abundant and larger than spot 1269, and thus would serve as controls for the 
identification methods. These proteins were trypsin digested and masses were 
measured by MALDI-TOF.
The peptide masses generated for each protein were submitted to the MS-FIT 
database for protein identification. The top matches for each protein are shown in 
Table 4.2 and the top match for spot 1269 was the interleukin-6 (IL-6) precursor. 
The IL-6 precursor has an isoelectric point of pi 7 and a molecular weight of 24384 
Daltons. The number of peptides matched of a possible 46 was 4 (8%) and the 
peptide coverage of the protein was 18%.
Spot Protein matched by 
MS-FIT
pi Mw
(Daltons)
Number (% ) of 
peptides matched
Peptide
Coverage
A Serum albumin precursor 5.7 68693 20 (38) 41 %
B ATP synthase beta chain, 
mitochondrial precursor
5.2 56301 28 (50) 48%
1269 Interleukin-6 precursor 7 24384 4(8) 18%
Table 4.2 Identification of protein spots A, B and 1269 using MS-FIT. The masses 
of each trypsin digested protein spot were submitted to the MS-FIT database. The 
proteins matched in the table were the highest scoring matches as determined by 
the algorithms used by the database to assign proteins to the masses measured 
by MALDI-TOF.
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Figure 4.9 Preparative 2D-PAGE separating cardiac protein from a TrpSJ"/' mouse. For spot extraction and identification by 
mass spectrometry, 400 pg of cardiac protein was separated by 2D-PAGE. The protein spot of interest that was observed as having 
increased in expression in hearts from 77p5?/' mice by ImageMaster analysis was excised from the gel for identification. Two other 
proteins (Spots A and B) were also excised from the gel for identification.
4.7 Analysis o f IL-6 expression in knockout mice
4.7.1 IL-6 expression in the heart
The most differentially expressed protein, spot 1269, was identified as the IL-6 
precursor protein by PMF. Therefore, IL-6 mRNA and protein expression was 
analyzed further in knockout tissue using other techniques to support this finding. 
Western blotting was used to detect IL-6 expression in the cardiac protein samples 
used in 2D-PAGE. However, IL-6 could not be detected in these samples by Western 
blotting. Therefore, recombinant IL-6 protein was used to test the IL-6 antibody in 
Western blotting. However, immunodetection of recombinant IL-6 was only observed 
when recombinant IL-6 was in a high quantity, 100 ng (Figure 4.10A). Therefore, the 
IL-6 antibody may have too low an affinity to detect IL-6 expressed in the tissue.
Within the literature, detection of IL-6 has been achieved by Enzyme-Linked 
Immunosorbent Assay (ELISA), and accordingly for this study an ELISA kit was used 
for the detection of IL-6 in cardiac protein samples. The buffer for which cardiac 
protein samples were prepared for 2D-PAGE contains substances such as Urea that 
would inhibit the ELISA. Therefore these samples were diluted in PBS and then 
concentrated through porous membranes by centrifugation to remove ELISA 
inhibiting substances. IL-6 was detected in very low quantities in all samples, at 
levels close to background, and all groups were highly similar (Figure 4.108).
Relative IL-6 mRNA expression in hearts of mice was quantified by quantitative, real 
time PCR. The mRNA samples tested were from different mice to the ones used in 
the proteomic experiments. There were no significant differences in IL-6 mRNA 
expression between animal groups. However, the mean expression of IL-6 was 
approximately 4-fold less in Statl'^' hearts and one Trp5J^' heart showed an 
approximately 23-fold increase in IL-6 mRNA expression compared to the wild type 
group.
4.7.2 IL-6 expression in MEF cells
There was insufficient sensitivity in the Western blotting and ELISA techniques to 
detect IL-6 in the cardiac protein samples. Furthermore, although there were
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differences in IL-6 mRNA between the groups they were not statistically significant. 
Therefore, IL-6 expression was measured in MEF cells to find any supporting 
evidence for the regulation of IL-6 by STATl.
MEF cells from wild type and Statl'^' mice were not used as they had become 
senescent. Therefore, the regulation of IL-6 by STATl was investigated in Trp5J^' 
and TrpSJ^'lStatr^' MEF cells. Trp5J^' and TrpSJ^'/Statl'^ ' MEF cells were pooled 
from 5 animals. Relative IL-6 mRNA expression was 4.26 ±2.11 fold higher in Trp5J 
^'IStatr^' MEF cells compared to Trp5J^' MEF cells (Figure 4.11). However, this was 
not a statistically significant difference. The IL-6 secreted from MEF cells was 
measured by ELISA. Secreted IL-6 was 1.73 ± 0.45 fold higher in Trp5J^'/Statl'^' 
MEF cells compared to Trp5J^' cells, however, was not significant.
The enhanced IL-6 mRNA and protein expression observed in Trp5J^'/Statl'^' MEF 
cells compared to Trp5J^' MEF cells was not a statistically significant one. However, 
enhanced IL-6 expression is associated with different types of cancers and is 
involved in the growth of renal cell carcinomas (Paule et al., 2000). Thus, the lack of 
any statistically significant difference may be due to a small sample size. 
Furthermore, TrpSJ^'/Statl'^ ' mice are more susceptible to the spontaneous 
development of tumours compared to Trp5J^' mice. This posed the question: is the 
growth rate of TrpSJ^'/Statl'^ ' MEF cells faster compared to Trp5J^' MEF cells and if 
so, is it dependent on enhanced IL-6 expression? Therefore, the growth rates of MEF 
cells from knockout mice were determined by the MTS assay.
MEF cells were passaged seven days after isolation and were cultured in low (1%) or 
high (10%) serum. MEF cells from wild type and Statl'^' mice ceased to proliferate 
after the first passage whereas Trp5J^' and TrpSJ^'jStatr^' MEF cells continued to 
proliferate (Figure 4.12). The abnormal growth of MEF cells was correlative with the 
observation that Trp5J^' and TrpSJ^'/Statl'^ ' mice, but not wild type or Statl'^' mice, 
spontaneously developed tumours. The growth rates of Trp5J^' and TrpSJ^'/Statr^’ 
MEF cells were highly similar when grown in either low or high serum (Figure 4.12). 
Therefore, the increased susceptibility of Trp5J^'/Statl'^' mice to generate tumours, 
compared to Trp5J^' mice, was not reflected in the growth rates of MEF cells from 
these mice.
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Figure 4.10 IL-6 protein and mRNA expression. (A) Western blot of purified IL- 
6 detection using anti-IL-6 antibody showing only 100 ng of IL-6 was detectable. (B) 
Measurement of IL-6 protein by ELISA of samples following dilution and 
concentration to remove ELISA inhibiting substances. (C) IL-6 mRNA expression in 
hearts. Values shown are normalised medians relative to wild type group. Statistical 
analysis of mRNA expression was performed by a Kruskal-Wallis test with Dunn's 
post test. There were no significant differences between any animal groups.
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Figure 4.11 Relative IL-6 mRNA and protein expression in Trp53^ '^ and 
TrpSJ^'/Statr^' MEFs. (A) Relative IL-6 mRNA in MEFs was quantified by real 
time PCR. (B) Secreted IL-6 in the culture media of MEFs was quantified by ELISA. 
Values shown are the mean fold difference ± SEN relative to Trp5J^\ Statistical 
analysis of mRNA and protein expression was performed by a two-tailed Student's t 
test and there were no significant differences between Trp5J^' and TrpSJ^'/Statl'^ ' 
MEF cells.
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Figure 4.12 Growth assay of cultured MEFs from gene knockout mice. MEFs were passaged after seven days following isolation 
and were seeded at a density of 1 x 10^  cells in 96 well plates and were grown in low (1%) or high (10%) serum. Growth was measured 
by the MTS assay on days 8, 10, 12 and 15.
4.8 Analysis of IFNy induced IL-6 expression in knockout mice
STATl is induced by IFNy and is the primary mediator the regulation of gene 
expression induced by this cytokine. There was increased mRNA and protein 
expression observed in TrpSJ^'/Statl'^ ' compared to Trp5J^' and MEF cells. 
Therefore, to further investigate the role of STATl in regulation of IL-6 expression, 
Trp5J^' and TrpSJ^'/Statr^' MEF cells were treated with IFNy and IL-6 expression 
was compared between the two cell types.
4.8.1 IFNy induced IL-6 expression in MEFs
To determine a time of IFNy treatment that elicits STATl induced expression 
changes in MEF cells, a time course of IFNy treatment was undertaken in TrpSJ '^ 
MEF cells, as they contain STATl and are responsive to IFNy. Tyrosine 
phosphorylation at position 701 of STATl (STAT1^ °^^ ) was assayed by Western 
blotting and relative mRNA expression of a STATl inducible gene, p2-microglubulin, 
was quantified by real time PCR. STAT1^°  ^phosphorylation was observed in Trp5J^' 
MEF cells following IFNy treatment for 1, 2 and 4 hours and at all concentrations of 
IFNy used (Figure 4.13). Maximal STAT1^°  ^ phosphorylation was observed at 60 
minutes and decreased after this time. STAT1^°  ^ phosphorylation was similar in cells 
following treatment with 5, 10, 20 or 40 ng/ml of IFNy.
The induction of p2-microglubulin mRNA was measured at 240 minutes following 
IFNy stimulation, as STAT1^°  ^ phosphorylation was still prominent at this time. The 
mRNA expression of p2-microglubulin was induced by IFNy in Trp5J^' MEF cells but 
not in TrpSJ^'lStatr^' MEF cells (Figure 4.13B). p2-microglubulin mRNA induction 
occurred in a dose dependent manner with maximal expression observed following 
treatment with 40 ng/ml or IFNy. p2-microglubulin mRNA induction was not observed 
in MEF cells treated with 5 ng/ml of IFNy.
The relative mRNA expression of IL-6 was quantified in Trp5J^' and TrpSJ^'/Statl'^ ' 
MEF cells treated with IFNy (Figure 4.14). IL-6 mRNA expression was induced in 
Trp5J^' and TrpSJ^'/Statl'^ ' MEF cells treated with 5, 10, 20 and 40 ng/ml of IFNy for 
240 minutes. Maximal induction was observed in both Trp5J^' and TrpBJ^'jStatr^'
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MEF cells following treatment with 40 ng/ml IFNy. Total IL-6 mRNA expression was 
higher in TrpSJ^'IStatr^' MEF cells compared to Trp5J^' MEF cells following 
treatment with IFNy at all concentrations. However, this was not statistically 
significant.
The secreted IL-6 in the culture media of TrpSJ '^ and Trp5J^'/Statl'^' MEF cells 
following treatment with 5 ng/ml of IFNy for 24 hours was assayed by ELISA (Figure 
4.15). Secreted IL-6 in the culture medium of TrpSJ^'/Statr^' MEF cells treated with 
IFNy increased 1.55 ± 0.22 fold higher compared to TrpSJ^'/Statl'^ ' MEF cells without 
IFNy treatment. Secreted IL-6 in the culture medium of Trp5J^' MEF cells was not 
increased following IFNy treatment (0.97 ± 0.23 relative to control). The induction of 
IL-6 protein expression by IFNy in TrpSJ^'/Statl'^ ' MEF cells was statistically 
significant. Therefore, IFNy induces expression of IL-6 in TrpSJ^'/Statl'^ ' MEF cells 
but not Trp5J^' MEF cells.
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Figure 4.13 STATl phosphorylation and p2-microglobulin gene expression 
in IFNy treated MEFs. (A) Western blot of IFNy treated Trp5J '^ MEFs 
immunoblotted for phosphorylated tyrosine residue 701 of STATl. (B) Relative IL-6 
mRNA in Trp5J^' and Trp5J^'/Statl'^ ' MEF cells treated with IFNy was quantified by 
real time PCR. Values shown are mean fold difference ± SEM relative to relevant 
control (untreated MEF cells of the same genotype).
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Figure 4.14 IL-6 mRNA expression in IFNy treated MEFs. IL-6 mRNA 
expression was quantified by real time PCR and is presented in two ways; (A) IL-6 
mRNA expression in Trp5J^' and TrpSJ^'/Statl'^ ' relative to respective control 
(untreated cells of the same genotype); (B) IL-6 mRNA expression relative to Trp5J^' 
control (untreated Trp5J^' cells). Values shown are mean fold difference ± SEM of 
three experiments. For each experiment, IFNy treatments and PCR reactions of each 
treatment were performed in triplicate. Statistical analysis was performed by a two- 
way ANOVA with Bonferroni post-tests and there were no significant differences 
between Trp5J^'and TrpSJ^'/Statl'^ ' ceWs.
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Figure 4.15 Secreted IL-6 from IFNy treated MEFs quantified by ELISA.
MEFs were treated with 5 ng/ml of IFNy and media was collected after 24 h. Values 
shown are mean fold differences ± SEM of 5 experiments. For each experiment IFNy 
treatments performed in triplicate. . Statistical analysis was performed by a two-way 
ANOVA with Bonferroni post-tests. <0.05 compared to p53/STATl null -IFNy 
treated cells.
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4.8.1 IFNy induced IL-6 expression in the heart
There was increased expression of IL-6 in Trp5J^'/Statr^' MEF cells compared to 
Trp5J^' MEF cells in response to IFNy treatment and when untreated. This suggests 
STATl may have a repressive effect on IL-6 expression. However, the highest level 
of IL-6 expression in the hearts of untreated mice was observed in Trp5J^' hearts, as 
determined by 2D-PAGE expression analysis and PM F identification of IL-6. This 
suggests that STATl may have positive effect on IL-6 expression in the absence of 
p53 repression. To further investigate the role of STATl in IL-6 regulation in the 
heart, knockout mice were treated with IFNy and cardiac IL-6 mRNA expression was 
quantified.
The optimal dose and time of IFNy treatment required for studying the expression of 
STATl regulated genes in the hearts of gene knockout mice was determined by 
undertaking a dose response and time course of IFNy treatment in wild type mice. 
Cardiac STAT1^ °^^  phoshorylation was assayed by Western blotting and the relative 
mRNA expression of several STATl regulated genes was quantified by real time PCR.
Wild type mice aged 8 weeks were injected intraperitoneally with IFNy in doses of 1, 
10, 50, 100 or 200 ng, or a vehicle control for 2 hours. STAT1^ °^^  phoshorylation 
increased in a dose dependent manner and maximal phosphorylation was observed 
in mice injected with 200 ng of IFNy, the maximum dose used (Figure 4.16).
Interferon regulatory factor-1 {IRF-1), major histocompatibility complex class II 
transactivator (C2fa) and p2-microglobulin (B2m) are three genes that have been 
demonstrated to be positively regulated by STATl. The mRNA expression of IRF-1 
and C2ta increased in hearts following IFNy in a dose dependent manner (Figure 
4.17). B2m mRNA expression was increased following IFNy treatment and maximal 
induction was observed with 10 ng/ml of IFNy.
FBJ osteosarcoma oncogene (Fos) mRNA expression has been shown to be 
repressed by STATl. Repression of Fos mRNA expression in hearts following IFNy 
treatment was observed although not for all doses of IFNy. Similar results were 
observed when mRNA expression levels were normalized to the mRNA expression of 
p-Actin and Gapdh.
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The optimal time of IFNy treatment was determined using a dose of 200 ng of IFNy. 
Mice were injected intraperitoneally with 200 ng of IFNy for 1, 2, 4 or 24 hours. 
STAT1^ °^^  phoshorylation in hearts was observed following 1 and 2 hours following 
IFNy treatment (Figure 4.18). STAT1^°  ^phoshorylation was not observed following 4 
or 24 hours of IFNy treatment. Maximal induction of IRF-1 and B2m mRNA was 
observed at 2 hours and C2ta was highest at 4 hours (Figure 4.19). The mRNA 
expression of these genes had returned to near normal levels after 24 hours of IFNy 
treatment. Fos mRNA expression was lowest at 24 hours following IFNy treatment.
These experiments demonstrated that IFNy responsive genes were responding in the 
classical manner according to the literature. Therefore, IL-6 mRNA expression was 
quantified to determine the optimal time and dose for investigating IL-6 expression 
in knockout mice in response to IFNy. IL-6 mRNA expression was highest in response 
to the maximal dose of IFNy used, 200 ng. The peak of IL-6 mRNA expression was at 
2 hours following IFNy treatment (Figure 4.20). Therefore, cardiac IL-6 mRNA 
expression was measured in knockout mice at 2 hours post 200 ng of IFNy.
The induction of cardiac IL-6 mRNA expression by IFNy was determined in wild type 
and Statr^' mice. Thus, for this experiment, the direct effect of STATl on IL-6 was 
tested. Cardiac IL-6 mRNA expression was induced by IFNy in both wild type and 
Statr^' mice (Figure 4.21). The level of cardiac IL-6 mRNA expression following IFNy 
treatment was less in Statl'^' mice compared to wild type mice, although the basal 
level of cardiac IL-6 expression was also less in Statl'^' mice. Moreover, there were 
no statistically significant differences between the groups.
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Figure 4.16 Western blot showing dose dependent induction by IFNy of 
STAT1^ °^  ^ phosphorylation in hearts of mice. Wild type mice were treated with 
IFNy by intraperitoneal injection for 2 h. 25 pig of protein was separated by 12% 
SDS-PAGE and immunoblotted for STAT1^°\ total STATl and p-Actin.
184
B15-1 lActin
IGapdh
Vehicle 1 10 50 100 200
IFNy Concentration ng/ml
l ~ n p-Ar.tln
■ IG a p d h
Vehicle 1 10 50 100 200
IFNy concentration ng/ml
3i n fVActin
Gapdh
Vehicle 1 10 50 100 200
IFNy concentration ng/ml
r**~lf\-Artin 
I B  Gapdh
Vehicle 1 10 50 100 200
IFNy concentration ng/ml
Figure 4.17 Dose dependent mRNA induction by IFNy of STATl regulated 
genes in hearts of mice. Wild type mice were treated with IFNy by intraperitoneal 
injection for 2 h. The mRNA expression of IRF-1 (A), C2ta (B), p2m (C) and Fos (D) 
was quantified by real time PCR and normalised to the expression of p-Actin or 
Gapdh. Values shown are mean fold difference of 2 animals for each treatment 
group relative to vehicle group. For the 200 ng treatment group only 1 animal was 
used.
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Figure 4.18 Western blot showing time course of induction by IFNy of 
STAT1^ °^^  phosphorylation in hearts of mice. Wild type mice were treated with 
200 ng of IFNy by intraperitoneal injection for 1, 2, 4 or 24 h. Each time-point was 
performed in three animals (N l-3); 12 animals used in total. 25 pig of protein was 
separated by 12% SDS-PAGE and immunoblotted for STAT1^°\ total STATl and 
Gapdh.
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Figure 4.19 Time dependent mRNA induction by IFNy of STATl regulated 
genes in hearts of mice. Wild type mice were treated with 200 ng of IFNy by 
intraperitoneal injection for 1, 2, 4 or 24 h. The mRNA expression of IRF-1 (A), C2ta 
(B), B2m (C) and Fos (D) was quantified by real time PCR and normalised to the 
expression of p-Actin or Gapdh. Values shown are mean fold difference of 2 animals 
for each treatment group relative to vehicle group. For the 2 h treatment group only 
1 animal was used.
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Figure 4.20 Dose and time dependent induction of IL-6 mRNA by IFNy in 
hearts of mice. Wild type mice were treated with IFNy by intraperitoneal injection 
for 2 h for the dose response (A) and with 200 ng for the time course (B). IL-6 
mRNA expression was quantified by real time PCR and normalised to p-Actin or 
Gapdh. Values shown are mean fold difference of 2 animals for each treatment 
group relative to vehicle group. For the 200 ng and 2 h treatment groups only 1 
animal was used.
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Figure 4.21 Cardiac IL-6 mRNA expression in IFNy wild type and Statl'^' 
treated mice. Values shown are normalised medians relative to wild type vehicle 
group. Statistical analysis of mRNA expression was performed by a Mann-Whitney U 
test. There were no significant differences between wild type and STATl'^' mice 
following vehicle or IFNy treatments.
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4.11 Discussion
The results described in this chapter show that mice doubly deficient in p53 and 
STATl, derived from commercially available B6.129-rrp5y^^^'^N12 and 129S6/SvEv- 
Stg^ miRds strains, are viable. It has previously been demonstrated that mice deficient 
in p53 and STATl are viable when derived from 1 2 9 / S v / J a n d  129/Sv/Ev- 
Statr^' strains (Kaplan et al., 1998).
These transgenic mice, with the disrupted Statl gene, express a truncated STATl 
protein of 72 kDa in the heart, a finding that has been previously described (Meraz et 
al., 1996, Stephanou et al., 2002). Expression of p53 was not detected in the hearts 
of wild type or p53 deficient mice. In normal physiological conditions, the expression 
of p53 is negatively regulated by the E3 ubiquitin ligase Mdm2, which results in its 
degradation by the proteosomal pathway (Lukashchuk and Vousden, 2007). 
Therefore, the expression of p53 was tested in MEF cells treated the etoposide, a 
DNA-damaging agent that induces p53. Etoposide treated Trp5J^' and Trp5J^'/Statr 
MEF cells were shown to be deficient in the p53 protein compared to immortalized 
wild type MEF cells cultured in our laboratory.
MEF cells isolated from wild type and Statl'^' mice became senescent after 
approximately eight days in culture whereas Trp5J '^ and Trp5J^'/Statl'^' MEFs 
continued to proliferate. Studies have shown that senescence of cultured wild type 
MEF cells occurs within weeks of isolation and it has been demonstrated that MEF 
cells deficient in p53 grown for over 50 passages never entered a non-growing 
senescent phase (Harvey et al., 1993).
One of the principal aims of this work was to investigate the role that p53 plays in 
the increased sensitivity to I/R-injury of Statl knockout mice that express a C- 
terminal fragment of STATl. The experimental system for this was the use of a 
hypoxic chamber to simulate I/R-injury in isolated NMCM cells. Trp5J''!StatT'' mice 
were susceptible to the spontaneous development of a variety of tumours at an early 
age. A previous study also demonstrated that Trp5J''IStatï'' mice developed a 
wider variety of tumours, with increased frequency at an earlier age compared to 
TrpSJ'' mice (Kaplan et al., 1998). In this study, the majority of Trp5J''IS tatï'' mice 
that were generated either died or were culled because of ill health between three
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and six months of age. Male and female Trp5J''IStatT'' mice were required to 
generate pure Trp5J''IStatT'' litters of mice in synchronisation with the generation of 
pure wild type, Trp5J'' and Statl'^' mouse litters. This methodology was thought 
necessary for the following reasons. Firstly, pure litters were required to generate a 
sufficient number of cells for experimentation and to eliminate the majority, and 
surplus, production of mice that would be heterozygous knockout for either Trp53 or 
Statl if homozygous crosses were not the approach used to generate the mice of 
required genotype. Secondly, the synchronisation of matings and generation of litters 
of all genotypes was required so that I/R-injury in cardiac myocytes would have been 
simulated in the ischaemic chamber at the same time, therefore eliminating a cause 
for potential variability. However, TrpSJ'lS tatï'' mice were of a poor physical 
condition at an early age and consequently were poor breeders. Thus, pure TrpSJ'' 
IS ta tï'' litters could not be produced without an exhaustive breeding programme 
that would generate a huge surplus of wild type, TrpSJ '^ and Statl'^' mice that would 
be generated concurrently for comparison to TrpSJ' lStatT'' mice. The use of NMCM 
cells as an experimental system for testing the hypothesis in question was 
impractical and was not used. Therefore, the role that p53 plays in the increased 
sensitivity of Statl'^' mice, compared to wild type mice, to cardiac I/Rinjury remains 
to be determined. This is currently being investigated in the adult mouse heart using 
Langendorff perfusion to simulate I/R-injury in our laboratory.
Expression profiling by 2D-PAGE revealed few differences in the cardiac proteomes of 
wild type, TrpSJ '^, Statl'^' and TrpSJ''IS ta tï'' mice. However, one protein that was 
highly abundant in hearts from TrpSJ '^ mice when compared to wild type, Statl'^' 
and TrpSJ''IS ta tï'' mice was identified by peptide mass fingerprinting as the IL-6 
precursor protein.
IL-6 is a pleiotropic cytokine that is involved in antibody production, inflammation 
and growth (reviewed by Kishimoto, 2006). Studies have demonstrated that p53 is a 
transcriptional repressor of the IL-6 promoter in cancer cell lines (Santhanam et al., 
1991, Angelo et al., 2002) and using TrpSJ '^ mice it has also been shown that p53 
represses IL-6 expression in the thymus following treatment with LPS (Komarova et 
al., 2005). In this study, the finding that IL-6 is highly abundant in TrpSJ '^ cardiac 
samples supports those previous studies showing that p53 is a repressor of IL-6. 
However, IL-6 was not found to be highly abundant in the cardiac proteome of 
TrpSJ''IS ta tï'' mice, suggesting that STATl is a potential activator of IL-6 in the
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heart. The relative differences observed in the level of IL-6 protein expression were 
not observed in the level of mRNA expression. Therefore, the differences may be due 
to post-translational regulation, for example, altered degradation of the protein.
IL-6 is expressed in cardiac myocytes and IL-6 mRNA expression is induced in an 
awake canine model of I/R-injury (Kukielka et al., 1995). IL-6 protein expression has 
been shown to increase in NRCM cells following hypoxic stress and this is augmented 
by reperfusion (Yamauchi-Takihara et al., 1995). IL-6/soluble IL-6 receptor complex 
reduces infarct size in rats following I/R injury (Matsushita et al., 2005). Induction of 
IL-6 by hypoxia in NRCM cells has been demonstrated to be mediated by the 
transcription factor, nuclear factor (NF)-kB (NF-kB) (Matsui et al., 1999). In human 
monocytic cells, induction of the IL-6 gene by IFNy and TNFa involves cooperation 
between IRF-1 and NF-kB (Sanceau et al., 1995). Although STATl was not directly 
implicated, it is a primary mediator of the IFNy signalling pathway and IRF-1 is 
positively regulated by STATl. Therefore, STATl may be inducing cardiac IL-6 
expression in the absence of p53 and would explain why this induction was not 
observed in Trp5J''IS ta tï'' mice.
The ELISA and Western blotting techniques used in this chapter were not sensitive 
enough for the detection of IL-6 in cardiac protein samples. Thus, there was no 
additional evidence to support the enhanced IL-6 protein expression in hearts of 
TrpSJ^' mice identified by proteomic screening. The protein samples required diluting 
and concentrating prior to ELISA, possibly resulting in too dilute a concentration or 
degradation of the protein. Furthermore, the antibody used in Western blotting was 
shown to have a low affinity for IL-6.
The increased IL-6 expression observed in cardiac tissue of TrpSJ '^ compared to
TrpSJ''IS ta tï'' mice was not equalled in MEF cells. Conversely, IL-6 mRNA
expression was higher in TrpSJ''IS ta tï'' compared to TrpSJ '^ MEFs. Moreover, the
induction of IL-6 protein expression by IFNy treatment in TrpSJ''IS ta tï'' MEFs was
not observed in TrpSJ '^ MEF cells. It has been demonstrated that STATl is not
required for IL-6 production in MEF cells treated with IFNy (Samardzic et al., 2001).
IL-6 has been implicated in inflammation-induced causes of cancer (Rose-John and
Schooltink, 2007) and the increased IL-6 expression in TrpSJ''IS ta tï'' mice may
contribute to why spontaneous development of tumours occur at a higher frequency
and at an earlier age in these mice compared to TrpSJ '^ mice. However, the reason
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why IL-6 mRNA expression and IFNy induced protein expression is higher in Trp5J^' 
IS ta tï'' MEF cells compared to TrpSJ '^ MEFs remains to be determined.
Cell type specific regulation may explain why such dissimilar observations were made 
for IL-6 expression between hearts and MEF cells. A limitation of this work was the 
few number of animals used in the proteome study, only three for each group. The 
mixed genetic background of the mice, coupled with them possibly in different stages 
of tumour development, may have been causes of variable IL-6 expression between 
mice. However, little variability in the proteome was observed between groups, 
therefore suggesting the IL-6 finding was specific to the genotype of the mice.
In summary, mice deficient in p53 and STATl are viable when derived from 
129IS\/p-Trp5J^' and 129/Sv/Ev-Sfafi'^' strains. However, due to poor health and 
consequent poor breeding isolated neonatal cardiac myocytes from pure TrpSJ'' 
jS ta tï'' litters were not produced. A proteomic approach was used to identify that 
the IL-6 precursor protein was highly abundant in hearts from TrpSJ^' mice when 
compared to wild type, Statï^' and TrpSJ' jS ta tï'' mice. The normal level of IL-6 
observed in Trp5J''jS tatï'' mice suggests that STATl may be a potential activator of 
IL-6. Conversely, IL-6 mRNA expression was higher Trp5J''jS tatï'' MEF cells 
compared to TrpSJ '^ MEF cells. Furthermore, induction of IL-6 protein expression by 
IFNy in TrpSJ''IS ta tï'' MEF cells was not observed in TrpSJ '^ MEF cells. Therefore, 
STATl may be involved in inducing the level of IL-6 in the heart but not in all tissue 
types.
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CHAPTER FIVE 
The role of hsp56 In ischaemla/reperfusion Injury and 
hypertrophy In the mouse heart
5 .1 1ntroduction and aims of this chapter
Circulating levels of the cytokine cardiotrophin-1 (CT-l) are increased in humans with 
chronic heart failure (Ta I war et al., 1999) and expression of CT-l is increased in the 
ventricles of humans with cardiomyopathies (Zolk et al., 2002) and in a variety of 
animal models of heart failure (Jougasaki et al., 2000, Aoyama et al., 2000). CT-l 
has been shown to be a potent hypertrophic molecule in isolated rodent cardiac 
myocytes (Pennica et al., 1995) and to a lesser extent in vivo following chronic 
administration of the peptide in mice (Jin et al., 1996). In addition to inducing 
hypertrophy, CT-l has been shown to confer protection from simulated I/R-induced 
injury in the isolated Langendorff perfused rat heart (Liao et al., 2002) and isolated 
NRCM cells (Brar et al., 2001).
Progress has been made in experiments using isolated rat cardiac myocytes to 
uncover the signalling pathways that connect CT-l and the physiological responses it 
elicits. The expression of the heat shock protein hsp56 increases in isolated myocytes 
following CT-l treatment and when expression of hsp56 was inhibited the 
hypertrophic effect of CT-l was abrogated (Railson et al., 2001). However, the 
protection conferred by CT-l from I/R-injury was not dependent on hsp56 (Brar et 
al., 2001). An earlier study demonstrated that hspSS over-expression did not protect 
isolated NRCM cells from I/R-injury (Brar et al., 1999). However, identification of 
hsp56 as a mediator of CT-l induced hypertrophy led to experiments that showed 
that over-expression of hspSG in isolated myocytes was sufficient for the induction of 
hypertrophy (Railson et al., 2001). The hypertrophy induced by hsp56 was 
demonstrated to be dependent on several well-characterized signal transduction 
pathways (Jamshidi et al., 2004).
The expression profile of hsp56 in human heart failure or animal models of heart 
failure is not known, other than in the context of CT-l induced hypertrophy in rodent
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hearts and isolated cardiac myocytes. However, as CT-l expression has been shown 
to increase in heart failure and that CT-l induced hypertrophy in vitro is dependent 
on hsp56. Considering this relationship between CT-l and hsp56, coupled with the 
observation that over-expression of hsp56 alone induces hypertrophy of cardiac 
myocytes in vitro, the following question remains to be answered: is hsp56 a 
mediator of hypertrophy in vivol To answer this question this chapter describes how 
transgenic mice that over-express hsp56 were generated and assayed for myocardial 
hypertrophy by measuring heart-to-body weight ratios, myocyte cell size and the use 
of real-time PCR for quantifying the expression of genes that are commonly 
reactivated as part of the foetal growth program in hypertrophy.
Studies using isolated cardiac myocytes found that over-expression of hsp56 did not 
confer any protection from I/R-injury. However is not known if hsp56 over­
expression is cardio-protective in the intact heart. To test this, hearts from hsp56 
over-expressing mice were subjected to I/R-induced injury ex vivo by the 
Langendorff perfusion method.
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5.2 Generation of hsp56 over-expressing transgenic mice
5.2.1 Mouse pronuclear injection of pCAGGS-hsp56 expression vector
Pronuclear injection of pCAGGS-hsp56 in FVB/N strain zygotes was undertaken at the 
ICH transgenic facility and resulted in the birth of 22 potential founder transgenic 
mice. At 3 weeks of age the genomic DNA from tail biopsies of the mice was 
screened for the integration of pCAGGS-hsp56 by PCR (figure 5.1a, upper row). 
pCAGGS-hsp56 was not detected in the genomic DNA of mice generated by 
pronuclear injection at the Institute of Child Health transgenic facility. The quality of 
the genomic template was shown to be sufficient for PCR by the amplification of an 
endogenous DNA control (figure 5.1a, lower row).
Subsequent to the initial attempt of pronuclear injections, the ICH transgenic facility 
was being relocated, therefore further pronuclear injections were undertaken by the 
KI facility. Pronuclear injection of pCAGGS-hsp56 in B6CBAF1 strain zygotes resulted 
in the birth of 45 potential transgenic founder mice. pCAGGS-hsp56 was detected in 
the DNA of 5 mice (numbers 5, 6, 21, 36 and 46) by PCR amplification of a 451 bp 
sequence of the transgene (figure 5.2). The percentage of mice born from 
pronuclear injection of pCAGGS-hsp56 that were transgenic was 11%.
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Figure 5.1 PCR screening of hsp56 transgenic mice generated by 
pronuclear injection using the ICH (A) and KI (B) transgenic services. PCR
products were separated by agarose gel (2%) electrophoresis. A) PCR products from 
screening of the hsp56 transgene (upper) and an endogenous DNA control (lower). 
Lane 1; DNA molecular weight marker. Lanes 2-8; potential founders. Lane 9; PCR 
positive control. B) hsp56 transgene products. Lane 1; DNA molecular weight 
marker. Lanes 2-11; potential founders.
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5.2.3 Transmission of hsp56 transgene
Hsp56 founder transgenic mice were of the B6CBAF1 strain. Mice of this strain are 
the progeny of a C57BL6 and CBA cross and therefore hsp56 transgenic mice were 
backcrossed to C57BL6 to reduce genetic variation. All five transgenic founders 
generated progeny with C57BL6 mice and all except hsp56/45 transmitted the 
transgene to their progeny (Table 5.1).
Transgenic founder Transgene transmission
Hsp56/5 53.1 %
Hsp56/6 18.2 %
Hsp56/21 18.6 %
Hsp56/36 23.7 %
Hsp56/45 0%
Table 5.1 Transgene transmissions in hsp56 transgenic lines
5.2.3 Over-expression of hsp56 in mice carrying pCAGGS-hsp56 
transgene
Over-expression of hsp56 in pCAGGS-hsp56 transgenic mice was determined by 
Western blotting. Progeny from all four of the transgenic founder mice generated 
over-expressed hsp56 in the heart compared to wild-type littermates (figure 5.2). 
Protein expression of transgenic hsp56 varied between the lines with the highest 
observed in line 36 and the lowest in line 21.
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Figure 5.2 Western blot analysis of transgenic hsp56 over-expression.
Heart protein lysates from hsp56 transgenic mice from lines 5, 6, 21, 36 and wild- 
type littermates were separated on 12% SDS-PAGE gels and immunoblotted for 
hsp56 (A) or Gapdh (B). Two animals from each line are shown.
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5.3 Hearts from hsp56 over-expressing mice failed to be protected 
from ischaemia/reperfusion induced injury
The effect of over-expression of hsp56 In the mouse heart when challenged with I/R 
was assessed using Langendorff perfusion for inducing I/R-injury and infarct sizes as 
the measurement for I/R-injury.
Isolated hearts from 10-12 week-old male hsp56 transgenic mice and wild-type 
controls were subjected to I/R or normoxia protocols by Langendorff perfusion. 
Infarct measurements were made from transverse sections of TTC stained hearts 
(figure 5.3 A) and infarct sizes are expressed as a percentage of the whole heart 
(figure 5.3 B). Infarcts were not observed in hsp56 transgenic or wild-type hearts 
following the normoxia protocol. Hsp56 transgenic and wild-type hearts had similar 
infarcts following the I/R protocol (wild-type; 48.5% ± 3.6 and hsp56; 44.7% ± 4.2).
A retrospective power calculation measured the power of the statistical test 
performed on the difference in infarct sizes observed between hsp56 transgenics and 
wild-types to be 9% (see appendix). In these experiments 4-6 animals were used per 
group. In order to rule out a type II statistical error the required sample size for 
these experiments would need to be increased to 40.
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Figure 5.3 Infarct size analysis of Langendorff perfused hearts from hsp56 
transgenic mice and wild-type controls. (A) Transverse sections of TTC stained 
hearts following I/R or normoxia control protocols. Infarct appears white and viable 
tissue appears red. (B) Infarct sizes were measured using a planimetry board and 
are expressed as a percentage of total heart. Means are shown as horizontal lines. 
See appendix for power calculation.
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5.4 Over-expression o f hsp56 alone in mice did not induce 
myocardial hypertrophy
5.4.1 Measurement of heart to body weight ratio
The heart-to-body weight ratios of mice from hsp56 transgenic lines 5 and 36 were 
measured at 4 months of age. The heart-to-body weight ratios of wild-type and 
hsp56 transgenic mice were similar for males and females from both transgenic lines 
(figure 5.4).
The heart-to-body weight ratios of mice from hspSS transgenic lines 5, 6, 21, and 36 
were measured at 1 year of age (figure 5.5). An increase in heart-to-body ratio was 
observed in hsp56 transgenic males from line 5 (wild-type; 4.78 ± 0.34 and 
transgenic; 6.33 ± 0.51), line 6 (wild-type; 4.64 ± 0.21 and transgenic; 5.88 ± 0.07) 
and transgenic females from line 36 (wild-type; 3.89 ± 0.18 and transgenic; 4.52 ± 
0.02). An increase observed in hsp56 transgenic males from line 36 (wild-type; 4.98 
± 0.26 and transgenic; 5.42 ± 0.29) was not significant.
Reduced body weight was observed in all groups (1-year-olds) that exhibited an 
increased heart-to-body weight ratio and was significant for transgenic males from 
line 6 (wild-type; 53.92 ± 0.91 and transgenic 45.85 ± 2.25). Reduced body weight 
was a trend observed in lines 5, 6 and 36 with exception of females from line 6. The 
body weights and heart-to-body weight ratios of wild-type and transgenic mice from 
line 21 were similar for males and females.
5.4.2 Myocyte width measurements
Crude cardiac myocyte width measurements were made from haematoxylin and 
eosin stained sections from transgenic line 36 mice (figure 5.7). This is a crude 
method because for each section the myocytes are sectioned at different planes and 
thus the width measured is not consistent for each cell in the same way measuring 
the maximum width of isolated myocytes would be. Nevertheless, there were no 
differences observed between transgenics and their wild-type littermates with this 
method.
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Figure 5.4 Heart-to-body weight ratios of 4-month-old hsp56 transgenic 
mice and their wild-type littermates from line 5 (A) and line 36 (B). Values 
represent the mean ± SEM of 3 animals. There Is no significant difference between 
male or female transgenics and their wild-type littermates in either line 5 or 36, as 
determined by two-way ANOVA with Bonferroni post-tests.
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Figure 5.5 Heart-to-body weight ratios of 1-year-old hsp56 transgenic 
mice and their wild-type littermates from line 5 (A), line 6 (B), line 21 (C) 
and line 36 (D). At least three mice from each group were analyzed and values 
represent the mean ± SEM. Statistical analysis was performed by a two-way ANOVA 
with Bonferroni post-tests.
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Figure 5.6 Body weights of 1-year-oid hsp56 transgenic mice and their 
wild-type littermates from line 5 (A), line 6 (B), line 21 (C) and line 36 (D).
At least three mice were analyzed from each group and were those used in heart-to- 
body weight ratio measurements. Values represent the mean ± SEM. Statistical 
analysis was performed by a two-way ANOVA with Bonferroni post tests.
206
Chapter F n e Results
Maanification
B
Wild types Transgenics
Figure 5.7 Cardiac myocyte width measurements in hsp56 transgenic mice 
and wild-type controls. (A) Cross sections of haematoxylin and eosin stained 8 
pm heart slices. Single black arrows show myocyte nuclei. Double black arrows show 
myocyte width. (B) Relative cell width measurements were made using Axiovision 
analysis software. Values represent means of 100 cells measured from 3 animals per 
group
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5.4.3 Gene expression analysis of hypertrophic markers
The reactivation of the foetal growth program commonly associated with
hypertrophy was assessed by quantification of atrial natriuretic factor (ANF), p-
myosin heavy chain (p-MHC) and brain natriuretic peptide (BNP) gene expression in 
hearts from 1-year-old mice from transgenic lines 5 and 36 (figures 5.8-5.10).
The median value for AN F gene expression was reduced in transgenics from both
lines 5 and 36 when compared to wild-types (100%), although was not significant 
(line 5; 48% and line 36; 44%). p-MHC gene expression was reduced, but not 
significantly, in transgenics from line 5 (46%) and in transgenics from line 36 (79%) 
compared to wild-types. BNP gene expression was increased in transgenics from line 
5 (126%) and decreased in transgenics from line 36 (38%) compared to wild-types. 
These changes were not significant.
Induction of the serum glucocorticoid kinase 1 (Sgkl) gene has recently been 
implicated in hypertrophy (Lister et al., 2006) and was therefore measured inhsp56 
transgenics. Sgk gene expression was highly similar in transgenics from line 5 
(103%) and line 36 (97%) when compared to wild-types (figure 5.11)
The data shown for the expression of ANF, p-MHC, BNP and Sgk were normalized to 
the endogenous expression of p-actin. The expression of these genes were also 
normalized to the expression of p2-microglobulin and Gapdh (figure 5.12) and the 
median values obtained were highly similar with exceptions of the p-MHC in line 5 
and BNP from line 36.
When normalized to p-Actin the expression p-MHC in line 5 decreases (46%), 
however expression of p-MHC increases when normalized to p2-microglobulin 
(161%) and Gapdh (129%). The expression of BNP in line 36 is reduced when 
normalized to p-Actin (38%) and Gapdh (65%), however, is increased when 
normalized to p2-microglobulin (172%). These results suggest there may be some 
variation in the reference genes.
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Figure 5.8 ANF mRNA expression in hearts from hspS6 transgenic mice and 
their wild-type littermates from line 5 (A) and line 36 (B). Values represent 
ANF mRNA expression normalized to p-actin. Results with p-actin, Gapdh and p2- 
microglobulin normalizations are highly similar. Medians are shown as horizontal 
lines.
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Figure 5.9 p-MHC mRNA expression in hearts from /i5p55 transgenic mice 
and their wild-type littermates from line 5 (A) and line 36 (B). Values 
represent p-MHC mRNA expression normalized to p-actin. Results with p-actin, 
Gapdh and p2-microglobulin normalizations are highly similar. Medians are shown as 
horizontal lines.
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Figure 5.10 BNP mRNA expression in hearts from hsp56 transgenic mice 
and their wild-type littermates from line 5 (A) and line 36 (B). Values 
represent BNP mRNA expression normalized to p-actin. Results with p-actin, Gapdh 
and p2-microglobulin normalizations are highly similar. Medians are shown as 
horizontal lines.
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Figure 5.11 Sgk mRNA expression in hearts from hsp56 transgenic mice 
and their wild-type littermates from line 5 (A) and line 36 (B). Values 
represent Sgk mRNA expression normalized to p-actin. Results with p-actin, Gapdh 
and p2-microglobulin normalizations are highly similar. Medians are shown as 
horizontal lines.
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Figure 5.12 Comparison of normalizing expression of ANF (A), p-MHC (B), 
BNP (C) and Sgk (D) to 3 reference genes. Normalizing to p-Actin, p2- 
microglobulin and Gapdh gave highly similar results with the exceptions of p-MHC in 
line 5 and BNP in line 36. Values shown are normalised medians.
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5.5 Discussion
The results described in this chapter show that transgenic mice over-expressing 
hsp56 in a ubiquitous and constitutive manner are viable in the B6CBAF1 mouse 
strain, and also when these mice and are backcrossed to the C57BL6 mouse strain. It 
has been well documented that transgenics with the same over-expressed gene or 
gene knock-out in different mouse strains can result in very diverse phenotypes and 
in some cases this can be even as extreme as to the viability of the mouse. For 
example, strain background can alter the incidence and type of tumours in mice 
deficient of the tumour suppressor p53 (Blackburn and Jerry, 2002), and targeted 
deletion of the hypoxia transcription factor, endothelial PAS domain protein-1 (EPAS- 
1) results in embryonic lethality in some but not all mouse strains (reviewed by 
Williams and Wagner, 2000). Therefore, it is possible that the failure to identify adult 
hsp56 over-expressing mice in the FVB/N mouse strain could be due to embryonic 
lethality resulting from the over-expression of hsp56 in this strain. However, as only 
adult mice were screened for the presence of the transgene and the fact that 
successful generation of hsp56 over-expressing mice of the B6CBAF1 strain was 
achieved at a separate facility it is also possible that failure to generate hsp56 over­
expressing mice of the FVB/N strain was due to a technical matter.
The five founder transgenic mice that were generated did not all transmit the hsp56 
transgene at the expected Mendelian frequency of 50%. The integration of foreign 
DNA into the embryonic genome normally occurs in the form of a concatemer 
transgene copies at a single site and is a random event with respect to the 
chromosomal locus (Brinster et al., 1985). If integration doesn't occur until the two­
cell stage or later-stage embryo then a mosaic mouse will be generated. Therefore 
those founders transmitting the transgene at a frequency of less than 50% may be 
mosaic. The transgenic founder hsp56/^5 did not transmit the transgene to any 
progeny and it is possible that integration of the transgene occurred so that is was 
then only present in the somatic cells of this mouse.
As integration is random, the transgenic founders generated are unique and 
transgenic mice derived from the four transmitting founders represent four distinct 
hsp56 transgenic lineages. Furthermore, the large majority of the genome consists of 
non-coding sequences and although the likelihood of disrupting a host gene and
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inadvertently affecting the phenotype Is small, the possibility does exist. Therefore It 
Is favourable to have generated several transgenic lines, as findings that are 
reproduced In different lines give a greater confidence that they are a direct result of 
the over-expressed protein and not the consequence of disrupting a host gene.
One phenotypical characteristic that Illustrates how transgenics generated from 
different founders are distinctly different Is In the range of hsp56 protein expression 
exhibited between the lines. Having differential expression between transgenic lines 
Is also a favourable feature as this may allow determination of relationships between 
quantity of protein expression and any physiological responses.
Hearts from mice over-expressing hsp56 were not protected from I/R-lnjury 
simulated by Langendorff perfusion. The lack of cardioprotection exhibited by hsp56 
over-expresslon Is consistent with a previous study that demonstrated there was no 
cardioprotective effect of hsp56 over-expresslon In cardiac cells subjected to a lethal 
dose of hypoxia (Brar et al., 1999). However, that particular study also 
demonstrated that unlike hsp56, over-expresslon of heat shock proteins hsp27 and 
hsp70 did protect cardiac cells from hypoxia. Moreover, hearts from transgenic mice 
that over-express hsp27 (Efthymlou et al., 2004) or hsp70 (Marber et al., 1995, 
Plumier et al., 1995) are protected from I/R-lnjury. This study further highlights how 
different heat shock proteins are distinctly different In conferring cardioprotection 
from I/R-lnjury.
Myocardial hypertrophy was not observed In hsp56 over-expressing mice aged 4- 
months, as measured by heart-to-body weight ratio. This observation was made In 
two transgenic lines. This finding Is contradictory to the effects of hsp56 over- 
expresslon In Isolated NRCM cells (Rallson et al., 2001, Jamshldl et al., 2004). 
However, myocardial hypertrophy Is progressive and studies of transgenic mice over- 
expressing the hypertrophy Inducing protein Myotrophin (Sarkar et al., 2004) and 
knock-out mice deficient In the hypertrophy suppressing protein HDAC9 (Zhang et 
al., 2002) have demonstrated that differences In heart-to-body weight ratios Increase 
with age and may only become apparent In older mice.
Myocardial hypertrophy was therefore measured In 1-year-old mice from four 
transgenic lines. Heart-to-body weight ratios Increased for both transgenic male and 
female groups from line 5, line 6 and line 36. Of these. Increases In the male
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transgenic groups from line 5 and line 6, and in the female transgenic group from 
line 36 were statistically significant. Interestingly, although there were increases in 
heart-to-body weight ratios for male and female transgenics from line 5, line 6 and 
line 36, the body weights for all these groups were reduced when compared to their 
wild-type littermates, with the exception of the female transgenic group from line 6. 
Therefore, the observed increase in heart-to-body weight ratios was a function of the 
reduced body weight in hsp56 over-expressing mice and not increased heart weight. 
This observation also contradicts the finding that hsp56 causes hypertrophy.
Myocardial hypertrophy occurs as cardiac myocyte volume increases as a result of 
increasing length and/or width. The hypertrophic effect of hsp56 over-expression in 
isolated cardiac myocytes in some instances manifested as a 20% increase in cell 
size (Jamshidi et al., 2004). Such subtle increases in vivo could go undetected in the 
heart-to-body weight ratio assay as the heart consists of a large proportion of cell 
types other than cardiac myocytes that do not undergo hypertrophy. However, the 
width of cardiac myocytes were measured in haematoxylin and eosin stained cross 
sections of heart tissue and no increase was observed in transgenics when compared 
to wild-type controls.
A characteristic feature of myocardial hypertrophy is the reactivation of the foetal 
growth program that commonly includes the high expression of ANF, BNP and p-MHC 
mRNAs. mRNA expression for each of these genes was quantified and were not 
elevated in transgenics of either of the two lines assayed. It has been previously 
shown that over-expression of hsp56 in isolated NRCM cells induces a luciferase 
reporter containing the ANF promoter (Jamshidi et al., 2004). However in this study 
ANF mRNA expression in hsp56 over-expressing mice was reduced in two transgenic 
lines although not statistically significant.
Glucocorticoids have been have shown to induce myocardial hypertrophy (Whitehurst 
et al., 1999) and it was recently demonstrated that such hypertrophy involves the 
increased expression and requirement of serum and glucocorticoid induced kinase 1 
(SGKl) (Lister et al., 2006). Hsp56 is part of the glucocorticoid receptor complex 
(Peattie et al., 1992) and thus may have in role glucocorticoid induced hypertrophy. 
As hsp56 over-expression induces hypertrophy in isolated cardiac myocytes, SGKl 
mRNA expression was quantified in order to determine if hsp56 over-expression
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could induce the expression of SGKl, however, no increase was observed in 
transgenics from the two lines analyzed.
In summary, hearts from transgenic mice that over-express hsp56 in a constitutive 
and conditional manner are not protected from I/R-injury and are not hypertrophic. 
The lack of cardioprotection is consistent with hsp56 over-expression in isolated 
NRCM cells (Brar et al., 1999) but the absence of hypertrophy does not reproduce 
the findings in vitro. (Railson et al., 2001, Jamshidi et al., 2004).
An unexpected observation was that mice from three transgenic lines over­
expressing hsp56 had reduced body weight compared to wild-type controls. The 
effects of glucocorticoid signalling include the stimulation of fat breakdown in 
adipose tissue and the ability of hsp56 to bind the glucocorticoid receptor may be 
modulating this effect. A reduction in body weight was not exhibited by transgenics 
from line 21. Line 21 was the lowest hps56 expressing transgenic line and this may 
be why a reduction in body weight was not observed. Although defects in 
reproductive tissues of mice deficient in hsp56 have been demonstrated (Cheung- 
Flynn et al., 2005, Tranguch et al., 2005), no changes in body weight were reported. 
It may be expected that the opposite effect would occur in a knock-out mouse 
compared to on over-expressing transgenic for the same gene however abnormally 
high levels of a protein has the potential to produce artificial results. Nevertheless, 
these findings suggest that hsp56 may have a physiological role in glucocorticoid 
signalling that could be studied in either mice deficient or over-expressing hsp56.
The findings in this study do not necessarily preclude hsp56 from having a role in 
hypertrophy. Although hsp56 over-expression in mice was not sufficient to induce 
hypertrophy it may still be required for hypertrophy induced by other stimuli. For 
example, hsp56 is required for hypertrophy induced by CT-1 in isolated NRMC cells. 
The hsp56 over-expressing mice generated in this study could therefore be used to 
further examine this role by testing their sensitivity to CT-1 treatment.
Over-expression of hsp56 in the mouse could potentially induce hypertrophy if an 
alternative approach to the one taken in this study was used. In this study transgenic 
mice were transformed with an expression construct for hsp56 that was under 
control of a chicken p-actin promoter that gave ubiquitous and constitutive 
expression. The null hypertrophic phenotype observed in these mice could be a
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result of physiological compensation. Expression of hsp56 in the developing embryo 
may have at some stage induced compensatory factors to overcome and hide the 
hypertrophic effect of hsp56. This may explain why ANF mRNA expression was lower 
in transgenics from the two lines assayed. If this were the case, an alternative 
approach to consider would be to generate a transgenic in which the temporal 
expression of hsp56 could be controlled. One such example would be to use a 
tetracycline transactivator system.
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CHAPTER SIX 
Urocortin mediated protection from simulated I/R injury in the 
adult rat heart and ARVO cells is associated with inhibition of 
mitochondrial permeability transition pore opening (AmV)
6 .1 1ntroduction and aims of this chapter
The expression of the endogenous cardioprotective peptide CT-1 has been shown to 
be induced by a further, possibly upstream, endogenous cardioprotective peptide, 
Urocortin (Ucn) (Janjua et al., 2003). Cardiac myocyte survival in heart biopsies 
exposed to I/R injury is associated with induced Ucn expression (Searabelli et al., 
2004). Exogenous application of Ucn has been shown to protect NRCM cells and the 
Langendorff perfused rat heart from simulated I/R injury, when given prior to 
ischaemia or at reperfusion (Brar et al., 2000, Sea ra belli et al., 2002). Therefore, 
clearly Ucn may have some therapeutic benefit, for example by minimizing ischaemic 
damage in patients undergoing cardiac surgery or as adjunct in patients with 
undergoing thrombolytic intervention.
The mechanism by which Ucn protects from I/R-injury has been under investigation 
although it is not fully understood. Activation of p42/p44 MARK and PI-3K/Akt 
pathways have been demonstrated to be necessary for Ucn mediated protection 
(Brar et al., 2000, Brar et al., 2002b). Mediators of the protective effect of ischaemic 
preconditioning (IRC), RKCe (Scarabelli et al., 2004) and the Katp channel subunit 
Kir6.1, have also been implicated (Lawrence et al., 2002, Lawrence et al., 2005). 
Furthermore, Ucn mediated protection in NRCM cells has also been shown to involve 
prevention of mitochondrial damage and associated inhibition of opening of the 
mitochondrial permeability transition pore (MRTR) (Lawrence et al., 2004). However, 
the relationship between Ucn mediated protection in the adult heart and 
mitochondrial permeability, designated by AmW, remains to be assessed.
Cardiac I/R-injury is predominantly an adult disease and many differences exist 
between the neonatal and adult heart, therefore, the aim of this study is to ascertain
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whether the protection conferred by Ucn in the adult rat heart and adult cardiac 
myocytes involves inhibition of MPTP opening. One major aim of the work presented 
in this chapter was the setting up and establishment of adult rat ventricular myocyte 
(ARVC) cultures. In this chapter, the relationship between Ucn and the MPTP in 
protection from simulated I/R-injury will be presented. The data uses both ARVC 
cells and in the intact isolated rat heart by Langendorff perfusion.
6.2 Isolation and culture of adult rat ventricular cells
The isolation and culture of adult rat ventricular cells (ARVC) was not an established 
technique in our laboratory. Therefore, the enzymatic dissociation by retrograde 
perfusion and rapid attachment technique was observed in Professor Chris Proud's 
laboratory (Dundee University) and was then successfully reproduced in our 
laboratory.
Isolations of ARVC cells varied between approximately 50-90% in the proportion of 
viable cells, as measured by the distinctive rod-shaped morphology of viable ARVC 
cells, compared to round necrotic cells. Cultured ARVC cells have distinctive rod 
shaped morphology and are bi-nucleated (Figure 6.1). Spontaneous contraction was 
observed in only a few of the cultured ARVC cells. Unlike cultures of neonatal cardiac 
myocytes, spontaneous contraction of cultured ARVC cells is associated with stress 
and a progression towards apoptosis (Maruyama et al., 2001). Expression of the 
cardiac myocyte specific marker desmin was observed in all rod shaped cells and the 
ventricular specific marker MLC2v was observed in the majority of rod shaped cells 
by immunocytochemistry (Figure 6.1).
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6.3 Simulating I/R and assessment o f survival in ARVC cultures
Simulation of I/R resulted in death of ARVC cells, as observed by the increased 
number of rounded up cells following I/R (Figure 6.2). Membrane blebbing, a 
characteristic feature of apoptosis, was initially observed in ARVC cells in early 
reperfusion. However, our standard biochemical techniques for detection of 
apoptosis were not successful in ARVC cells. It was observed that the buffer used for 
annexin V staining induced rapid death of ARVC cells. Shortly after incubation with 
annexin V buffer all cells began to contract, followed by shortening of cells and 
absolute death of cultures within 5 minutes as observed by rounding up of all cells. 
Neither ARVC cells subjected to simulated I/R or normoxic conditions showed 
positive Terminal-dUTP nucleotide end labelling (TUNEL). Thus, the use of standard 
biochemical techniques could not be used in subsequent experiments to measure 
apoptotic cell death. Therefore, only total cell death was determined, which was 
based on cell morphology; rod-shaped viable cells compared to round dead cells.
Simulated I/R resulted in death of ARVC cells in an ischaemic time dependent 
manner (figure 6.3). ARVC cells were subjected to 2, 4 or 6 h of ischaemia followed 
by 2 h of re perfusion (figure 6.3A). Increased cell death, measured as the 
percentage of rounded up cells, was observed following increased lengths of 
ischaemia. ARVC cells were subjected to 2 h of ischaemia followed by 2, 4 or 24 h of 
reperfusion (Figure 6.3B). Maximum cell death was observed at 4 h of reperfusion. 
After 24 h of re perfusion the percentage of dead cells was less compared to 4 h of 
reperfusion, however, the total number of adhered cells was less. This suggests 
there were more dead cells following 24 h reperfusion except they were not 
accounted for as a result of them detaching from the culture dish.
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Figure 6.1 Cultured adult rat ventricular myocytes. (A) Myocytes visualized 
under light microscopy (magnification x25). (B) Fluorescence microscopy of cardiac 
myocyte showing nuclei stained with Hoechst 33258 (magnification xlOO). (C and D) 
Immunoflourescence of cardiac myocytes showing staining of (C) the cardiac 
myocyte specific protein, desmin (magnification xlOO), or (D) the ventricular 
myocyte specific protein, MLC2v (magnification xlOO).
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Figure 6.2 Morphological changes of ARVC cells following I/R . Images show 
ARVC cells viewed under light microscopy (magnification x25). (A) ARVC cells 
subjected to normoxic conditions. (B) ARVCs subjected to I/R (2h/4h). Thin arrows 
point towards rod shaped viable cells and thick arrows point towards round dead 
cells. Cultures of ARVC cells subjected to I/R show a higher number of rounded up 
cells compared to cultures of cells not subjected to I/R.
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Figure 6.3. Ceil death of ARVC ceils following simulated I/R . (A) The effect 
of ischaemic time on death in cultured ARVC cells. ARVC cells were subjected to the 
indicated time of ischaemia followed by two hours of reperfusion. (B) The effect of 
reperfusion time on death of cultured ARVC cells. ARVC cells were subjected to two 
hours of ischaemia followed by the indicated re perfusion time. Cells were fixed in 4% 
PFA. Cell morphology was used to determine cell viability. A total of 300 cells were 
counted per well and each time-point was performed in duplicate. Values represent 
the mean ± SEM of three experiments. Statistical analysis was performed by a 
student's ftest. *P<0.05 compared to normoxia.
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6.4 Urocortin protects ARVC cells from simulated l/R-induced 
death and is associated with inhibition of the MPTP from opening
Pre-treating ARVC cells with Ucn for 1 h protected them from simulated I/R-induced 
death (Figure 6.4A). The percentage of dead celis foilowing simuiated I/R in cuitures 
pre-treated with Ucn was 36.33% ± 6.06%, compared to 50.67% ± 4.91% in 
cultures treated with a vehicie control. In cultures subjected to normoxic conditions, 
the percentage of dead ceils in Ucn treated cultures was 14.33% ± 5.24% compared 
to 19.67% ± 3.18% in cuitures treated with a vehicle control. Thus, fewer dead cells 
were observed in the Ucn treated cuitures that were subjected to simulated I/R and 
a small reduction in ceii death in normoxic conditions was observed when treated 
with Ucn. Therefore, Ucn may confer some resistance to death of ARVC celis in 
cuiture.
The protective effect of Ucn was compared when ischaemia was simulated either 
immediately (1 h) or when delayed (16 h) after Ucn treatment. ARVC cells pre­
treated with Ucn for 1 or 16 h were protected from simuiated I/R-induced death 
(Figure 6.4B). The percentage of dead cells following simulated I/R in cultures pre­
treated with Ucn for 16 h (46.23% ± 11.75%) or 1 hr (38.00% ± 6.17%) was 
significantly lower than in cuitures pre-treated with a vehicie controi (65.17% ± 
11.06%). Statisticai analysis was performed by a student's ftest, demonstrating that 
I/R induced ceil death in both 1 h and 16 h pre-treatments was significantly less 
compared to cultures not treated with Ucn (P <0.05).
The protective effect of Ucn was more potent when ischaemia was simuiated 
immediately (1 h) after Ucn treatment compared to when it was deiayed (16h). The 
reduced ceii death observed in ARVC celis pre-treated with Ucn for 1 h prior to 
simuiated I/R was associated with reduced MPTP opening (Figure 6.5). The 
mitochondria of ARVC ceils were preloaded with Tetramethyi rhodamine methyi ester 
(TMRM). Simulated I/R caused a decrease in the amount of TMRM retained by 
mitochondria, as determined by the mean fluorescent intensity (MFI). The reduction 
of MFI was attenuated in ceils pre-treated with Ucn for 1 h. Statisticai analysis was 
performed by a student's ftest, demonstrating that the MFI was significantiy higher, 
following simuiated I/R, in Ucn pre-treated ceiis compared to cultures not treated 
with Ucn (P<0.05). This suggests that Ucn treatment may inhibit MPTP opening.
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Figure 6.4 Urocortin protects ARVCs from simulated l/R . (A) Effect of Ucn 
pre-treatment for 1 h on survival of ARVCs subjected to simulated I/R (2h/4h). (B) 
Comparison of immediate and delayed ischaemia on the protective of 10 nM Ucn in 
ARVC cells. Cell viability was determined based on cell morphology, 300 cells per well 
were counted for each treatment group and each treatment group was performed in 
triplicate. The values for (A) represent the means ± SEM of three separate wells. The 
values for (8) represent the means ± SEM of three separate experiments. Statistical 
analysis was performed by a student's t-test. *P <0.05 compared to -Ucn (I/R).
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Figure 6.5 Urocortin treatment of ARVCS protects the MPTP from opening 
in response to simulated I/R . ARVC cells were pre-treated with 10 nM Ucn or a 
vehicle control for 1 h prior to simulated I/R. Cells were also stained with TMRM prior 
to simulated I/R. The mean fluorescent intensity is shown from 5000 separate events 
assayed by flow cytometry. Statistical analysis was performed by a student's ftest.
<0.05 compared to relevant control.
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6.5 Urocortin improves recovery and survival of adult rat hearts 
following l/R and decreases MPTP opening
Simulated I/R in adult rat hearts was performed by Langendorff perfusion and 
haemodynamic data are shown in Table 6.1. Ucn significantly reduced the time taken 
to initiate ischaemic contracture (11.9 ± 0.6 versus 7.6 ± 0.5 min, P<0.01) although 
the time taken to reach maximal ischaemic contracture (19.0 ± 0.7 versus 18.4 ± 1.0 
min) and its magnitude (32.1 ± versus 33.6 ± 1.6 mmHg) remained unaltered. Upon 
reperfusion, the recovery of left ventricular developed pressure (LVDP) was 
significantly greater in Ucn treated hearts (32.1 ±7.1 versus 64.6 ±4.1 mm Hg, 
P<0.01) whilst elevation of end diastolic pressure (EDP) was significantly reduced 
(48.1 ± 6.3 versus 20.9 ± 4.0 mmHg) and there was no change in heart rate.
This improvement in haemodynamic recovery shown by restoration of LDVP was 
associated with a significant decrease in lactate dehydrogenase (LDH) activity (Figure 
6.6), which is indicative of less necrotic death and was maintained for at least 30 min 
after the start of reperfusion. Necrotic cell death results in release of cellular contents 
and the quantity of LDH in the perfusate is an index of necrotic death. Thus, Ucn 
prevented necrotic cell death in the Langendorff perfused rat heart from simulated 
I/R.
In these experiments, in order to examine whether Ucn mediated haemodynamic 
recovery (Figure 6.7A) protects the heart by reducing the extent of opening of the 
MPTP, the mitochondrial entrapment of a radioactive marker, pH]2-deoxyglucose 
([^H]-DOG) was used. During perfusion, [^H]-DOG is present in the buffer and 
mitochondrial uptake of pH]-DOG is an indication of MPTP opening. Ucn treatment 
significantly reduced the extent of pH]-DOG uptake in Langendorff perfused rat 
hearts subjected to I/R compared to hearts not treated with Ucn (Figure 6.7B). The 
yield of mitochondria in these experiments, determined as the total citrate synthase 
activity of the mitochondrial pellet, was not altered by Ucn treatment (Table 6.1). 
Therefore, Ucn mediated protection from I/R injury is associated with inhibition of 
MPTP opening in the intact adult rat heart.
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Pre-ischaemic End-ischaemic Reperfused
Control Urocortin Control Urocortin Control Urocortin
LVDP (mmHg) 90.0 ± 1.8 91.6 ±3.1 - - 32.1 ±7.1 64.6 ± 4.1**
EDP (mmHg) 3.4 ± 0.4 3.6 ± 0.5 - - 48.1 ± 6.3 20.9 ± 4.0 **
Heart rate (bpm) 307.5 ± 7.6 296.3 ± 10.6 - - 315.0 ± 9.9 315.0 ± 16.2
Aortic pressure (mmHg) 86.6 ± 3.8 78.8 ± 2.3 - - 107.5 ± 6.6 86.4 ± 2.2*
Time to IC (min) - - 11.9 ± 0.6 7.6 ± 0.5** - -
Time to max IC (min) - - 19.0 ± 0.7 18.4 ± 1.0 - -
Max IC (mmHg) - - 32.1 ± 1.6 33.6 ± 1.6 - -
Citrate synthase recovery - - - - 1.87 ± 0.2 1.77 ± 0.2
(Units/g wet weight heart)
Table 6.1 The effects of Urocortin on heart function. Langendorff perfused hearts were stabilized and subjected to 30 
minutes of ischaemia followed by 30 minutes of reperfusion. Urocortin was present in perfusion buffer throughout experiment 
except for control hearts. Values shown are means ± SEM for 8 control and 8 Urocortin treated hearts. Statistical analysis was 
performed by Student's ftest. **P<0.05; *P<0.05 compared to control.
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Figure 6.6 Ucn reduces lactate dehydrogenase (LDH) release following 
Ischaemia. LDH measurements were made in samples of the coronary perfusate 
that were collected every minute for the first 5 minutes of reperfusion and every 5 
minutes thereafter. The thick black line shows measurements for control hearts and 
the Ucn treated hearts the thin black line. LDH release is lower in Ucn treated hearts. 
Values shown are means ± SEM of 8 control and 8 Ucn-treated hearts. Statistical 
analysis was performed by a student's t  test. *P <0.05 compared to matched time 
point for control.
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Figure 6.7 Urocortin mediated Improvement of haemodynamic recovery of 
hearts following I/R  Is associated with decreased MPTP opening.
Langendorff perfused rat hearts were preloaded with [^H]-DOG during stabilisation of 
hearts and were subjected to 30 minutes of ischaemia foliowed by 30 minutes of 
reperfusion. (A) Recovery of LVDP at the end of reperfusion is shown as a 
percentage of the pre-ischaemic value. (B) Mitochondria were isoiated from hearts 
and pH]-DOG entrapment was measured. Values shown are means ± SEM of 8 
controi and 8 Ucn-treated hearts.
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6.6 Discussion
The data presented here show that a technique of enzymatic digestion and rapid 
attachment for the isolation and culture of ARVC cells observed in Professor Chris 
Proud's Laboratory (Dundee University) was successfully reproduced in our 
laboratory. Enzymatic dissociation by perfusion is the preferred method as it yields a 
higher proportion of viable cells compared to digesting pieces of tissue. Furthermore, 
the rapid attachment technique has an advantage over an alternative technique of 
culture that maintains cells in suspension, which dedifferentiate and lose their adult 
phenotype (Mitcheson et al., 1998).
The ARVC cells prepared here have distinctive rod shaped morphology and are bi­
nucleated, consistent with previous reports describing the morphology of cultured 
adult cardiac myocytes (Bird et al., 2003). All rod shaped cells expressed the 
sarcomeric protein desmin and the majority expressed the ventricular specific 
isoform of myosin light chain, MLC-2v, as determined by immunocytochemistry. 
Presumably, a minority of the cells did not express MLC-2v as they were of atrial 
origin. Few cells could be seen to be spontaneously contracting, consistent with 
published findings using the rapid attachment technique (Volz et al 1991). This is an 
indication that the cultures were not only viable but also not stressed as spontaneous 
contraction of cultured ARVC cells is associated with apoptosis (Maruyama et al., 
2001).
A proportion of ARVC cells were necrotic following the isolation procedure and this 
proportion varied between cultures. The quality of ARVC isolations depend in part on 
the source of collagenase used in the enzymatic dissociation of cardiac myocytes. 
Therefore, the quality of several batches of collagenase were tested, assayed by 
measuring the ratio of rod-shaped to rounded-up cells isolated, and the batch giving 
the highest proportion of rod shaped cells was used for the experiments in our study. 
Although there was variation in the amount of necrotic cells between preparations, 
the isolations reproducibly yielded high quantities of viable cells.
NRCM cells are commonly used as a model system for investigating I/R-injury. 
However, I/R-injury is predominantly an adult disease and there are phenotypical 
differences that exist between neonatal and adult cardiac myocytes, which include
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the expression of different ion channel and sarcomeric protein isoforms (Mitcheson et 
al., 1998). Therefore, it is desirable to use adult cardiac myocytes as a model system 
for investigating I/R injury as opposed to using neonate derived cardiac myocytes. 
The common use NRCM cells to investigate I/R-injury is presumably because they 
are technically easier to prepare than adult cardiac myocytes cells.
Cell death of ARVC cells was induced by simulated I/R, as assayed by the 
percentages of viable rod shaped versus rounder up dead cells. The buffer used in 
annexin V staining induced spontaneous contraction and rapid death of ARVC cells. 
Annexin Vi sa calcium-dependent phospholipid-binding protein with high affinity for 
phosphatidylserine (Vermes et al., 1995). The annexin V buffer contains a relatively 
high concentration of calcium compared to the medium ARVC cells are cultured in. 
Thus, ARVC cells, which are intolerant of high concentrations of calcium, possibly 
were induced by the high calcium buffer to contract rapidly and die. Furthermore, no 
ARVC cells could be identified as positive for TUNEL staining following simulated I/R 
or control treatments. Although there are some publications describing the use of 
TUNEL staining in ARVC cells it is not common, which suggests that the current 
TUNEL protocols are not optimal in ARVC cells. Membrane blebbing, a characteristic 
feature of apoptosis, was observed in cardiac myocytes following I/R, however this 
was only observed in the first few minutes immediately after ischaemia Therefore, 
cell morphology was the single determinant used for measuring cell death of ARVC 
cells in subsequent experiments. Thus, the effects of Ucn on survival could not be 
attributed to inhibition of apoptosis but on cell death as a whole.
A time-course of simulated I/R was undertaken to test the model and select an 
optimal time for use in subsequent experiments. Simulated I/R induced cell death of 
ARVC cells in an ischaemic time dependent manner. This is consistent with a study 
by Kang and colleagues, although they found that reperfusion induced death was 
maximal after 24 hours whereas in our study cell death was near basal levels by this 
time point (Kang et al., 2000). Maximal cell death was observed after four hours of 
reperfusion, the reduced cell death observed after 24 hours could be explained by 
the fact that by this time many dead cells had detached from the culture dish.
Ucn protected ARVC cells from simulated I/R-injury, as has been demonstrated for 
NRCM cells and the isolated adult rat heart (Okosi et al., 1998, Brar et al., 2000, 
Schulman et al., 2002, Scarabelli et al., 2002). Ucn was able to protect cardiac
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myocytes from simulated I/R-injury when given 1 or 16 hours prior to ischaemia, an 
effect also seen in NRCM cells (Brar et al., 2002a). Gordon and colleagues have also 
demonstrated that Ucn protects ARVC cells from simulated I/R when given 1 or 16 
prior to ischaemia, as measured by LDH and creatine kinase release (Gordon et al., 
2003). However, they used glucose deprivation and acidosis as their model of 
ischaemia whereas in this study the cells were hypoxic during simulated ischaemia.
The protection conferred by Ucn from simulated I/R may have dependent on 
p42/p44 MARK and PI-3K/Akt signalling pathways, as has been shown in neonatal 
cardiac myocytes and the isolated heart (Brar et al., 2000, Brar et al., 2002b, 
Schulman et al., 2002). The mechanism by which Ucn protects may also have been 
through the pathways by which ischaemic preconditioning (IRC) protects. There are 
two phases of protection conferred by IRC, an immediate and a delayed phase 
(Murry et al., 1986, reviewed by Yellon and Baxter, 1995). It is possible that the 
protection conferred by Ucn when given 1 hour prior to simulated ischaemia may be 
through activation of RKCe, an event that ischaemic preconditioning and Ucn 
mediated protection are dependent upon (Liu et al., 1999, Lawrence et al., 2005). It 
has been demonstrated that the RKCe inhibitor chelerythrine inhibits Ucn mediated 
protection from simulated I/R injury in a model of ischaemia without hypoxia 
(Gordon et al., 2003).
Opening of the MRTR under stressful conditions such as reperfusion injury can lead 
to apoptotic and necrotic cell death (reviewed by Halestrap et al., 2004). In our 
study, the protection conferred on ARVC cells by Ucn treatment for 1 hour prior to 
simulated I/R was associated with inhibition of MRTR opening, a finding also 
observed in NRCM cells (Lawrence et al., 2004). Although there are advantages of 
using adult cardiac myocytes, they are not a substitute for in vivo or ex vivo 
investigation. A number of changes occur in myocytes when in culture, including 
reorganisation of cytoskeletal components and contractile proteins as they adapt 
from a three-dimensional to a two-dimensional environment (Decker et al., 1991). 
Therefore the effect of Ucn on MRTR opening in the isolated rat heart subjected to 
simulated I/R injury was also investigated.
Ucn protected rat hearts from simulated I/R-injury, determined by improved 
functional recovery and reduced LDH release following ischaemia when compared to 
untreated hearts, as has been previously demonstrated (Scarabelli et al., 2002). Ucn
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mediated protection was associated with inhibition of MPTP opening, as determined 
by the [^H]-DOG entrapment technique. This relationship between Ucn mediated 
cardioprotection and the MPTP is consistent to what was found here in ARVC cells 
and previously in NRCM ceils (Lawrence et al., 2004).
It has recently been demonstrated in our laboratory that the inhibition of the MPTP 
from opening that is associated with Ucn mediated protection is not additive with 
that of Cyclosporin A (CsA), a compound known to prevent MPTP opening, which 
therefore suggests that Ucn treatment prevented MPTP opening (Townsend et al., 
2007). The mechanism by which Ucn inhibits the MPTP from opening was found to 
be independent of PKCe translocation to the mitochondria, however inhibition of 
MPTP opening may occur indirectly through the ability of Ucn to reduce oxidative 
stress, as determined by reduced carbonylation levels in the mitochondria (Townsend 
et al., 2007).
The cardioprotective effect of Ucn from simulated I/R injury is well documented 
(reviewed by Lawrence and Latchman, 2006). Ucn has been shown to be protective 
when given at reperfusion, suggesting it could be of therapeutic benefit in a clinical 
setting (Brar et al., 2000, Scarabelli et al., 2002). In our study, the role of the MPTP 
in the cardioprotective effect of Ucn has been investigated when Ucn is given prior to 
an ischaemic insult followed by reperfusion. Cardioprotective agents given prior to an 
ischaemic insult may be useful to minimize the effects of ischaemic damage during 
cardiac surgery or, in the case of transplantation, during transportation of the heart. 
The potential use of Ucn as a therapeutic agent will be dependent on any undesirable 
effects that it may have, for example, it has been shown to induce hypertrophy 
(Railson et ai., 2002). Nevertheless, understanding the mechanism of how 
endogenous molecules provide protection provides valuable knowledge, for example 
analogues of Ucn that provide protection without any harmful side effects could be 
developed.
In summary, the data presented here show that Ucn mediated protection from I/R- 
injury in the isolated perfused rat heart and death of primary ARVC cells is associated 
with inhibition of the MPTP from opening. In the perfused heart, the enhanced 
recovery of haemodynamic function mediated by Ucn treatment and the decreased 
necrotic damage determined by the release of LDH was accompanied by less MPTP 
opening, as determined by the [^H]-DOG entrapment technique. Similarly, in cultured
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ARVM cells, measurement of mitochondrial membrane potential showed Ucn pre­
treatment reduced MPTP opening following simulated I/R in association with reduced 
cell death.
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CHAPTER SEVEN 
Overview and ideas for future work
Components of the IFNy and CT-1 signalling pathways are endogenous regulators of 
cardiac I/R injury and pathological hypertrophy. Therefore, the investigation of these 
pathways improves our understanding of how the disease processes are regulated 
and how these pathways may be targeted therapeutically to improve the clinical 
outcome in patients with I/R-injury or hypertrophy. The work described in this thesis 
increases our understanding of the mechanisms involved in the regulation of cardiac 
I/R injury or hypertrophy by components of the IFNy and CT-1 pathways.
The experimental approaches that have been used to test the hypotheses in this 
thesis have included the use of in vitro, ex vivo and in vivo systems. Furthermore, 
these different approaches have been used to test the same hypothesis. For 
example, the involvement of the MPTP in Ucn mediated protection from I/R injury 
was demonstrated in ARVC cells. The finding that inhibition of MPTP opening is 
associated with Ucn mediated protection in ARVC cells was corroborated in the 
Langendorff perfused rat heart. Having demonstrated similar results in two different 
systems there is more confidence in the data. An in vivo approach has been used to 
test a finding previously demonstrated in vitro. Over-expression of hsp56 has been 
shown to induce hypertrophy of NRCM cells and the hypertrophic effect of hsp56 
over-expression in the mouse was tested here. However, over-expression of hsp56 in 
the mouse did not induce hypertrophy. Once again, this underlines the importance of 
testing hypotheses in more than one system, especially when using neonatal cells as 
a model system to investigate disease.
The transcription factor STATl is the key mediator of the IFNy response and has 
been shown to be involved in I/R-injury. The role of the mitochondrial and death 
receptor apoptotic pathways in STATl mediated I/R-injury was investigated with the 
generation of transgenic mice that have impaired mitochondrial or death receptor 
signalling. The generation of transgene expressing mice using the Tet-inducible 
system was achieved in this thesis. However, due to the incorrect orientation of the 
C9s insert in the pBIG-C9s transgenic mice and the failure of any pBIG-FUP lines to 
express the transgene, these mice could not be used to ask the question; what are 
the relative contributions of the mitochondrial and death receptor apoptotic pathways
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in STATl-mediated I/R-induced injury? The expression of p-galactosidase in aMHC- 
tTA/pBIG-C9s expressing lines was proof of principle that the binary Tet system did 
indeed work. Therefore, the generation of pBIG-C9s and pBIG-FLIP transgenic mice 
could once again be attempted in the knowledge that the Tet-inducible system used 
here was functional. Furthermore, although the aMHC-tTA/pBIG-C9s and aMHC- 
tTA/pBIG-FLIP transgenic lines produced here did not express the transgene of 
interest, a transgenic approach was successfully applied in the generation mice over­
expressing hsp56.
There are some limitations with the Tet-inducible system that may warrant 
consideration of using an alternative conditional system. One limitation of the Tet- 
inducible system is the squelching caused by the viral VP16 activating domain of the 
tTA protein. Squelching is a phenomenon caused by protein over-expression and 
affects the equilibrium of other cellular proteins, resulting in pleiotropic effects 
(Lewandoski, 2001). A second limitation is the leakiness associated with the Tet- 
inducible systems. This refers to the residual expression observed in Tet-on systems 
in the absence of tetracyclines, or the lack of complete inhibition of expression in 
Tet-off systems in the presence of tetracyclines. The effect of tetracyclines on tTA- 
induced expression was not tested in the p-galactosidase expressing aMHC- 
tTA/pBIG-C9s transgenic mice generated here. Should pBIG-C9s and pBIG-FLIP be 
generated again, the potential of leakiness in the system could be tested on p- 
galactosidase expressing aMHC-pBIG-C9s transgenic mice beforehand. Improved 
Tet-based systems that have reduced leaky expression have been developed (Van, 
2007). Thus, the use of these improved systems could be considered if the aMHC- 
pBIG-C9s transgenic mice exhibit any leaky expression.
STATl is a transcriptional transactivator of many genes. However, it is now also 
recognised that STATl induces transcription as a transcriptional co-activator for 
other transcription factors such as p53. Both STATl and p53 are induced by forms of 
stress, including I/R, but are also involved in the constitutive expression of some 
genes. Here, a proteomic screen of cardiac protein samples revealed that IL-6 was 
highly abundant in samples from mice deficient in p53 but not in wild type mice, 
mice deficient in STATl or mice deficient in both STATl and p53. This suggests that 
STATl is involved in the regulation of IL-6, although here it was only identified in the 
context of p53 deficiency. The relative expression of IL-6 in MEF cells from p53 and 
p53/STATl knockout mice was different to that in heart samples. This demonstrates
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that STATl mediated regulation of IL-6 occurs in a tissue specific manner. However, 
the heart is composed of several cell types including myocytes, endothelial cells and 
fibroblasts, and the abundant IL-6 observed might have been derived from any one 
or more cell type. Therefore, further investigation is required to understand how 
STATl regulates IL-6 in specific cell types.
Binding of p53 to the IL-6 promoter has previously been demonstrated to repress its 
expression (Santhanam et al., 1991, Angelo et al., 2002).Thus, highly abundant IL-6 
in hearts from p53 deficient mice is a finding that agrees with these previous studies. 
IL-6 confers protection from I/R-injury and may be responsible for the observed 
attenuation of I/R injury in p53 deficient mice compared to wild type mice 
(Matsushita et al., 2005, Matsusaka et al., 2006) . The positive role of STATl in IL-6 
regulation was apparent only in mice deficient in p53. This questions the 
physiological relevance of this finding, as p53 would not normally be absent in the 
heart. However, it does offer a possible explanation as to the mechanism involved 
when the p53 gene is disrupted or when the p53 protein expression or function is 
inhibited.
In the context of cardioprotection conferred by p53 inhibition, IL-6 may be a 
mediator of this effect. In this regard, it might be considered that p53 inhibition is a 
viable treatment option for limiting the damage caused by I/R-injury, as compounds 
that inhibit p53 have been reported. For example, Komorava and colleagues 
discovered a small molecule inhibitor, named Pifithrin-alpha, which inhibits p53 and 
found that it protected mice from genotoxic stress induced by anticancer treatment 
(Komarov et al., 1999). Interestingly, they also demonstrated that treatment of mice 
with Pifithrin-alpha did not promote the formation of tumours, a complication 
associated p53 inhibition. Moreover, inhibition of p53 by Pifithrin-alpha has been 
shown to reduce p53-mediated apoptosis and improve cardiac function following I/R- 
injury in rats (Liu et al., 2006).
The cytokine, CT-1, is produced by cardiac myocytes and has both cardioprotective 
and hypertrophic effects. The hypertrophic effect, but not the cardioprotective effect, 
of CT-1 has been shown to be dependent on hsp56, and over-expression of hsp56 in 
NRCM cells is sufficient for inducing hypertrophy (Jamshidi et al., 2004). To test this, 
transgenic mice over-expressing hsp56 were generated. Over-expression of hsp56 
did not protect from I/R injury, which was consistent with findings in NRCM cells
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(Brar et al., 1999). However, myocardial hypertrophy was not detected In any of the 
transgenic lines generated. Therefore, the hypertrophic effect of hsp56 Is unclear. 
The hypertrophy observed In NRCM cells may be an artefact of protein over- 
expresslon rather than a specific effect of hsp56. Furthermore, the expression profile 
of hsp56 has not been determined In adult cells, either treated with CT-1 or any 
other hypertrophic stimuli. Studies on the relationship between CT-1 Induced 
hypertrophy and hsp56 should be conducted In cultured adult cells. Thus, hsp56 
over-expressing mice may also be used to help determine this relationship by testing 
If hsp56 over-expresslon Increases sensitivity to CT-1 Induced hypertrophy. 
Furthermore, the expression profile of hsp56 In cardiac myocytes following treatment 
with other hypertrophic stimuli and In biopsies from hypertrophied hearts should be 
examined.
The expression of CT-1 Is Induced by Ucn In cardiac myocytes (Janjua et al., 2002). 
Ucn Is also produced by cardiac myocytes and has cardioprotective and hypertrophic 
effects. The cardioprotective effect of Ucn was previously shown to be associated 
with Inhibition of the MPTP In NRCM cells. Here, this association was demonstrated In 
ARVC cells and In the Langendorff perfused heart. Thus, the significance of the MPTP 
In the mechanism of Ucn mediated protection Is supported by this work. 
Pharmacological Inhibition of the MPTP Is considered to be an effective and 
promising strategy for reducing the damage caused by I/R-lnjury (Javadov and 
Karmazyn, 2007). Therefore, Ucn has the potential to be used therapeutically In the 
treatment of reperfuslon Injury. However, Inhibiting the hypertrophic effect of Ucn 
needs to be addressed. The Identification or synthesizing of molecules that have the 
cardioprotective effect of Ucn, but not Its hypertrophic effect, may provide the 
necessary adjunct to reperfuslon of the myocardium.
Although It has been shown here that the cardioprotection conferred by Ucn from 
I/R-lnjury Is associated with the Inhibition of the MPTP, the mechanism by which this 
occurs Is unclear. Additional work since the completion of this thesis suggests that 
Inhibition of MPTP opening may occur Indirectly through the ability of Ucn to reduce 
oxidative stress, as determined by reduced carbonylation levels In the mitochondria 
(Townsend et al., 2007). It Is Interesting that Ucn Is able to confer protection from 
I/R-lnjury when given to cells either 1 or 16 h before I/R. Thus, It should be 
considered that there might be distinct differences that exist In the mechanism of 
Ucn mediated protection when given just prior to I/R and when I/R Is delayed. As
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mitochondrial protection seems to be key to the function of Ucn, it would be 
interesting to investigate what effects Ucn is having on other aspects of 
mitochondrial function.
Mitochondria are involved in many processes including the generation of usable 
energy in the form of ATP in the process of oxidative phosphorylation, Fe-S and 
haem synthesis. Mitochondria also contain to their own genome, consisting of 
circular double stranded DNA of approximately 16.5 kb (Anderson et al., 1981). 
Mitochondrial DNA (mtDNA) is closely linked to oxidative phoshorylation, as it 
encodes 13 essential polypeptides of the respiratory chain. Each mitochondrion is 
host to several copies of mtDNA and the maintenance of their genome is necessary 
for proper respiratory chain function. Hence, respiratory chain dysfunction is a direct 
consequence of mutated mtDNA. Furthermore, ischaemic disease is also associated 
with reduced mtDNA copy number and respiratory chain enzyme activities. Several 
nuclear encoded proteins are responsible for mtDNA maintenance and mutations in 
genes encoding for those proteins result in respiratory chain dysfunction. 
Transcription factor A (TFAM) is a nuclear encoded protein involved in mtDNA 
transcription and replication. Reduced TFAM expression has also been observed in 
association with reduced mtDNA copy number in cardiac failure. Overexpression of 
TFAM in mice has been shown to ameliorate the reduced mtDNA copy number and 
respiratory chain enzyme activities in post-MI hearts (Ikeuchi et al., 2005). The 
ability to induce the expression of mtDNA maintenance proteins seems an attractive 
therapeutic approach. Therefore, it would be interesting to test if the protective 
effect of Ucn is dependent on modulating the expression of mtDNA maintenance 
proteins, as this would lend further support the idea that inducing expression of 
these proteins would be beneficial in cardiac disease.
It is also interesting that p53, in addition to functioning as a transcription factor in 
the nucleus and interacting with STATl, has also been found to locate to the 
mitochondria (Achanta et al., 2005). Furthermore, Chen and colleagues 
demonstrated that p53 is involved in mitochondrial DNA maintenance by a base 
excision repair mechanism (Chen et al., 2006). This highlights the potential problem 
of targeted inhibition of proteins that have beneficial effects in addition to the 
undesirable functions that we would like to prevent.
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This thesis describes the IFNy and CT-1 signalling pathways as being distinct from 
one another. However, they both regulate I/R and hypertrophic signalling pathways. 
Furthermore, previous work has shown that there is crosstalk between the two 
pathways. For example, hsp56 induced hypertrophy in NRCM cells has been shown 
to be dependent on STATl (Jamshidi et al., 2004). The role of p53 in the 
mitochondria also raises the possibility that p53 may be involved in Ucn mediated 
protection from I/R-injury. Furthermore, CT-1 induced hypertrophy is mediated by 
STAT3, which also modulates IFNy signalling. Therefore, it is of interest that the data 
in this thesis suggest STATl may be involved in IL-6 regulation; CT-1 is an IL-6 
family cytokine and therefore is a candidate for STATl regulation. Thus, STATl may 
also regulate cardioprotective and hypertrophic effect pathways in addition to death- 
inducing ones. Jin and colleagues have shown that IFNy has inhibitory effects on 
myocardial hypertrophy (Jin et al., 2005). However, enhancing STATl expression to 
inhibit hypertrophy might have complications given its role in promoting apoptosis of 
cardiac myocytes. Therefore, more work is required to investigate the role of STATl 
in hypertrophy.
The work presented in this thesis describes a novel regulation of IL-6 expression in 
the heart. This occurs in a manner dependent on p53 and STATl to repress or 
activate IL-6 expression respectively. As IL-6 has the ability to confer protection from 
I/R, this may explain the mechanism of protection in the absence of p53 and 
therefore, this pathway may be an attractive target for therapy. Furthermore, this 
work has shown that mitochondrial dysfunction is a contributing factor in I/R-injury 
and that the protection conferred by Ucn in the adult heart is associated with 
inhibition of MPTP opening. These findings therefore further demonstrate that 
preventing the MPTP from opening is an attractive treatment option for reducing the 
damage of I/R-injury.
It is therefore necessary to continue the work described here since it would help to 
further unravel the complexities of the IFNy and CT-1 signalling pathways in cardiac 
I/R injury and hypertrophy. The long-term goal of this future research would be to 
design more effective therapies in the treatment of cardiac reperfusion injury and 
pathological hypertrophy.
244
Plasma 
membrane
hsp56 I  ?
iC  12*
MPTP
Cardiac Injury Cardioprotection Hypertrophy
Figure 7.1 The regulation of cardiac injury, cardioprotection and 
hypertrophy by IFNy, Ucn and CT-1 signalling pathways: the roles of 
STATl/p53, MPTP and hsp56. Inhibition of p53 enables STATl mediated 
induction of IL-6, possibly conferring cardioprotection. Ucn mediated cardioprotection 
is associated with inhibited opening of the MPTP. The role of hsp56 in hypertrophy is 
unclear but over-expression of hsp56 is not sufficient to induce hypertrophy.
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Appendix
Power calculations
Fig 4.11
Significance level obtained 0.27
Actual Difference observed 3.16
Original sample size 3
Power of test 19%
Minimum detectable difference 5.64
Required sample size 10
Fig 5.3
Significance level obtained 0.54
Actual Difference observed 3.82
Original sample size 4
Power of test 9%
Minimum detectable difference 12.14
Required sample size 40
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